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xAbstract
Bronchiolitis is the commonest cause of acute respiratory failure in 
infancy and several hundred children need respiratory support for the 
condition each year in the United Kingdom. Continuous negative 
extrathoracic pressure (CNEP) has been used to support such children 
but concerns about its possible association with significant harm 
prompted a government enquiry into the conduct of research at a UK 
centre using the technique. This retrospective study was designed to 
address these concerns by careful evaluation of outcome in two 
matched cohorts. Fifty children who had received CNEP for 
bronchiolitis as infants were compared with 50 controls who were 
treated in another hospital during the same period. Pre-treatment 
variables, demographics and neonatal factors were well matched in the 
two groups. In all subjects questionnaires and clinical examination were 
used to assess respiratory symptoms, disability and health-related 
quality of life whilst respiratory function was assessed by measuring 
airway resistance using the interrupter technique (!int), by spirometry 
and by bronchodilator responsiveness. CNEP was associated with 
reduced need for, and shorter duration of, positive pressure ventilation 
but with longer periods in oxygen and hospital. Median !int was 16.5% 
higher in the CNEP cohort (p<0.001) and median FEF25-75 was 9.3% 
lower (p=0.029). There were no significant differences between the 
groups in FEV1, FVC, bronchodilator responses or respiratory 
symptoms, or in the prevalence of moderate or severe disability 
xi
(Mantel-Haenszel statistic 1.40, 95% confidence intervals: 0.64 -3.04, 
p=0.39). Median health utility indices were similar; CNEP 1.00 
(interquartile range: 0.85-1.00), controls 0.99 (interquartile range: 0.81 -
1.00), n=48 pairs, p= 0.37. The higher !int and lower FEF25-75 in the 
CNEP group represent a small difference in respiratory function that 
may be attributable to population differences but a CNEP effect cannot 
be excluded. Further evaluation of the use of CNEP in bronchiolitis 
requires a prospective, controlled study.
xii
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11 Literature Review
1.1 Introduction 
Bronchiolitis is the commonest lower respiratory tract infection in 
infancy and the most frequent cause of acute respiratory failure in 
children admitted to paediatric intensive care units in the UK and North 
America (PICANet National Report, 2006, Randolph et al., 2003). 
About 2% of children admitted with bronchiolitis require ventilatory 
support (Behrendt et al., 1998). Babies with pre-existing lung disease, 
such as infants born preterm who develop chronic lung disease or 
infants with congenital heart disease, are more likely to require 
respiratory support with a bronchiolitis illness - ventilation rates as high 
as 17% in infants with chronic lung disease and 18.8% in infants with 
congenital heart disease have been reported (Navas et al., 1992). 
Respiratory support is provided in most cases by positive pressure 
ventilation (PPV) (Lebel et al., 1989, Outwater and Crone, 1984) which 
requires intubated subjects to be sedated and can lead to 
complications including injury to the airway or lungs (Orlowski et al., 
1980). The complications of mechanical ventilation have prompted a 
number of investigators to explore less-invasive methods of respiratory 
support. Nasal continuous positive airway pressure (CPAP) has been 
used successfully since the early 1970s to manage children with 
bronchiolitis-associated respiratory failure (Beasley and Jones, 1981, 
Soong et al., 1993). Continuous negative extrathoracic pressure 
(CNEP) has also been used following improvements in the 1980s in the 
delivery of this mode of respiratory support (Samuels and Southall, 
21989). In some cases intermittent negative extrathoracic pressure 
(INEP) has been used in addition to CNEP thus providing a further 
level of respiratory support, i.e. negative pressure ventilation (Al-balkhi 
et al., 2005). Neither CPAP nor CNEP has been assessed in a 
randomised trial. 
Samuels and Southall (1989) were the first to report the use of CNEP 
in children with bronchiolitis in an uncontrolled trial of 88 infants with 
respiratory failure due to a variety of disorders, including 7 with ‘asthma 
or bronchiolitis’. When used as an adjunct to positive pressure 
ventilation, CNEP was associated with a 15% mean reduction in 
oxygenation after 2 hours in the group as a whole, without significant 
complications. However, the small number of infants with bronchiolitis 
and the lack of a control group limit the significance of these findings. 
An abstract report by Hartmann et al. (1994b) describes the findings of 
a randomised controlled pilot study of the use of CNEP for bronchiolitis 
in 15 subjects and 18 controls. Infants with bronchiolitis were recruited 
if they required an inspired oxygen fraction ≥ 0.4 to maintain 
saturations between 96-99%. CNEP was associated with a reduction in 
FiO2 to ≤ 0.3 within 1 hour in 4 subjects compared to none of the 
controls. One child in the control group and none in the CNEP group 
subsequently required positive pressure ventilation. 
3Negative pressure ventilation (NPV) was used routinely at the North 
Staffordshire Hospital (NSH) from 1993-1999, for the management of 
infants with bronchiolitis-associated respiratory failure. A retrospective 
cohort study of 52 infants with bronchiolitis-related apnoea, 31 of whom 
were treated at NSH (a CNEP centre) and 21 who were treated at the 
Queen’s Medical Centre (QMC), a centre which did not use NPV, 
suggested that its use was associated with a reduced rate of intubation 
and a shorter PICU stay (Al-balkhi et al., 2005).
The safety of CNEP was questioned following a trial in which 244 
premature babies were randomly assigned to receive conventional 
respiratory support (standard group) or a combination of CNEP and 
conventional respiratory support (CNEP group) for the treatment of 
respiratory distress syndrome (Samuels et al., 1996). There were 28 
deaths in the CNEP group and 22 deaths in the standard group. 
Cranial ultrasound abnormalities were identified in 15 babies in the 
CNEP group and in 10 babies in the standard group. Neither outcome 
measure was significantly different between the groups, however the 
findings led to public concern that CNEP use might result in a higher 
rate of later neurodisability. These concerns were extended to the use 
of CNEP in bronchiolitis.  A government enquiry was commissioned to 
investigate these and other apprehensions about the conduct of the 
research. One of the outcomes of the enquiry was a recommendation 
that “---a substantial audit of the use of CNEP at NSH be carried out to 
4see if claims of significant benefit or damage can be substantiated” 
(Griffiths, 2003). 
No previous studies have reported long-term outcome following the use 
of this technique for bronchiolitis. This thesis reports the findings of a 
matched cohort study of children treated with CNEP for bronchiolitis, 
which was designed in response to this report. The study aim was to 
evaluate the previous clinical experience of the treatment of 
bronchiolitis with CNEP, with the public concerns in mind, so as to 
identify any long-term respiratory or neurological consequences of its 
use. By way of background to the study, the literature relating to short 
and long-term outcome following bronchiolitis has been reviewed. The 
published data on short-term outcome following the use of CNEP for 
bronchiolitis is evaluated and results from studies reporting the use of 
CNEP in children with other relevant conditions is discussed. A number 
of the studies evaluated included children where both "#$%&'"$$%#$ 
(INEP) and ()#$"#*)*+ negative pressure support (CNEP) were 
provided. These children have been referred to as receiving negative 
pressure ventilation (NPV) in the review that follows. Areas of research 
where data are lacking have been highlighted. 
51.2 Acute bronchiolitis
1.2.1 Incidence and aetiology
Bronchiolitis is the most common lower respiratory tract infection in 
infants admitted to hospital. It is estimated that 100,000 cases are 
admitted annually in the United States (Shay et al., 1999). In the United 
Kingdom, respiratory syncytial virus (RSV) bronchiolitis is reported to 
account for about 20,000 hospital admissions annually, which is 
approximately 3% of the birth cohort (Handforth et al., 2000). RSV is 
the commonest aetiological agent in the clinical syndrome of 
bronchiolitis and accounts for 50-90% of all admitted cases (Hall, 
1998). New techniques of virus isolation such as reverse transcription 
polymerase chain reaction (RT-PCR) are helping to identify the role of 
other viruses in acute bronchiolitis and its subsequent long-term 
outcome. Human Metapneumovirus (hMPV), identified as a significant 
respiratory pathogen in 2001, causes a similar spectrum of illness to 
RSV and may be the second most common cause of bronchiolitis (van 
den Hoogen et al., 2001, Foulongne et al., 2006). It has become 
evident that hMPV co-infection with RSV is the cause of particularly 
severe bronchiolitis in some cases (Williams et al., 2004, Foulongne et 
al., 2006). Similar virus isolation techniques have identified rhinovirus 
as a frequent cause of bronchiolitis in an older age group than that 
typically affected by RSV. Rhinovirus bronchiolitis is also more 
frequently associated with subsequent wheezing than is RSV 
bronchiolitis (Kotaniemi-Syrjanen et al., 2003). Other aetiological 
agents known to cause bronchiolitis include adenovirus, influenza, 
6parainfluenza, coronavirus, enterovirus and human bocavirus 
discovered in 2005 (Jartti et al., 2005, Allander et al., 2005). In addition 
,-()./0+'0 .#%*')#"0% is occasionally associated with a wheezing 
illness in infants.
1.2.2 Clinical features 
Bronchiolitis is a clinical diagnosis. In the United Kingdom the term 
describes an illness in infants that begins as an upper respiratory tract 
infection (URTI) followed by signs of respiratory distress, a harsh 
cough, bilateral crepitations, air trapping and wheezing (Gardner, 
1968). In the United States and some European countries, the 
diagnosis of bronchiolitis may include children up to 2 years of age with 
an acute wheezing illness who have a history of recurrent bouts of 
wheezing. In the UK such children would be diagnosed as having viral 
induced wheeze rather than bronchiolitis. The differences in definition 
are important when evaluating the results of therapeutic interventions in 
clinical trials and when comparing data about incidence, morbidity, 
mortality and long-term outcomes between studies. Most children with 
bronchiolitis have a self-limiting illness and are managed conservatively 
at home. Infants with moderate or severe bronchiolitis who have 
marked difficulty breathing with hypoxia require hospital admission. 
Mortality in infants who are otherwise healthy is about 0.5% (Behrendt 
et al., 1998) but is higher (∼3.5%) in children with underlying conditions 
such as cardiac or chronic lung disease (Navas et al., 1992). Other 
7groups at ‘high-risk’ of severe disease are preterm infants and children 
with congenital or acquired immunodeficiency (Stretton et al., 1992) as 
well as children with cystic fibrosis.
A subgroup of children requiring ventilation for RSV infection 
traditionally presumed to have bronchiolitis have recently been 
identified as having a different pattern of illness characterised by the 
radiological appearances of diffuse consolidation without hyperinflation 
as opposed to the classical appearance of gross hyperinflation without 
consolidation. The pattern of illness is more accurately described as 
RSV pneumonia and these children generally fulfil the clinical criteria of 
Acute Respiratory Distress Syndrome (ARDS). The distinction between 
the different clinical entities is important because the response to 
treatment and outcome may well be different for the 2 groups. One 
obvious difference is the prolonged length of ventilation in the group 
with pneumonia compared to those with bronchiolitis (Tasker et al., 
2000).  
1.2.3 Pathophysiology 
The pathological changes found in bronchiolitis were first described in 
autopsy specimens from infants dying of the condition and are 
presumed to be similar in those with a milder form of the illness who 
survive (Aherne et al., 1970). The observed post mortem changes are 
8those of acute inflammatory obstruction in the small airways. The virus 
colonises the respiratory tract epithelium and replicates causing 
epithelial necrosis and destruction of the cilia. The epithelial cell 
destruction triggers an inflammatory response with cellular infiltrate 
(predominantly lymphocytes) and oedema of the submucosa. There is 
also increased secretion of mucus from goblet cells, which combines 
with desquamated epithelial cells to form thick mucus plugs. The 
mucus plugs cause obstruction of the bronchioles, which results in both 
air trapping and lobular collapse to varying degrees. This leads to 
ventilation perfusion mismatch resulting in hypoxaemia (Aherne et al., 
1970, Hall, 1998).
1.2.4 Preventative therapies
1.2.4.1 Vaccine
There is currently no vaccine available to prevent RSV infection, which 
is responsible for up to 90% of admissions with bronchiolitis. The first 
trials of a formalin-inactivated RSV vaccine in the 1960’s induced a 
good IgG response in healthy volunteers but when assessed in clinical 
trials, the severity of subsequent infection was increased rather than 
decreased in those who had been immunised (Kapikian et al., 1969, 
Kim et al., 1969). Problems to be surmounted in the development of a 
vaccine include the need to induce immunity to multiple strains of the 
virus. A series of boosters would be required for a vaccine to be 
9effective because natural infection with RSV does not prevent re-
infection.
1.2.4.2 Immunoprophylaxis:
The most significant progress in the management of bronchiolitis in 
recent years has been in the development of agents giving passive 
immunisation against RSV. Two products are currently available for 
use as immunoprophylaxis in infants at high-risk of developing severe 
RSV bronchiolitis. The first to become available was intravenous RSV 
immunoglobulin (RSV-IG). The prophylactic administration of RSV-IG 
to high-risk infants and young children was evaluated in a prospective,
multicentre, blinded, randomised controlled trial involving 249 children 
(Groothuis et al., 1993). Subjects were randomly assigned to treatment 
groups, which received high dose (750mg/kg) or low dose (150mg /kg) 
monthly infusions of RSV-IG, or to a control group that received no 
infusions. The investigators reported significantly fewer lower 
respiratory tract infections (7 versus 20 in the controls; p=0.01) and 
hospitalisations (6 versus 18 in the controls; p=0.02) and in addition 
reduced days in intensive care (1 versus 34; p=0.05) in children treated 
with high dose RSV-IG when compared with controls. Subjects in the 
low dose group were reported to have a significant reduction only in the 
number of days in intensive care (0 versus 34; p=0.03). Disadvantages 
of RSV-IG include the need for intravenous administration of a large 
volume (15ml/kg) with its potential for fluid overload, a long duration of 
10
administration (2- 4hrs) and expense. The study found an increased 
incidence of adverse events in infants with cyanotic congenital heart 
disease and so RSV-IG is not recommended for this high-risk group. 
Another form of passive immunisation uses a humanised monoclonal 
antibody (Palivizumab). In a randomised, double blind, multi-centre trial 
(IMpact-RSV Trial), monthly palivizumab prophylaxis or placebo was 
administered to 1502 children by intramuscular injection over the 5 
months of the RSV season (The IMpact-RSV Study Group, 1998). 
Palivizumab use was associated with a 55% reduction in RSV-related 
hospitalisation (95% confidence intervals 38% -72%), fewer days in 
hospital (62.6 days/ 100 children- placebo group, 36.4 days/ 100 
children- Palivizumab group) and a lower incidence of intensive care 
admission (3% -placebo group and 1.3% in Palivizumab group, 
p=0.026). The effect of Palivizumab remained evident in subgroups of 
infants with bronchopulmonary dysplasia and haemodynamically 
significant congenital heart disease (Feltes et al., 2003). The main 
advantages of palivizumab over RSV-IG are its relative ease of 
administration and lack of interference with normal immunisations; its 
main disadvantage is its high cost. The benefits of palivizumab over 
RSV-IG have been assessed to outweigh any disadvantages by most 
clinicians and as a result it is preferred (Kimpen, 2002). A recent study 
of the healthcare utilisation of 190 prematurely born children with 
chronic lung disease found significantly increased respiratory morbidity 
and health service cost following RSV infection (Greenough et al., 
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2004). In light of these data, the UK Department of Health advisory 
body on immunisations, the Joint Committee on Vaccination and 
Immunisation (JCVI), has revised its recommendations for the use of 
palivizumab prophylaxis (Joint Committee on Vaccination and 
Immunisation, 2005) - it was previously recommended only for children 
with chronic lung disease (CLD) who also required home oxygen but is 
now recommended for 0// children with CLD, even those not needing 
home oxygen. The groups recommended to receive palivizumab by the 
JCVI are:
1. Children under 2 years of age with chronic lung disease who 
have required supplementary oxygen for at least 28 days from 
birth or who are receiving home oxygen. 
2. Infants less than 6 months of age who have a left to right shunt, 
haemodynamically significant congenital heart disease and/or 
pulmonary hypertension. 
3. Children under 2 years of age with severe congenital 
immunodeficiency. 
1.2.5 Treatment
Children with bronchiolitis require hospital admission if they are hypoxic 
or are unable to maintain adequate hydration; those in high-risk groups 
may require admission at an earlier stage of illness than otherwise 
healthy children. Supportive care with oxygen and nasogastric feeding 
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(if fluid intake is inadequate) are the mainstays of treatment for children 
with mild or moderate bronchiolitis. Results from numerous studies on 
a range of other treatment options have been disappointing with 
inconsistent findings or no evidence of benefit. Despite the prominent 
role that inflammation plays in the pathogenesis of airway obstruction, 
a systematic review of randomised controlled trials of systemic 
corticosteroids in acute bronchiolitis found no benefit in terms of length 
of hospital stay or of clinical scores (Patel et al., 2004). The lack of 
benefit from corticosteroids has recently been confirmed in a multi-
centre randomised controlled trial, which compared a single dose of 
oral dexamethasone with placebo in 600 children diagnosed with 
bronchiolitis in the A&E department. No significant difference was 
found in the rates of hospital admission, respiratory status after 4 hours 
or later outcomes such as length of hospital stay, later medical 
consultations or admissions (Corneli et al., 2007).  
Evidence relating to the use of bronchodilators in bronchiolitis is 
inconclusive; most studies suggest they have no benefit and might be 
deleterious whilst a few studies have found some clinical improvement 
(Schuh et al., 1990, Wang et al., 1992, Ho et al., 1991, Dobson et al., 
1998, Klassen et al., 1991). A systematic review of randomised 
controlled trials comparing bronchodilators with placebo in bronchiolitis 
concluded that bronchodilators produce a modest short-term 
improvement in clinical scores but no reduction in the rate or duration 
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of hospitalisation (Kellner et al., 2000) - however, the definition of 
bronchiolitis used in some of the trials allowed inclusion of children with 
recurrent wheeze which will have biased the results in favour of 
bronchodilators. 
Ribavarin is currently the only licensed antiviral agent for use in RSV-
bronchiolitis but its use seems to bring limited clinical benefit. A
prospective, double blind multi-centre study (Groothuis et al., 1990) 
was undertaken to assess the efficacy of early ribavarin intervention in 
mild RSV illness compared with placebo. Forty seven children with 
bronchopulmonary dysplasia or congenital heart disease were enrolled.
Early administration of ribavarin (<72hrs after onset of symptoms) was 
associated with improved oxygenation and clinical scores in 20 infants 
compared with 27 controls. In a later prospective controlled study, the 
Pediatric Investigators Collaborative Network on Infections in Canada 
conducted a subset analysis of 750 children with RSV lower respiratory 
tract infection enrolled in the 1993-1994 RSV database (Law et al., 
1997). They observed no significant benefit of ribavarin therapy in 
premature infants, infants with congenital heart disease or chronic lung 
disease with respect to a range of outcome measures including 
hospitalisation, duration of ventilation, stay in intensive care, and 
mortality. A Cochrane review of randomised trials comparing ribavarin 
with placebo in infants with RSV lower respiratory tract infection found 
that ribavarin may reduce duration of mechanical ventilation and days 
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of hospitalisation but concluded that it has not been shown to 
significantly reduce respiratory deterioration (treatment failure defined 
by pre-specified criteria leading to withdrawal from the study) or 
mortality (Ventre and Randolph, 2007). Trials of ribavarin have 
generally been inadequately powered to determine the outcome 
measures reliably. Ribavarin is currently only recommended for use in 
immunocompromised patients to reduce the duration of viral shedding 
(Kneyber et al., 2000). 
1.2.6 Management of respiratory failure
Infants with bronchiolitis may need respiratory support for either 
recurrent apnoea or increased work of breathing with respiratory 
failure. Depending on which denominator is used the estimated 
proportions needing respiratory support vary between 2% and 9%. Two 
large, retrospective, population-based studies have estimated that 
about 2% of all infants admitted with bronchiolitis require ventilatory 
support (Shay et al., 1999, Behrendt et al., 1998) but larger proportions 
(7-9%) have been reported in hospital-based studies which tend to be 
from tertiary centres with a referral bias (Wang et al., 1995, Outwater 
and Crone, 1984). The population-based studies provide a more 
accurate assessment of the frequency with which respiratory support is 
required, whereas the hospital-based rates may be of more relevance 
to tertiary centres, which are seeking to plan service provision. 
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Several modes of respiratory support have been used in the 
management of bronchiolitis-associated respiratory failure. Intermittent 
positive pressure ventilation (Downes and Striker, 1966, Lebel et al., 
1989, Outwater and Crone, 1984), continuous positive airway pressure  
(Beasley and Jones, 1981, Soong et al., 1993), negative extrathoracic 
pressure (Samuels and Southall, 1989, Al-balkhi et al., 2005), high 
frequency oscillation ventilation (Duval et al., 1999) and extracorporeal 
membrane oxygenation (Flamant et al., 2005) have all been used 
successfully - but none in the context of a randomised controlled trial. A 
helium/oxygen mixture (Heliox) has been used in infants with 
bronchiolitis-related respiratory failure to observe if it might improve 
clinical scores or reduce the need for mechanical ventilation (Cambonie 
et al., 2006, Liet et al., 2005, Hollman et al., 1998). A prospective, 
randomised, double-blind study of 20 infants with moderate to severe 
bronchiolitis found a significant difference in the modified ‘Wood clinical 
asthma score’ after 1 hour of heliox use (Cambonie et al., 2006). 
However, a multi-centre, randomised, double-blind placebo controlled 
study of 39 infants with severe bronchiolitis, found no difference in the 
need for intubation between subjects and controls following the use of 
heliox for at least 24 hours (Liet et al., 2005). Exogenous surfactant is 
another adjunct that has been investigated for its use in severe 
bronchiolitis. A randomised controlled pilot study of the use of a bovine 
surfactant (survanta) in 9 ventilated infants with RSV bronchiolitis found 
a significant improvement in oxygenation at 60 hours compared to 10 
controls treated with air placebo (Tibby et al., 2000). There was a 
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significant reduction in lung compliance and a corresponding increase 
in respiratory resistance at 30 hours in the placebo group but not the 
treatment group. These findings warrant further evaluation in a larger 
study. 
1.2.6.1 Positive pressure ventilation 
Positive pressure ventilatory support was first reported in the treatment 
of bronchiolitis-associated respiratory failure in the 1960s as this mode 
of ventilation was beginning to gain wide use. Downes and Striker 
(1966) reported its use in a cohort of 86 children, 23 of whom had 
respiratory failure due to bronchiolitis, acute asthma or pneumonia. 
Respiratory failure was defined using the following criteria:
1. Decreased or absent inspiratory breath sounds.
2. Severe inspiratory retractions and use of accessory muscles.
3. Cyanosis in 40% ambient oxygen.
4. Depressed level of consciousness and response to pain.
5. Poor skeletal muscle tone.
The presence of any 3 of these criteria for one hour was invariably 
found to be associated with respiratory acidosis (PaCO2 > 65 mm Hg) 
and was used as an indication for starting PPV.  All 23 children with 
respiratory failure (including 5 infants with bronchiolitis) who would 
normally have been expected to progress to circulatory arrest, 
recovered after receiving mechanical ventilation. 
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The definition of respiratory failure used by Downes and Striker reflects 
a previous focus on oxygenation as the essential criterion. A more 
contemporary definition of respiratory failure distinguishes between a 
failure in gas exchange manifest as hypoxaemia (PaO2 < 8.0kPa; Type 
I respiratory failure) and ventilatory failure manifest as hypercapnia 
(PaCO2 > 6.0kPa; Type II respiratory failure) with or without 
hypoxaemia (Roussos and Koutsoukou, 2003). 
Outwater and Crone (1984) retrospectively evaluated 15 infants aged 
2-12 weeks who had presented with bronchiolitis-associated respiratory 
failure and were managed with PPV; none had preceding chronic lung 
or heart disease. All infants survived to discharge with no clinically 
apparent respiratory sequelae.
In another retrospective review, Lebel et al. (1989) also found that PPV 
was well tolerated in 62 infants (over 10 years) with bronchiolitis-
associated respiratory failure and all survived. This study too, excluded 
cases with preceding lung disease, congenital heart disease or multiple 
congenital malformations. Compared with previously well babies, these 
‘high risk’ cases have been shown to have an increased risk of 
morbidity and death when they have been specifically evaluated 
(Navas et al., 1992, Stretton et al., 1992). These and other 
investigators have shown that PPV is effective in managing respiratory 
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failure and since its introduction it has become an established mode of 
treatment for children with severe bronchiolitis requiring respiratory 
support. Most studies have described a good outcome for infants who 
were previously healthy. However, complications can occur, the 
commoner ones are listed in table 1, and are found at a higher 
frequency among high risk groups (Stretton et al., 1992, Leclerc et al., 
2001). 
Table 1: Complications of intubation found in 100 consecutive cases 
admitted to a paediatric intensive care unit (Orlowski et al., 1980) 
1. Post extubation stridor
2. Obstruction of tube from inspissated mucus
3. Obstruction from kinking of tube
4. Endobronchial intubation
5. Accidental extubation
6. Gastric distension
7. Nasal, oral or neck ulceration 
8. Laryngotracheal ulcerations, granulomas, stenoses
9. Infection
10.Pneumothorax, pneumomediastinum
11.Atelectasis
12.Pneumonia
13.Oxygen toxicity
14.Tracheitis at post mortem
15.Cardiopulmonary arrest 
16.Asphyxia with temporary or permanent brain injury
17.Death
1.2.6.2 Ventilator associated lung injury (VALI) 
Ventilator-associated lung injury (VALI) is a term that describes a range 
of lung complications arising from PPV, which have become 
increasingly evident in recent years. The potential for pressure-
induced damage (barotrauma) from the use of mechanical ventilation 
has been known for several decades (Mellins et al., 1972). What has 
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become clear more recently, from studies in adults and in animal 
models, is that more subtle lung injury can result from alveolar 
overdistension (volutrauma) and manifest as increased alveolar-
capillary permeability (Slutsky, 1999, The ARDS Network, 2000). There 
has also been recognition of the effects of increased cytokine release 
from injured lungs which may have systemic effects in addition to 
further exacerbating lung injury (biotrauma) (Tremblay et al., 1997, 
Ranieri et al., 1999, Cheng et al., 2002). 
Evaluation of positive pressure ventilatory strategies on the effects of 
cytokine release has been carried out in a randomised trial of 37 adults 
requiring PPV for acute respiratory distress syndrome (ARDS) (Ranieri 
et al., 1999). A lung protective strategy of tidal volume and positive end 
expiratory pressure (PEEP) selected on the basis of the flow volume 
curve (study group) was compared with a ventilatory strategy designed 
to achieve maximum oxygenation and normal paCO2 without worsening 
haemodynamics (control group). Tidal volumes were significantly lower 
in the lung protective strategy (7.1ml/kg [SD 1.1] versus 11.1ml / kg 
[SD 1.3]; p<0.001) as was peak inspiratory pressure (24.6 cm H2O [SD 
2.4] versus 31.0 cm H2O [SD 4.6], p< 0.001). PEEP was significantly 
higher in the lung protective strategy group (14.8 cm H2O [2.7] versus 
6.5 cm H2O [1.7], p< 0.001). Pre-randomisation levels of the cytokines 
(tumour necrosis factor [TNF] α, Interleukin [IL]-1β, IL-6 and IL-8) did 
not differ between the groups in either broncho-alvealar fluid or serum. 
20
Thirty-six hours after study entry, the lung protective strategy was 
associated with a significant reduction from baseline levels in the 
cytokines in broncho-alveolar fluid (p<0.05 to p<0.001), whilst in 
controls the cytokines had increased (p<0.05 to p<0.001). Compared to 
controls, the levels of cytokines and polymorphonuclear cells in 
broncho-alveolar fluid were significantly lower in the lung protective 
group at 36 hours post randomisation (p<0.05). Post hoc analysis 
found that the lung protective strategy was associated with a 
significantly higher mean number of ventilator-free days (12 days [SD 
11] versus 4 days [SD 8]; p<0.01) and a non-significant lower mortality 
(38% versus 58%; p=0.19). These results suggest that positive 
pressure ventilation is associated with an inflammatory response that 
may be attenuated by a lung protective strategy of higher PEEP (to 
maintain alveolar opening and minimise collapse) and low tidal 
volumes (to reduce lung injury due to over distension). The clinical 
implications of a raised cytokine response have not been evaluated in 
this study but interesting evidence is provided to show that mechanical 
ventilation may be associated with lung injury independent of the 
condition for which it is being used.
A multi-centre randomised trial of 861 adults with acute lung injury and 
acute respiratory distress syndrome (ARDS) compared traditional 
ventilation strategy, using tidal volumes of 12mls/ kg, with a strategy of 
low tidal volumes of 6 mls/ kg (The ARDS Network, 2000). Ventilatory 
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rates were significantly higher in the low tidal volume group (29+ 7 
versus 16 + 6 on day 1) and the mean PaCO2 was greater (4-7 mm Hg 
higher than the traditional ventilation strategy group). The use of low 
tidal volumes was associated with a 22% reduction in mortality, 
significantly more ventilator-free days and significantly less multi-organ 
failure. There were no significant differences in the rates of barotrauma 
between the two groups - defined as pneumothorax, subcutaneous 
emphysema, pneumomediastinum, or a pneumatocele greater than 2 
cm in diameter. These findings suggest that a ventilatory strategy 
involving excessive alveolar distension is associated with increased 
lung injury resulting in significant morbidity and mortality in adults. 
Complications associated with PPV have prompted some investigators 
to evaluate other less invasive modes of ventilation. 
1.2.6.3 Continuous positive airway pressure (CPAP)
Continuous positive airway pressure (CPAP) is another commonly 
used mode of respiratory support for infants with bronchiolitis-
associated respiratory failure which has been employed since the 
1970’s. Its main advantages over IPPV are that it can be delivered non-
invasively (via nasal prongs) thereby avoiding the complications 
associated with intubation, and can be used without the infants needing 
to be sedated. A number of uncontrolled studies have found CPAP to 
be effective in bronchiolitis (Beasley and Jones, 1981, Cahill et al., 
1983, Soong et al., 1993) despite the pathophysiological process of the 
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illness involving air trapping, which CPAP might be expected to make 
worse. Beasley and Jones (1981) first reported the use of CPAP for 
bronchiolitis in a cohort of 23 infants; 14 received nasal CPAP via a 
short nasal cannula and 9 via an endotracheal tube (ET). All 23 infants 
showed clinical improvement with CPAP and survived to be 
discharged. One infant suffered a pneumothorax, which was drained. It 
is noteworthy that CPAP was started at an earlier stage in these 
infants, before the development of uncompensated respiratory failure, 
than was PPV in a previous cohort. The authors observed that in the 5 
years before they began to use CPAP, 288 infants were admitted with 
bronchiolitis and 13 were managed with PPV. In the 5 years after its 
introduction, just 2 infants (both with congenital heart disease) out of 
305 with bronchiolitis required PPV. This study suggested that, if 
started early, CPAP might be an effective mode of respiratory support 
for bronchiolitis. 
An uncontrolled study (Cahill et al., 1983) of 7 infants with bronchiolitis 
found that 6 could be managed successfully with nasal CPAP 
(NCPAP). One required intubation and mechanical ventilation, having 
shown no improvement after one hour on NCPAP. Soong et al. (1993) 
similarly found nasal CPAP to be effective in 10 out of 11 children with 
impending respiratory failure from bronchiolitis; one child with 
immunodeficiency required intubation and ventilation after showing no 
improvement on nasal CPAP.
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It is postulated that CPAP works by keeping small airways open 
throughout the respiratory cycle. Paradoxically this reduces 
hyperinflation and air trapping and results in improved gas exchange 
(Soong et al., 1993). Studies have found CPAP to be relatively free of 
complications although pneumothoraces can occur. Children with very 
severe bronchiolitis may still require intubation and mechanical 
ventilation, as CPAP may be less effective than PPV once exhaustion 
and respiratory failure have developed. There are no randomised trials 
comparing the use of CPAP with other modes of ventilatory support for 
bronchiolitis.
1.2.6.4 Continuous negative extrathoracic pressure 
Continuous negative extrathoracic pressure (CNEP) has been used as 
respiratory support in adults and children for a number of disorders but 
its use in children with bronchiolitis is limited to work by one team of 
doctors at two centres. Their work has resulted in 4 reports, 2 of them 
in abstract form only (Al-balkhi et al., 2005, Samuels and Southall, 
1989, Linney et al., 1997, Hartmann et al., 1994b). Samuels and 
Southall (1989) reported their findings of an uncontrolled trial in 88 
infants and young children with respiratory failure due to a variety of 
causes; most had either bronchopulmonary dysplasia [n=47] or 
respiratory distress syndrome [n=13] but 7 were reported to have 
‘bronchiolitis or asthma’. For the group as a whole, the use of CNEP 
was found to result in a 15% median reduction in FiO2 after 2 hrs 
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(range 0 -20%) and a 20% reduction at 48hrs (range 2 -79%). CNEP 
was reported to facilitate extubation in 28 out of 40 intubated children 
(no specific data are provided to substantiate this) and no potential 
complications such as fluid retention, pneumothorax or reflux with 
aspiration were experienced. Fifty-four of the 88 patients survived and 
were discharged, including 6 children who received long-term 
ventilatory support at home with CNEP. This study suggests CNEP 
may be an effective form of respiratory support but the lack of a control 
group reduces the significance of the findings.
Hartmann et al. (1994b) reported, in abstract form, the findings of a 
randomised controlled pilot study of 33 infants with bronchiolitis who 
needed ≥ 40% oxygen to maintain saturations between 96-99%. 
Fifteen infants were assigned to receive CNEP and 18 to conventional 
treatment. Administered oxygen was reduced to ≤ 30% within 1 hour of 
treatment for 4 children in the CNEP group with no change observed in 
the control group. There was no difference in the overall duration of 
oxygen therapy between the two groups. One child in the control group 
required intubation and ventilation and another required CPAP. None of 
the children treated with CNEP required intubation. The low rate of 
intervention in the control group and the criteria for selection of subjects 
(FiO2 ≥ 0.4) suggest that most of the children receiving CNEP would 
not have needed respiratory support had they not received it.  CNEP 
was used predominantly to avoid intubation and PPV in this group of 
patients rather than as ‘rescue’ therapy. The small numbers involved 
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and lack of reported detail makes it difficult to draw conclusions from 
this study about the role of CNEP in bronchiolitis.  
The other abstract report of the use of negative pressure ventilation 
(NPV) for bronchiolitis was of an uncontrolled study by Linney et al. 
(1997) and describes the outcome of 56 children with bronchiolitis 
referred to the paediatric intensive care unit at the NSH over  39 
months (Figure 1). Intermittent negative extrathoracic pressure (INEP) 
with pressures of -20 to -30cm H2O was used in addition to CNEP in 
some children. 
Figure 1: Summary of the management of children admitted to NSH with 
bronchiolitis over 39 months (Linney et al., 1997)
56 children
17 admitted 
locally
39 referred from 
other hospitals
1
CPAP
3
PPV
13
NPV
1
O2 only
10
PPV
27
NPV
1
*U/K
2
PPV
1
PPV
* 1 child is unaccounted for in the abstract (U/K = Unknown)
Of the 56 children, 29 were referred to PICU because of severe 
respiratory distress, 21 for recurrent apnoea and 6 for other unspecified 
symptoms. Thirteen children were intubated and ventilated, either at or 
before retrieval. Of the 40 children treated with NPV as their primary 
respiratory support, 3 (7.5%) subsequently needed intubation and 
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another 5 (12.5%) were managed with nasal CPAP and NPV 
combined. The authors suggest that the use of NPV may be associated 
with reduced intubation rates, presumably based on their previous 
experience of most of these children needing intubation. Caution is 
required in interpreting these data because there is no control group. 
A retrospective review (Al-balkhi et al., 2005) was conducted of the 
paediatric intensive care unit databases and case notes of 52 children 
with bronchiolitis-related apnoea admitted to two centres (NSH, QMC). 
NPV was used in addition to other standard treatment modalities: PPV, 
CPAP and methylxanthines, for infants admitted to NSH. Infants 
admitted to QMC received standard treatment modalities but not NPV. 
All 31 infants at NSH received respiratory support (23 NPV, 8 PPV) and 
19 of 21 infants at QMC received respiratory support (18 PPV, 1 
CPAP). There were no significant differences between the two groups 
in terms of neonatal data or bronchiolitis illness variables. The use of 
NPV was associated with a significantly reduced rate of intubation 
(26% v 86%; p <0.001) and shorter median duration of stay on PICU (2 
days v 7 days; p< 0.001). There was an increased use of 
methylxanthines at NSH (54% v 28%; p = 0.06) which could be a 
confounding factor in the difference in intubations rates. Nevertheless, 
the data suggest that the use of NPV was associated with lower rates 
of intubation and PPV as well as a shorter stay in PICU in the infants 
studied. 
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1.3 Outcome following bronchiolitis
1.3.1 Reactive airway disease
The long-term outcome following bronchiolitis has been extensively 
investigated and an association with subsequent reactive airway 
disease (RAD) has been found by most studies (Tables 2-5). RSV is 
the commonest cause of bronchiolitis and has been found most 
frequently to have an association with RAD but recent work suggests 
that rhinovirus may have an even stronger association with RAD than 
RSV (Kotaniemi-Syrjanen et al., 2003). Numerous studies have 
assessed the prevalence of RAD using a variety of criteria including: 
rates of wheezing, frequency of other respiratory tract illness, use of 
bronchodilators and lung function abnormalities. Uncontrolled studies 
have reported rates of wheezing as high as 75% in children in the first 
2 years following their bronchiolitic illness (Table 2). Controlled studies 
however, have reported rates of wheezing of 34-50% depending on the 
age at follow-up (Table 3). 
Sims et al. (1978) conducted a controlled retrospective study of 35 
children aged 8 years who were admitted with RSV bronchiolitis as 
infants. The controls were matched for age, sex and socioeconomic 
status. Wheezing was reported to have occurred on one or more 
occasions in 18 (51%) children who had bronchiolitis in infancy 
compared to just one child (3%) in the control group (p< 0.001). 
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Pullan and Hey (1982) subsequently confirmed these findings in a 
larger population of 130 children who had been admitted to hospital 
with bronchiolitis in infancy and 111 controls of comparable age, sex 
and social class.  When evaluated at 10 years of age, 42% of the index 
children had a history of wheezing at any age compared to19% of the 
controls (p<0.001). 
Murray et al. (1992) similarly found, in a matched cohort study of 73 
children admitted with bronchiolitis as infants, that 42.5% had wheezed 
in the previous 12 months compared to 15% of controls when assessed 
at 5.5 years (RR 2.8; p<0.001).  A further study of 61 children from this 
cohort and 47 matched controls found significantly more wheezing 
(34% versus 13%; p=0.018), coughing (48% versus 17%; p=0.002) and 
a diagnosis of asthma (39% versus 13%; p=0.004) in the index children 
9-10 years after their admission with bronchiolitis (Noble et al., 1997). 
McConnochie and Roghmann (1989) prospectively evaluated a cohort 
of 153 children (51 with mild bronchiolitis, 102 matched controls) at 8 
and 13 years of age, and found that a significant difference in wheezing 
at 8 years was no longer significant at 13 years of age.
The Tucson Children’s Respiratory Study was a large prospective 
epidemiological study of respiratory illness in which 1246 children were 
enrolled at birth and assessed at 3, 6, 11 and 13 years of age (Stein et 
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al., 1999). Two hundred and seven children were identified who had 
RSV positive lower respiratory tract illness (LRTI) that did not require 
hospitalisation in the first 3 years of life. Compared to controls who had 
no LRTI in that time, the group with mild RSV-LRTI had a significantly 
increased risk of frequent wheeze by age 6 years (odds ratio, 4.3; 95% 
C.I. 2.2 - 8.7). The risk of frequent wheeze remained significantly 
greater at 11 years but there was no significant difference at 13 years 
of age. 
Tables 2-5 summarise studies investigating the link between 
bronchiolitis and reactive airway disease. The different study designs 
and different definitions of wheezing account for much of the variation 
in the reported incidence of wheeze. Definitions used include: ‘current 
wheeze’, defined as wheezing in the 12 months prior to follow up; 
‘frequent wheeze’, defined as more than 3 episodes in the last year 
and ‘any wheeze’, defined as wheezing at any stage following the 
bronchiolitis illness. Some studies have only included wheezing 
episodes that have been verified by a doctor (Hall et al., 1984, Welliver 
and Duffy, 1993).
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1.3.2 Lung function abnormalities 
1.3.2.1 Spirometry
Most studies that have included spirometric tests in the assessment of 
children after bronchiolitis have found evidence of significant airflow 
limitation. Table 5 summarises the results from controlled studies. In 
that by Sims et al. (1978), compared with controls the post-bronchiolitis 
subjects had significantly lower peak expiratory flow rates  (237.7 L/min 
versus 265.1 L/min; p<0.02) and forced expiratory volume in 0.75 
seconds expressed as a percentage of forced expiratory capacity 
(FEV0.75/ FVC x 100; 83.2% versus 87.3%; p<0.05).
Mok and Simpson (1984) conducted a case-control study of 200 
children 7 years after their admission in infancy with lower respiratory 
tract infection. Bronchiolitis was the index illness in 104 of these 
children of whom 102 were able to perform lung function tests at follow-
up. An equal number of controls with no history of respiratory illness in 
infancy were recruited from the same school as the index cases and 
matched for age, sex and if possible height. Children who had suffered 
bronchiolitis had significantly lower % predicted FEV0.75 (87% versus 
92.6%; p ≤0.01), lower FEV1: FVC ratio (0.88 versus 0.91; p ≤0.01) and 
lower % predicted FEF25-75 (89.1 versus 101.3; p ≤0.01) compared to 
controls at age 7 years. 
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Stein et al. (1999) reported findings from the Tucson Children’s 
Respiratory Study in which 110 children who had suffered RSV- LRTI 
before 3 years of age were evaluated at 11 years of age with baseline 
and post bronchodilator forced expiratory volume (FEV1). They were 
found to have significantly lower FEV1 compared to 189 children who 
had had no LRTI (p=0.001) and were significantly more likely to 
respond to bronchodilators (odds ratio 2.4 [95% C.I. 1.0-5.8], p ≤0.05).
Other studies have reported airflow limitation following bronchiolitis 
(Pullan and Hey, 1982) and (Noble et al., 1997). Increased bronchial 
hyperactivity determined by the response to methacoline, histamine or 
bronchodilators has also been reported in controlled (Pullan and Hey, 
1982) and uncontrolled studies (Sly and Hibbert, 1989, Welliver and 
Duffy, 1993, Gurwitz et al., 1981). Pullan and Hey (1982), compared a 
cohort of children 10 years after bronchiolitis with controls; they found 
that 19 out of 102 index children had a positive histamine challenge 
(fall in FEV1 > 20% at histamine concentrations <16g/l) compared to 6 
out of 104 controls (p<0.01). Thirteen index children had a fall in FEV1
>15% following exercise compared to 5 controls (p<0.05). Evidence of 
bronchial lability was found using one or other measure in 26 of 105 
(25%) index children and 7 of 106 (7%) controls (p< 0.001). 
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1.3.2.2 Lung volumes and airway resistance (Raw) -
Plethysmography
Few outcome studies of children following bronchiolitis have used 
plethysmography to evaluate airway resistance, although it is the ‘gold 
standard’ method for assessing airway disease. It is difficult to perform 
in young children and the equipment required is very expensive. Stokes 
et al. (1981) prospectively studied 22 infants who had needed 
admission for bronchiolitis. They measured thoracic gas volumes and 
airways resistance by plethysmography during convalescence 
(between 1 and 18 days following admission), at 3- 4 months and at 12 
-15 months after admission. Fourteen out of 19 infants were assessed 
to be hyperinflated during convalescence, with thoracic gas volume 
measurements greater than 40ml/kg; the expected mean value being 
32.8ml/kg. Seven of 18 infants remained hyperinflated at 13 months. 
Eleven of 15 infants studied at all three time points showed a mean fall 
in airway resistance of 34% over the study period; 2 were unchanged 
and 2 rose by 60%. The lack of a control group, however, limits the 
significance of these findings. 
Gurwitz et al. (1981) evaluated 48 children in an uncontrolled, 
retrospective study 10 years after admission with bronchiolitis and 
measured lung volumes, airway resistance, spirometry and 
methacholine responses. Fifty seven percent of children (27/47) had a 
positive methacholine challenge. Total lung capacity (TLC) was raised 
in 3 children and the residual volume/ total lung capacity ratio was 
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raised in 20 children compared to values obtained on normal children 
tested in their laboratory.
Henry et al. (1983) evaluated 55 children in an uncontrolled prospective 
study 2 years after admission with bronchiolitis. They measured 
thoracic gas volumes (TGV), airways resistance (Raw) and total 
respiratory resistance (Rt) – using the forced oscillation technique 
before and after nebulised salbutamol. Twenty-two of 40 children able 
to complete lung function assessments were found to have a TGV 
more than 120% of the predicted value for weight (hyperinflated). In 9 
children airways resistance fell more than 15% following salbutamol. 
Once again the study findings are limited by the lack of a control group.
Noble et al. (1997) evaluated 61 children from an original cohort of 101 
infants, 9 -10 years after recruitment into a prospective study of 
outcome following admission with bronchiolitis. At the assessment at 
5.5 years, 73 controls were recruited to match the 73 index children 
who were still available for follow-up (Murray et al., 1992); at the 9-10 
year follow-up 47 of the controls were again available for assessment. 
Total lung capacity (TLC), residual volume (RV) and airways resistance 
(Raw) were measured by total body plethysmography in addition to 
spirometry and a histamine challenge. Measurements of TLC and RV 
were not significantly different between index cases and controls but 
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airway resistance (Raw) was significantly higher in index cases (2.87 
cmH2O/L/S versus 2.35cmH2O/L/S; p=0.002). 
These studies show that children who have had bronchiolitis have an 
increased prevalence of RAD, which returns close to that of the normal 
population by early adolescence. Evidence from studies which have 
included lung function testing suggest that there may be hyperinflation 
in the early years after bronchiolitis and increased airways resistance 
may still be evident after 10 years.
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Table 2: Uncontrolled prospective or retrospective studies showing an increased frequency of reactive airway disease following bronchiolitis
First author (Year)
No of 
cases
Age at follow
up (yrs)
Prevalence 
of wheezing
Definitions of wheeze Lung function tests done
Renzi et al. (1997) 26 0.6 58% Any wheeze -
Stokes et al. (1981) 18 1 50% Any wheeze
Lung volumes and airway 
resistance
Bont et al. (2000)
  
50 1
58% Recurrent wheeze -
Henry et al. (1983) 55 2 75% Any wheeze -
Korppi et al. (1993)
80
76
1 -2
2 -3
76%
58%
Recurrent wheeze -
Bont et al. (2004) 106 3
60%
42%
Any wheeze
Wheeze in last 12 months
-
Webb et al.  (1985) 81 3.5 59% Current wheeze -
Rylander et al. (1988) 67 4 -7 64% Any wheeze Spirometry
Eisen and Bacal (1963) 63 4 -14 46%
Any wheeze - (asthma / previous 
recurrent wheeze)
-
Sly and Hibbert (1989) 35 5 71% Asthma
Spirometry pre & post 
histamine challenge
Welliver and Duffy (1993) 43 7-8
60%
33%
Any wheeze (physician diagnosed)
Wheeze in last 2 yrs
Spirometry pre and post 
methacoline/ bronchodilation
Hall et al. (1984) 29 8 45% Any wheeze (physician diagnosed) Spirometry
Gurwitz et al. (1981) 48 9-10 29% Recurrent wheeze
Spirometry pre and post 
methacoline, lung volumes and 
airway resistance
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Table 3: Retrospective controlled studies indicating a link between bronchiolitis and later reactive airway disease
First author (Year)
Number of
cases / controls
Age at follow up 
(years)
Prevalence of 
wheezing
Significance (p) Definition of wheeze
Osundwa (1993) 70 / 70 2 44% vs 12.9% <0.001 Recurrent wheeze
Murray et al. (1992)* 73 / 73 5.5 42.5% vs 15% <0.001 Current wheeze
Mok and Simpson (1984) 104 / 104 7 44.2% vs 18.3% < 0.001 Any wheeze
Sims et al. (1978) 35 / 35 8 51% vs 3% < 0.0005 Any wheeze
McConnochie and 
Roghmann  (1984)
59 / 177 8 44.1% vs 13.6% < 0.001 Wheeze in last 2 yrs
Pullan and Hey (1982) 130 / 111 10 42% vs 19% < 0.001 Any wheeze
Noble et al. (1997)* 61 / 47 10 34% vs 13% 0.018 Current wheeze
Table 4: Prospective controlled studies indicating a link between bronchiolitis (or RSV lower respiratory tract infection before age 3 
years) and later reactive airway disease
First author (Year)
Number of
cases /controls
Age at follow 
up (years)
Incidence of 
wheezing
95% CI
Significance
(p)
Definition of 
wheeze
Sigurs et al. (1995)*
47 / 93
1
3
RR: 2.5
RR: 1.9
1.40 - 4.47
1.27 - 2.69
0.003
0.003
Any wheeze
Sigurs et al. (2000)*
47 / 93 7.5
RR: 1.98
RR: 17.81
1.40 - 2.79
4.31 - 73.54
<0.001
<0.0001
Any wheeze
Current wheeze
Stein et al. (1999)
68 / 601
56 / 489
79 / 555
49 / 420
6
8
11
13
OR: 4.3
OR: 1.9
OR: 2.4
OR: 1.4
2.2 - 8.7
0.9 - 4.2
1.3 - 4.6
0.7 - 2.6
<0.001
NS
<0.01
NS
Frequent wheeze
*Includes children from the same cohort, RR = Risk ratio, OR = Odds ratio, CI = Confidence Intervals, NS = Not significant.
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Table 5: Lung function results from controlled studies of outcome following bronchiolitis
First author, Year)
Number of
cases  /controls
Age at follow-
up (years)
Lung function tests
[Mean values: cases / controls]
Significance 
(p)
Other outcome
Murray et al. (1992)* 73 / 73 5.5
PEFR (% pred)
FEV0.75 (% pred)
FEV1 (% pred)
[96.2 / 97.8]     
[94.7 / 99.9]     
[96.4 / 100.1]
NS
NS
NS
Mok and Simpson (1984) 102 / 102 7
FEV0.75 (% pred)  
FEV1 (% pred)    
FEF25-75  (% pred)  
FEV1 / FVC
[87.0 / 92.6]      
[90.7 / 94.8]     
[89.1 /101.3]    
[0.88 / 0.91]
< 0.01
< 0.05
< 0.01
< 0.01
§ FVC - NS
§ 10% fall in 
PEFR - NS
Sims et al. (1978) 35 / 35 8
PEFR (l/min)                 
FEV1 / FVC (%)
[237.3 / 265.1]
[83.2 / 87.3]
< 0.02
< 0.05
§ FEV0.75 - NS
§ FVC - NS
Pullan and Hey (1982) 130 / 111 10
PEFR (l/min)
FVC  (litres)
FEV1 (litres)
MEF25-75  (litres)
FEV1 / FVC (%)
[301 / 335]
[2.26 / 2.38]  
[1.81 / 2.01]  
[1.90 / 2.27]     
[80.5 / 84.6]
< 0.001
< 0.005
< 0.001
< 0.001
< 0.001
Noble et al. (1997)* 61 / 47 10
PEFR (% pred) 
FEV0.75 (% pred)  
FEV1 (% pred)  
MEF50  (% pred)
Raw (cmH2O/l/s)
[93.2 / 102.0]    
[88.6 / 94.0]     
[91.0 / 96.1]     
[85.5 / 100.4]   
[2.87 / 2.35]
< 0.001
0.01
0.03
< 0.001
0.002
§ FVC - NS
Stein et al. (1999) 110 / 189 11
FEV1 litres (baseline)            
FEV1 litres (post 
bronchodilator)
[2.11 / 2.22]      
[2.26/2.31]
<0.001
NS
*Includes children from the same cohort. FEV = forced expiratory volume (FEV1 = in 1 sec, FEV0.75 = in 0.75 sec), FVC = forced vital capacity, MEF25-75 or 
FEF25-75 = forced mid-expiratory flow (between 25% and 75% of FVC), Raw = airways resistance, PEFR = peak expiratory flow rate, NS = Not significant.
38
1.3.3 Mechanism for link between RSV infection 
and reactive airway disease
The pathophysiological mechanisms by which RSV infection might 
cause reactive airway disease have not been fully elucidated despite 
convincing evidence from extensive research suggesting such a link. 
Three hypotheses have been postulated: first, that RSV infection 
damages the lung or alters host immunity resulting in RAD; second, 
that RSV infection unmasks an inherent susceptibility to RAD and third 
that host responses and the definition of bronchiolitis used accounts for 
the increased RAD. 
1.3.3.1 RSV effect on host inducing RAD
Evidence to support the first hypothesis is provided in a study by 
Piedimonte et al. (1999), in which the authors used a rat model to 
investigate the effect of RSV on the sub-epithelial neural network of the 
airway mucosa (figure 2). The three main factors determining airway 
patency are smooth muscle constriction, mucosal oedema and mucous 
secretion which are in turn controlled by adrenergic, cholinergic and 
non-adrenergic-non-cholinergic (NANC) neural pathways. The NANC 
neural pathways consist of an excitatory (NANCe) component inducing 
smooth muscle contraction and an inhibitory (NANCi) component 
inducing relaxation. The effects of the NANCe pathways are mediated 
by neurotransmitters including the neuropeptide substance P and 
neurokinins A &B. Substance P acts at three receptor subtypes (NK-1 
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NK-2, NK-3) of which the NK-1 subtype appears to have the highest 
affinity for it (Piedimonte, 2001). 
Piedimonte et al. (1999) studied the inflammatory response associated 
with the release of substance P in RSV-infected rats. They inoculated 
the tracheas of 5 rats with RSV and 6 with a virus-free medium; 5 days 
later they injected Evans blue-labelled albumin intravenously to 
measure extravasation of albumin from airway microvasculature and 
then infused the tracheas with vehicle alone, substance P or capsaicin 
(which stimulates endogenous release of multiple neuropeptides 
including substance P) in separate groups of rats. There was no 
significant difference in the extravasation of albumin between 
uninfected and RSV infected rats receiving vehicle alone. Extravasation 
(assessed by measuring optical density) was significantly increased in 
the RSV infected rats following infusion of substance P (p<0.001) and 
capsaicin, (p<0.001). The investigators further identified a 5 -fold 
increased expression of NK-1 receptors (p<0.001) in the airway and 
lungs of RSV infected rats compared to uninfected rats using RT-PCR 
techniques. These findings suggest that RSV LRTI in rats increases 
airway susceptibility to the inflammatory effects of substance P by 
upregulating NK-1 receptor gene expression. This model offers a 
potential mechanism for the observed effects of RSV in humans. 
Interestingly the authors also found that the neurogenically mediated 
inflammatory response in RSV-infected adult rats was most prominent 
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in the extra-pulmonary airways whilst in weanling RSV-infected rats it 
was most prominent in the intra-pulmonary airways. This observation 
probably reflects a maturational change in the distribution of NANCe 
fibres in the respiratory tract in rats which if true in humans might 
explain the difference in the acute effects of RSV infection in different 
age groups and the decline in RAD symptoms over time. 
Figure 2: Diagram showing how RSV may increase neurogenic inflammation by 
upregulating NK-1 receptors (Piedimonte, 2001)
1.3.3.2 RSV unmasks host factors 
Supporting the second hypothesis, that RSV infection is a provoking 
event in children with an inherent risk of wheezing, is the observation 
that diminished lung function before bronchiolitis is a risk factor for 
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wheezing afterwards (Young et al., 1995, Martinez et al., 1988). 
Martinez et al. (1988) evaluated 124 children enrolled as newborns into 
the Tuscon Children’s Respiratory Study who had lung function tests 
before any lower respiratory tract illness (LRTI). The risk of wheezing at 
one year of age was 3.7 times higher (95% CI, 0.9 -15.5; p=0.06) 
among infants whose respiratory pre-morbid conductance was in the 
lower third, compared to those whose conductance was in the upper 
two-thirds. Similar findings were described by Young et al. (1995) in a 
prospective study of 253 children. They performed respiratory function
tests (maximum flow at functional residual capacity [VmaxFRC] using 
thoracic compression) at 1, 6 and 12 months of age. In 17 infants who 
had bronchiolitis during the first 2 years of life, a significant trend for the 
baseline VmaxFRC values to be in the lowest tercile was observed at 5 
weeks of age (Young et al., 1995). 
1.3.3.3 Host factors determine RSV illness and 
subsequent RAD
An alternative view of how host responses may account for the 
increased prevalence of RAD following RSV bronchiolitis is that it is 
largely due to the definition of bronchiolitis used. It is postulated that a 
definition of bronchiolitis that specifies wheeze as an important 
diagnostic symptom, as is generally used in North America, selects out 
children with a predisposition to asthma and an increased likelihood of 
subsequent wheezing (Everard, 2006a). The UK and some European 
countries use a definition of bronchiolitis that includes signs of an upper 
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respiratory tract infection (URTI) associated with lower respiratory tract 
obstruction and characterised by the presence of crepitations. In North 
America and other parts of Europe, acute bronchiolitis is used to 
describe an infant presenting with their first wheezing illness associated 
with an URTI. In the UK, a number of the latter infants would have 
previously been described as having ‘wheezy bronchitis’, a term which 
has since been replaced by ‘viral induced wheeze’. The clinical 
progress of these children usually involves increased wheezing in the 
first few years of life which does not persist beyond the first decade, 
similar to that observed in infants with presumed RAD post bronchiolitis 
(Everard, 2006b).
This hypothesis is supported by a prospective cohort study by Elphick 
et al. (2007). The effect of 2 different phenotypes of acute RSV illness 
on subsequent outcomes was evaluated in 56 infants with RSV LRTI 
and 94 controls. The RSV infants were divided into those with 
bronchiolitis (RSVB) characterised by widespread crepitations with or 
without wheeze [n=42] and those with wheeze alone (RSVW) - viral 
associated wheeze [n=14]. At 3 years of age, 37 of the RSV cohort (28 
RSVB, 9 RSVW) and 77 controls were assessed with a respiratory 
questionnaire and skin prick testing (SPT). Children with RSVW were 
significantly more likely to have wheezed most days in association with 
colds odds ratio 42.0 (95% C.I. 3.5 - 501) compared to children with 
RSVB 9.9 (95% C.I. 1.0 -101). There was no significant increase in 
43
allergic sensitisation on SPT in the RSV group as a whole when 
compared to controls. However, within the RSV subgroups, allergic 
sensitisation was more common in the RSVW group. Eight of the 77 
controls (10%), 2/28 (7.1%) of the RSVB and 2/9 (22.2%) of the RSVW 
groups had evidence of allergic sensitisation defined as SPT positive to 
1 or more allergens. The group with RSVW also had increased 
healthcare utilisation compared to the RSVB group defined as visits to 
general practitioners and use of inhaled corticosteroids. These data 
suggest that host factors may determine the pattern of illness 
associated with RSV LRTI and influence the frequency and severity of 
subsequent symptoms. However, due to the small numbers studied in 
the RSV subgroups, caution is required in interpreting these findings. 
1.3.4 Effect of RSV prophylaxis on respiratory 
outcome
If RAD is largely a consequence of RSV infection and not just of an 
inherent susceptibility, it should be possible to minimise it by the acute 
management of the infection or by the use of prophylaxis. Promising 
results have come from studies in rats. Piedimonte et al. (2000) gave 
Palivizumab to rats 24 hours before infecting them with RSV. They 
again measured microvascular permeability using an Evans blue-
labelled tracer followed by infusion of capsaicin 5 days after inoculation 
with RSV. They found that palivizumab suppressed neurogenic 
inflammation in RSV-infected rats to the same level as that found in 
infection-free controls. The authors postulated that by preventing the 
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increased neurogenic inflammatory response at the time of RSV 
infection, it might be possible to avoid the long term RAD. 
A study comparing 13 children who received the prophylactic agent, 
RSV-IVIG, and 26 controls who did not, found that the FEV1/ FVC 
ratios were significantly higher (p=0.02) 7-10 years later in the 
treatment group. There was significantly less atopy (p =0.04) and a 
lower likelihood of ‘asthma attacks’ (p =0.03) (Wenzel et al., 2002). 
These results suggest that it may be possible to reduce the incidence 
of RAD by preventing or ameliorating RSV infection but more data are 
needed to confirm these findings.
1.3.5 Effect of acute therapies on respiratory 
outcome
The immediate benefits of treatments for acute bronchiolitis, apart from 
oxygen and fluids given as necessary, have remained largely 
unproven. However, there has, been interest in the   possibility of 
reducing the burden of post-bronchiolitis RAD by modifying the initial 
infection. Therapies that have been evaluated for their long-term 
respiratory outcome include ribavarin, corticosteroids and leukotriene 
receptor antagon
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1.3.5.1 Ribavarin
Long et al. (1997) conducted a prospective randomised study of 
ribavarin or placebo in 60 infants hospitalised with RSV bronchiolitis, to 
determine its effect on the incidence of lower respiratory tract infection 
and lung function. They found no significant difference between the 
groups in the rates or severity of respiratory tract illness, oxygen 
saturation, spirometry or peak expiratory flow measurements 4-6 years 
after their initial illness.  
In a 7 year prospective follow-up study, Rodriguez et al. (1999) 
evaluated outcome in 35 of 42 patients who had been randomly 
assigned to receive ribavarin or placebo during hospitalisation with 
RSV lower respiratory tract infection. Five were lost to follow-up 
immediately after discharge and 2 died during the initial admission. 
Follow-up included monthly phone calls, at least once yearly hospital 
assessments and lung function once children were 5 years old, 
including a methacholine challenge at 7 years. Over the period of 
study, 4 (17%) of the 24 ribavarin subjects had more than 1 wheezing 
episode compared to 6 (55%) of 11 controls (p=0.04). Nineteen 
patients (13 ribavirin and 6 controls) completed lung function tests; 
seven of the 13 ribavirin patients, but none of the 6 controls had normal 
lung function or just mild abnormalities (p=0.04). On methacholine 
challenge (7 ribavirin, 5 controls) there was a trend towards increased 
reactivity in the controls (p=0.07). The high drop out rate and small 
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numbers included in this study require cautious interpretation of these 
findings.
A prospective study by Edell et al. (2002) also evaluated long-term 
respiratory outcome, in 49 infants treated with ribavarin in the early 
phase of severe bronchiolitis. Infants aged less than 6 months admitted 
with RSV bronchiolitis were randomly assigned to receive conservative 
treatment (bronchodilators, corticosteroids, antacids and feed 
thickeners) or additional treatment with high dose ribavarin. Infants 
were recruited if the onset of symptoms was within 5 days. Forty-five 
infants were followed up for 12 months (24 treated with ribavarin; 21 
controls) with fortnightly telephone calls and clinical examination by a 
respiratory physician as required. Compared with controls the ribavarin 
group had fewer episodes of reactive airway disease (2.7 + 2.3 versus 
6.4 + 4.2 episodes/ patient/ year) which were less severe (0.08 versus 
1.09 episodes of moderate-severe illness / patient/ year). Treatment 
with ribavarin was associated with fewer in-patient days for respiratory 
illness; 6 of 21 patients in the control group were hospitalised for a total 
of 19 days compared to 2 of 24 patients in the ribavarin group for a 
total of 6 days (p<0.05). 
Several factors may account for the differences in findings in the 
studies by Edell et al (2002) compared to those by Long et al (1997) 
and Rodriguez et al (1999). The study by Edell et al (2002) used 
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ribavarin at an earlier stage in the bronchiolitic illness and also used a 
combination of therapies including corticosteroids, which may have 
worked synergistically with ribavarin to produce a more significant 
effect than either therapy alone. Follow up in this study was for a much 
shorter period; 12 months versus 4-6 years/ 7 years. It remains unclear 
therefore, whether ribavarin does indeed have beneficial long-term 
effects on respiratory outcome following bronchiolitis. 
1.3.5.2 Corticosteroids
Both systemic and inhaled corticosteroids have been evaluated for their 
long-term effect on respiratory outcome following bronchiolitis, most 
studies finding no benefit from their use. Studies of the use of inhaled 
corticosteroids have provided inconsistent results; most have found no 
long-term benefit but two Finnish studies did find significant differences 
in RAD between treated groups and controls.
A prospective randomised double blind placebo-controlled trial in 54 
patients given prednisolone for 7 days found no difference between the 
groups in the incidence of transient, persistent or late onset wheeze 
during 5 years of follow-up (van Woensel et al., 2000).  
Cade et al. (2000) conducted a randomised placebo-controlled trial of 
inhaled budesonide (1 mg) given twice daily in 161 hospitalised infants 
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with RSV bronchiolitis and continued for 2 weeks after discharge. They 
found no significant difference in the prevalence of wheezing, General 
Practitioner visits, respiratory-related hospital re-admission rates or 
bronchodilator use between the groups at follow-up 12 months later. 
In a prospective randomised placebo-controlled study by Fox et al. 
(1999) 49 infants hospitalised with viral bronchiolitis were allocated to 
receive 200 micrograms of inhaled budesonide or placebo, twice daily 
for two weeks. The authors achieved full follow-up data of the 49 
infants over 12 months. Twenty-one infants in the budesonide group 
reported symptom episodes compared to 12 in the control group 
(p=0.03). The authors concluded that, in the absence of a 
pharmacological explanation, the less favourable outcome in the 
treatment group was probably a ‘type one error’. This study found no 
evidence that the use of inhaled budesonide reduced post bronchiolitis 
coughing and wheezing. A randomised controlled study by Wong et al. 
(2000) similarly found no benefit from the 3 month use of inhaled 
fluticasone during 12 months of follow-up.
Two studies showing a benefit from inhaled steroids are reported by 
Kajosaari et al. (2000) and Reijonen et al. (1996). The first was an 
open study of 117 hospitalised infants with RSV bronchiolitis who were 
randomised to 3 possible groups of treatment - Group I: symptomatic 
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treatment; Group II: 500 micrograms of nebulised budesonide three 
times a day for 7 days; Group III: 500 micrograms of nebulised 
budesonide twice daily for 8 weeks. Both treatment groups also 
received symptomatic treatment. Two-year follow-up was achieved in 
109 infants. At 2 years, 14 of 38 infants (37%) who received 
symptomatic treatment alone were receiving asthma therapy compared 
with 7 of 39 (18%) in group II (p=0.006) and 4 out of 32 (12%) in group 
III (p=0.01). Similar results are reported by Reijonen et al. (1996) with 
the use of budesonide 500 micrograms twice daily for 8 weeks. 
Most studies evaluating the use of either systemic or inhaled 
corticosteroids have found no long-term benefit. Inconsistencies in the 
findings may reflect heterogeneity of the study populations and 
differences in study methods. There is currently insufficient evidence to 
support the use of corticosteroids for prevention of RAD post 
bronchiolitis.
1.3.5.3 Leukotriene receptor antagonists
The association of RSV infection with an increased production of 
cysteinyl leukotrienes (Piedimonte et al., 2005) has prompted 
investigation into the possibility of leukotriene receptor antagonist use 
to reduce the incidence of later reactive airway disease. Bisgaard and 
Study Group on Montelukast and Respiratory Syncytial Virus (2003) 
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conducted a double blind randomised trial of montelukast or placebo in 
130 infants aged 3 - 36 months with RSV infection needing hospital 
admission. Montelukast was started within 7 days of the onset of 
symptoms and given for 28 days. Follow-up data were available for 116 
infants at 28 days after starting treatment and for 87 infants at 56 days. 
Those treated with montelukast had significantly more symptom-free 
days compared to controls (6 / 28 [22%] versus 1 / 28 [4%] days, 
p=0.015), significantly less cough (p=0.04) and significantly longer 
periods between respiratory exacerbations (p= 0.04) for the 4 week 
duration of treatment. There were no significant differences in outcome 
at the later follow-up at 56 days. These findings are promising even 
though the benefit found at 28 days was no longer apparent at 8 
weeks. More studies are needed to evaluate the long-term effects of 
leukotriene receptor antagonists further.  The potential benefit of 
leukotriene receptor antagonists used in this way deserves further 
evaluation. 
1.3.6 Respiratory outcome after mechanical 
ventilation for bronchiolitis
There is surprisingly little evidence to suggest that bronchiolitis severe 
enough to need ventilation is more likely than mild bronchiolitis to be 
associated with respiratory sequelae. Outcomes in ventilated and non-
ventilated groups have rarely been compared. In one uncontrolled 
prospective study of 29 children with bronchiolitis, Hall et al. (1984) 
found that the 4 infants needing ventilation all had recurrent lower 
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respiratory tract illness over 8 years of follow-up, compared to 9 (26%) 
of the 25 non-ventilated infants . Other measures of illness severity, 
such as apnoea, duration of oxygen requirement and length of hospital 
stay, were not associated with an increased risk of later lower 
respiratory tract illness. The small sample size and lack of controls limit 
the significance of these findings. 
Priftis et al. (1990) retrospectively evaluated 19 children who had 
needed mechanical ventilation for severe bronchiolitis. Two patients 
had died at the time of their bronchiolitis and one later from spinal 
muscular atrophy. The median age of survivors at follow-up was 4.8 
years (range 1.1 - 10 years). Parents completed questionnaires and 
General Practitioners provided relevant medical information. Nine 
(56%) of the 16 surviving children had wheezing after discharge and 6 
(38%) had been diagnosed with asthma. The authors comment that 
these rates are similar to those reported in non-ventilated populations. 
As in the study by Hall et al. (1984), the small numbers and lack of 
controls severely limit the strength of evidence about the effect of 
ventilation during bronchiolitis on the rates of later wheezing. 
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1.3.7 Neurological outcome after mechanical 
ventilation for bronchiolitis
Adverse neurological outcome following bronchiolitis is rarely reported 
in the literature-; only 2 uncontrolled studies have been identified which 
provide limited data on this outcome measure. 
Bray and Morrell (1982) conducted a retrospective uncontrolled study 
of 58 children who had survived after mechanical ventilation for a 
variety of conditions, including bronchiolitis. Between 1971 and 1978, 
132 children were ventilated in the paediatric intensive care unit in 
Newcastle, UK; 66 (50% of the cohort) survived to discharge from 
hospital but 8 died later. The 58 long-term survivors were traced and 48 
were examined for evidence of auditory, visual, behavioural, 
developmental and central nervous system abnormalities; data were 
obtained through postal contact or via general practitioners for the 10 
children not attending for examination. The ages of children at 
ventilation ranged from <1 day to 7 years and at follow up was 1 year to 
11 years. Seven percent of the cohort was found to have definite 
neurological or learning disability and a further 14% had equivocal 
scores on the Denver Developmental Screening Test (DDST). No 
neurological or intellectual impairment was found in 79% of the cohort. 
Thirteen of the 58 children had been ventilated for respiratory 
problems, which included bronchiolitis in an unspecified number. Eight 
of these 13 children had no apparent neurological or intellectual 
impairment at follow up; of the five found to have abnormalities, three 
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had been ventilated for bronchiolitis; one for apnoeic attacks and one 
for croup. Two of the three children ventilated for bronchiolitis later had 
febrile seizures but had no disability at follow up; the third child had 
spastic quadriplegia, epilepsy, visual impairment, behaviour problems 
and an abnormal DDST score (reported to correlate with IQ < 70). The 
authors concluded that abnormalities found in the 4 most severely 
disabled children resulted from the presenting illness or previous 
events rather than from their ventilation therapy- in support of this 
assertion they cited the example of a child with severe disability 
following bronchiolitis who at presentation had a capillary blood pH of 
6.96 and pCO2 of 20 Kpa.
The second study (Wren et al., 1982) is of 9 infants admitted to 
intensive care in a tertiary centre in Dublin during the 12 months of 
1981. Six infants were intubated, of whom 5 were mechanically 
ventilated and one received CPAP via endotracheal tube. One with 
Pierre Robin sequence required a tracheostomy and was then able to 
breathe spontaneously; two were managed with nasal CPAP alone. 
One child who suffered a cardiac arrest was later found to have 
spasticity and neurodevelopmental delay, however; the child had had 
episodes of hypoglycaemia and twitching in the neonatal period which 
adds uncertainty as to the timing of the neurological injury. 
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The limited evidence from these 2 studies suggests that neurological 
injury may occur in severe cases of bronchiolitis that are associated 
with cardio-respiratory failure.  
1.4 Negative Pressure Ventilation
1.4.1 History of Negative Pressure Ventilation
Negative pressure ventilation was first described in the early 1800s but 
was not widely used until 1928 when Drinker and Shaw developed a 
device that was found to be clinically useful (Drinker and Shaw, 1929). 
Over the next 30 years negative pressure ventilators (so-called ‘iron 
lungs’) were widely and successfully used to give respiratory support to 
patients with paralytic poliomyelitis (Thomson, 1997). Their popularity 
waned towards the end of the 1950s with the development of positive 
pressure ventilation, delivered through a tracheostomy or endotracheal 
tube, which was found to be more efficient. At the peak of a polio 
epidemic in 1952, one Copenhagen hospital observed a fall in mortality 
among polio patients from 87% to 42% in just 3 months following the 
introduction of positive pressure ventilation (Lassen, 1953). Between 
1934-1944 the Blegdam hospital in Copenhagen treated 76 cases of 
polio-associated respiratory failure with NPV of whom 61 (80%) died. 
Between 1948 and 1950 the authors evaluated the use of a 
tracheostomy to manage upper airway obstruction in association with 
NPV and found the combination of therapies was associated with a 
worse outcome than with NPV alone as all 14 patients who had both 
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therapies died. In the first month of the 1952 polio epidemic 27 out of 
31 cases (87%) managed with NPV died. Over the next 2 months bag 
ventilation via tracheostomy was used instead and was associated with 
100 deaths in 250 patients (40% mortality). Negative pressure 
ventilation continued to be used by some investigators during the 
1960’s -70’s and was found to be effective in neonatal RDS (Chernick 
and Vidyasagar, 1972, Outerbridge et al., 1972, Fanaroff et al., 1973). 
From the 1970’s onwards it was no longer used routinely, having been 
largely replaced by positive pressure ventilation.
Non-invasive ventilation techniques have recently enjoyed renewed 
interest due to increased concern about the problems associated with 
invasive positive pressure ventilation, including the recognition of 
ventilator-induced lung injury (Slutsky, 1999). Both non-invasive 
positive pressure and negative pressure ventilation have been the 
focus of renewed interest. The original negative pressure ventilators 
had a number of problems; Drinker and Shaw’s ‘iron-lung’ was bulky 
and cumbersome with limited access to patients, there were difficulties 
maintaining a thermal environment and a lack of protection of the upper 
airway meant its use was associated with upper airway obstruction in 
some patients (Corrado et al., 1996, Thomson, 1997). Problems with 
the neck seal included pressure sores and impaired jugular venous 
drainage. The concerns about the latter were heightened following a 
study by (Vert et al., 1973), which suggested a possible association of 
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post-haemorrhagic hydrocephalus with the use of a similar neck seal in 
children treated with the ‘Gregory Box’, a non-invasive continuous 
positive pressure device. The authors identified 6 infants with 
hydrocephalus from a cohort of 61 (50 survivors), who had been 
treated with CPAP for respiratory distress syndrome. In the 6 infants 
with hydrocephalus (diagnosed by air encephalography) superior 
sagittal sinus pressures were measured using a manometer connected 
to a needle inserted directly into the sinus. The authors found the sinus 
pressure was consistently increased by 3.6 - 8.6cm H2O following the 
application of a loosely tied collar. In contrast the administration of 
10cm H2O of CPAP via a nasotracheal tube did not increase the sinus 
pressure by more than 1cm H2O in the 3 cases evaluated. The authors 
concluded that the collar was probably causing a ‘garrotting effect’, 
resulting in raised intracranial pressure and hydrocephalus (Vert et al., 
1973). 
Technical improvements in recent years have overcome most of the 
problems associated with older versions of the negative pressure 
ventilator. A recently modified negative pressure ventilator was used at 
the North Staffordshire Hospital between 1993 and 1999 to treat 
children with bronchiolitis-associated respiratory failure. The device is 
described in detail in a report by Samuels and Southall (1989).
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Figure 3: Picture of an infant in a negative pressure tank receiving nasal 
cannula oxygen
The depicted negative pressure tank is available in three sizes: 
neonatal (babies weighing < 4 kg), infant (3–8 kg) and toddler (5–20 
kg). The baby’s head protrudes through an arch in the top end of the 
chamber. The neck seal comprises a rectangular sheet of latex in 
which is cut a hole about two-thirds the cross-sectional area of the 
baby’s neck; the elasticity of the latex allows a tight seal to be 
maintained without circumferential pressure. The various portholes 
allow access to the baby and provide entrances for monitoring leads 
and lines whilst maintaining sub atmospheric pressure within the 
chamber. Sub atmospheric pressure is generated within the chamber 
by a suction unit, which has a twin valve system allowing the provision 
of intermittent negative extrathoracic pressure (INEP) in addition to 
CNEP. The circulation of warm air (servo-controlled to the ambient 
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temperature) within the chamber allows the body temperature of small 
babies to be adequately maintained. 
1.4.2 Principles and technique of Negative 
Pressure Ventilation
Negative pressure devices assist ventilation by applying sub 
atmospheric pressure around the thorax and abdomen causing the 
chest wall to expand and the lungs to inflate. Several devices are 
available and are either tank ventilators, which enclose patients up to 
their necks, or cuirass / jacket ventilators, which are applied to the 
chest and abdomen only. The cuirass ventilators are not available in a 
size small enough to use in small baby and so the tank ventilators are 
the only realistic mode of delivery of negative pressure support for 
babies. The modes of negative pressure that can be delivered are: 
1. Cyclical negative pressure - negative pressure applied only 
during inspiration; in the expiratory phase the pressure is the 
same as atmospheric. 
2. Continuous negative extrathoracic pressure (CNEP) -
negative pressure applied continuously throughout the 
respiratory cycle 
3. Intermittent negative extrathoracic pressure (INEP) / CNEP -
intermittent cycles of increased negative pressure superimposed 
on a background of CNEP
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4. Negative / positive pressure - a combination of negative 
pressure during inspiration and positive pressure during 
expiration.   
1.4.3 Physiological effects of Negative Pressure 
Ventilation
Gappa et al. (1994) studied the effect of CNEP on passive respiratory 
mechanics and respiratory timing in 18 preterm infants recovering from 
neonatal respiratory distress syndrome. The aim of the study was to 
assess the physiological effects of CNEP in this population. Twenty 
infants were recruited and lung function testing was completed in 18 
including compliance measured using the multiple occlusion technique 
(MOT), compliance and resistance measured by the single breath 
technique (SBT) and airflow measured with a pneumotachograph. 
Measurements were taken in atmospheric pressure and following the 
application of -6 cm H2O of CNEP. A significant decrease in the 
respiratory rate (from 63.6 +/- 10.0 to 49.3 +/- 9.1 breaths / minute, p< 
0.0001) was observed in all but 1 infant (n=18) during the application of 
CNEP. This reduction in respiratory rate was due to a 35% increase in 
the mean expiratory time (0.57 second pre CNEP, 0.77 second post 
CNEP, p<0.0001) which the authors attribute to increased tonic vagal 
activity caused by stimulation of stretch receptors. The mean 
compliance (Crs) measured with the single breath technique, increased 
from 23.2 (SD 5.1) mL.kPa-1 in atmospheric pressure to 27.1 (SD 4.7) 
mL.kPa-1, (p=0.006) following the application of CNEP. The compliance 
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(Crs) measured using the multiple occlusion technique did not change 
significantly. Further analysis showed that compliance was significantly 
increased in babies where the baseline measurement was low but not 
in babies whose baseline values were normal. There was no significant 
change in respiratory system resistance and minimal change in tidal 
volumes. The authors hypothesized that the application of CNEP 
results in the ventilation of previously collapsed lung and that a 
redistribution of lung volume from over distended units to recruited 
units improves compliance. They suggest the benefits are thereby 
achieved without a significant overall increase in lung volume. 
Essa et al. (1994) performed a comparative study of the effects of 
CNEP and positive end expiratory pressure (PEEP) in anaesthetised 
piglets receiving positive pressure ventilation after saline lung lavage 
was used to induce lung injury. Thirteen piglets were randomly 
assigned to receive CNEP or PEEP which was increased at 15 minute 
intervals to 3, 6, 9 and then 12 cm H2O (CNEP: -3,- 6, -9 and -12 cm 
H2O). The peak inspiratory pressure (PIP) was adjusted to maintain a 
constant tidal volume and significantly higher values were required in 
the piglets receiving PEEP. No significant difference was observed in 
the effects of PEEP and CNEP on lung compliance, resistance, arterial 
oxygen pressure or cardiac output. The only significant difference 
observed was a lower end-expiratory lung volume (EELV) in the PEEP 
piglets at pressures of 3, 6 and 9 cm H2O. The authors account for the 
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lower EELV in the piglets that received PEEP as probably a result of 
more severe lung injury in this group, evidenced by the trend towards 
lower compliance and higher resistance prior to commencing PEEP. An 
alternative explanation was a loss of volume in the PEEP piglets due to 
brief disconnection from the ventilator to allow measurement of EELV 
whereas the CNEP group continued to receive sub-atmospheric 
pressure during this procedure. They concluded that CNEP and PEEP 
are physiologically equivalent in an animal model; however, their data 
suggests that CNEP may have a beneficial effect of reducing the need 
for higher PIP when used in combination with positive pressure 
ventilation compared to PEEP.
The haemodynamic effects of negative pressure ventilation are 
dependent on the type of device used. Venous return to the heart is 
improved by the use of cuirass devices, which lower intrathoracic 
pressure relative to the rest of the body. Tank ventilators that enclose 
the whole body up to the neck do not generate a pressure difference 
between the thorax and lower parts of the body and thus the resulting 
effect on cardiac output is no different from that of positive pressure 
ventilators. The haemodynamic effects of the cuirass ventilators make 
them particularly useful in the management of children with low cardiac 
output following cardiac surgery. 
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Shekerdemian et al. (1997) conducted a prospective study to compare 
the effects of IPPV and NPV in 9 patients immediately after a Fontan 
procedure and in 9 patients undergoing cardiac catheterisation 
between 5 months and 15 years after Fontan-like procedures. Low 
cardiac output is a recognised complication of the immediate post 
operative recovery following a Fontan procedure but has also been 
reported to occur in some patients in the late convalescent period 
(Shekerdemian et al., 1997). All patients were intubated and ventilated 
with IPPV and received negative pressure ventilation for brief periods 
using the Hayek external high-frequency oscillator (cuirass type NPV). 
Pulmonary blood flow was measured using the Flick method during 
IPPV and again after starting NPV. In 6 patients further measurements 
were made after IPPV was reinstituted and after a second extended 
period (30- 45 minutes) of NPV. Pulmonary blood flow increased during 
the first period of NPV from 2.3±1.2 to 3.3± 1.9 L·min-1·m-2 (p=0.01) in 
acute patients and from 2.6±1.0 to 3.7±1.1 L·min-1·m-2 (p=0.01) in 
convalescent patients. Mean pulmonary blood flow for both acute and 
convalescent patients increased from 2.4±1.1 to 3.5±1.5 L·min-1·m-2
(p=0.003), with a mean increase of 42 ± 24%. The values reversed 
towards baseline after resuming IPPV. Following a second extended 
period of NPV in 6 patients the mean pulmonary blood flow increased 
by 53.6 ±17% (from 2.5±0.7to 3.8±1.2 L·min-1·m-2; p=0.01). During NPV 
there was no significant change in heart rate and the stroke volume for 
the group as a whole increased by 44% from 24.9±13 to 36.5±22 mL/m2  
(p=0.001). This study demonstrates that cuirass type NPV can 
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significantly improve pulmonary blood flow in patients following a 
Fontan procedure by encouraging venous return from the lower body 
thereby increasing stroke volume.
The same authors evaluated the haemodynamic effects of NPV in 23 
children in the early post operative period following tetralogy of Fallot 
repair, using a similar study protocol (Shekerdemian et al., 1999). They 
were able to categorise the patients further according to the presence 
or absence of restrictive right ventriclular physiology, defined as 
antegrade diastolic pulmonary arterial flow present throughout the 
respiratory cycle during echocardiography. They found that, in the 
group as a whole, the use of NPV resulted in an increase in pulmonary 
blood flow of 39% after a 15-minute period of NPV and of 67% after an 
extended period of 45 minutes. They noted, however, that the effect 
was most marked in those with restrictive right ventricular physiology 
(n=8), who had an 84% increase in pulmonary blood flow during the 
extended period of NPV compared to a 50% increase in the non-
restrictive group (n=15).  
Palmer et al. (1995) studied the effects of positive and negative 
pressure on cerebral blood flow in 29 newborn infants; 12 receiving 
CNEP and 17 receiving IPPV, for either respiratory distress syndrome 
(n=25), bronchopulmonary dysplasia (n=3) or pneumonia (n=1). All the 
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babies were studied during the recovery phase of their illness, before 
weaning from respiratory support. Near-infrared spectroscopy (NIRS) 
was used to measure cerebral blood volume (CBV) for about 2 minutes 
before and after a change in ventilation. NIRS detects changes in the 
oxygenated and deoxygenated haemoglobin (HbO2 and Hb) 
concentrations using light absorption, allowing CBV to be calculated 
from the total haemoglobin (sum of HbO2 and Hb). The sequence of 
ventilatory changes in the IPPV group was from IPPV to endotracheal 
CPAP, and then back to IPPV; in the CNEP group it was from CNEP to 
no ventilatory support, then back to CNEP. The study design and 
results are summarised diagrammatically in Figure 4. The authors 
found a median increase in cerebral blood volume (CBV) of 0.055 ml/ 
100 ml brain (95% C.I.  0.010 -0.115) on switching from IPPV to ET 
CPAP and a corresponding decrease of 0.045 ml/ 100 ml brain (95% 
CI. 0.010 -0.100) on switching back again. The changes in CBV were 
not accounted for by changes in arterial paCO2 in the 8 studies in which 
it was monitored. Stopping CNEP was associated with a median 
increase in CBV of 0.2 ml/ 100 ml brain (95% C.I. 0.012 - 0.316) whilst 
restarting it brought a reduction in median CBV of 0.14 ml/ 100 ml brain 
(95% C.I. 0.035 - 0.280). Both ventilatory modes resulted in a reduction 
in CBV but CNEP was associated with a reduction in both HbO2 and 
Hb whilst IPPV was associated with a reduction in HbO2 and an 
increase in Hb. The authors suggest that CNEP reduces CBV by an 
overall effect of increased cerebral venous drainage. Conversely, IPPV 
would be expected to "#(&%0+% CBV by impairing venous drainage, 
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therefore the &%1*(%1 CBV observed in the IPPV infants was 
postulated to be the result of a greater effect of IPPV in reducing 
cerebral arterial blood flow than in reducing venous drainage (Palmer 
et al., 1995).  
Figure 4: Diagrammatic representation of study design and results (Palmer et 
al., 1995)  
IPPV group (n=17)
IPPV → ET CPAP
Median CBV ↑ 0.06%
→ IPPV
Median CBV ↓ 0.05%
(HbO2  ↓, Hb ↑ )
CNEP group (n=12)
CNEP → No ventilatory support
Median CBV ↑ 0.2%
→ CNEP
Median CBV ↓ 0.14%
(HbO2  ↓, Hb ↓ )
Raine et al., (1994) examined cerebral blood flow velocity in a pilot 
study of 8 preterm babies receiving IPPV and CNEP for RDS. Using 
the Doppler technique they found no change in the middle cerebral 
artery flow after stopping CNEP and maintaining equivalent settings of 
PEEP or on switching back to CNEP. Removal of the neck seal also 
had no effect on middle cerebral artery flow suggesting it did not 
obstruct venous return (Raine et al., 1994). In a study of 10 preterm 
babies receiving CNEP for RDS, Palmer et al. (1994) similarly found 
that removal of the latex neck seal caused no significant change in 
cerebral blood volume measured by near- infrared spectroscopy. There 
was, however, an increase in cerebral volume when CNEP was 
stopped, consistent with the results of the same investigators’ later 
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study (described above), which found that CNEP enhanced cerebral 
venous drainage in the babies studied (Palmer et al., 1995). Tables 6 
and 7 are summaries of the studies reporting outcome or physiological 
effects of CNEP.
1.4.4 Outcome following Negative Pressure 
Ventilation
1.4.4.1 Respiratory distress syndrome (short-term 
outcome)
Fanaroff et al. (1973) conducted the first controlled trial of CNEP 
versus oxygen therapy alone for the management of neonatal 
respiratory distress syndrome (RDS). Preterm infants (< 37 weeks 
gestational age) with clinical, radiological and blood gas findings 
consistent with RDS were recruited if they were unable to maintain 
arterial oxygen tension ≥ 60 mm Hg despite an inspired oxygen 
concentration (FiO2) of 70%. Fifteen infants were randomly assigned to 
receive CNEP and 14 received oxygen therapy alone (control group). 
Accepted criteria for the initiation of mechanical ventilation at the time 
of the study were used to define ‘study failures’ i.e. inability to maintain 
PaO2 ≥ 50 mm Hg despite FiO2 of 100%, or the onset of apnoea. Study 
failure occurred in 5 of 15 infants (33%) treated with CNEP compared 
with 12 of 14 infants (86%) in the control group; p<0.05. The 5 study 
failures in the CNEP group required intubation and IPPV and 11 (79%) 
of the 12 control failures required intubation (3 CPAP, 8 IPPV). One of 
the control failures was successfully managed with CNEP alone. The 
mean duration spent needing FiO2 ≥ 70% was significantly shorter in 
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the CNEP group than in controls (41.5 hrs [SD 38.3] compared to 107.4 
hours [SD 85.6]; p<0.02). There was no significant difference in 
mortality between the groups (4 died in the CNEP group and 6 died in 
the control group). This study showed that CNEP improved 
oxygenation and significantly reduced duration of exposure to high 
oxygen concentration in preterm infants with RDS; its use was also 
associated with a significantly lower rate of intubation.
A later study by Alexander et al. (1979) compared the use of CNEP 
and nasal CPAP in preterm infants with RDS. Thirty-six preterm infants 
with clinical, radiological and blood gas evidence of RDS were recruited 
into a comparative study of CNEP versus nasal CPAP. Eighteen infants
were randomised to each group and treated with pressures of 6 to 8 cm 
H2O (CPAP) or -6 to -8 cm H2O (CNEP) when FiO2 > 45% was needed 
to maintain PaO2 between 50 -80 mm Hg. Both methods were effective 
in improving oxygenation with no significant differences between 
groups in the PaO2 at 30 minutes or 2 hours of treatment [CNEP 
Group: baseline PaO2 52 mm Hg (SD 3.6); at 30 mins 91 mm Hg (SD 
8.4), CPAP: baseline PaO2 50 mm Hg (SD 2.9) at 30 mins 74 mm Hg 
(SD 6.5). The mean FiO2 was not significantly different between the 
groups during the first 24 hours of treatment and decreased from about 
60% to 40% in both groups. The number of hours infants received FiO2
> 40% was also not significantly different between the groups. Four 
patients in the CNEP group and 7 in the CPAP group showed 
progressive deterioration requiring intubation and IPPV. Infants in the 
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CPAP group who ‘failed treatment’ deteriorated faster and then 
required assisted ventilation for longer than the failures from the CNEP 
group. The total time that respiratory support was required in the two 
groups was not significantly different. The authors found that both 
treatment methods improved oxygenation in preterm infants with RDS. 
They observed, however, that nasal CPAP was easier to administer 
and allowed easier access to patients but noted the smaller overall 
increase in PaO2 in the CPAP group, probably because the intended 
pressures could not be maintained when babies cried or opened their 
mouths. 
An abstract report by Monin et al. (1976) describes the findings of a 
controlled study in which intermittent negative pressure (NPV) 
ventilation was compared with intermittent positive pressure (IPPV) in 
115 babies with RDS (57 received NPV and 58 IPPV). Birth weight, 
gestational age and illness severity were reported to be comparable in 
the 2 groups although data are not provided. The duration of oxygen 
therapy was the same in both groups and there was no difference in 
the incidence of patent ductus arteriosus, intracranial haemorrhage or 
mortality. A significantly lower incidence of pneumothoraces (17% 
versus 36%; p< 0.05) and radiologically diagnosed broncho-pulmonary 
dysplasia (5% versus 24%; p< 0.01) were reported in the babies 
treated with negative pressure. 
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The advances made with non-invasive/ invasive positive pressure 
ventilation were such that by the end of the 1970s, negative pressure 
ventilation was largely superseded. However, following technical 
improvements to negative pressure ventilators some investigators have 
reassessed this mode of ventilation, particularly because of concerns 
about the increasing incidence of neonatal chronic lung disease and 
the possible lower incidence of bronchopulmonary dysplasia in babies 
treated with NPV compared to IPPV (Monin et al., 1976). It is plausible 
that negative pressure ventilators have a beneficial effect on chronic 
lung disease because they avoid some of the negative effects of 
intubation like interruption to physiological mechanisms such as the 
‘mucociliary escalator’.
In 1996, a two-centre randomised controlled trial evaluated the use of 
CNEP in 244 preterm infants with respiratory distress syndrome 
(Samuels et al., 1996). Patients were randomised to receive standard 
neonatal care or standard care plus CNEP at 4 hours of age. The 
primary outcome measure was a clinical score, calculated at 56 days, 
which included measures for mortality, respiratory outcome and the 
presence of other neonatal complications such as cranial ultrasound 
abnormalities, patent ductus arteriosus and necrotising enterocolitis. 
Individual components of the primary outcome score were evaluated as 
secondary outcome measures. The primary outcome score showed an 
overall benefit of CNEP. The mean duration of oxygen therapy was 
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significantly lower in the infants treated with CNEP (18.3 days versus 
33.6 days, mean difference -15.3 days 95% C.I. -30.4 to -0.2) with 
significantly fewer premature infants (< 36 weeks) requiring 
supplementary oxygen at 36 weeks post-conceptional age (11 [13%] 
versus 24 [26%], mean difference -13%, 95% C.I. -24 to -2). Five 
percent fewer infants in the CNEP group required intubation (95% C.I. 
0-10). There were 28 deaths (23%) in the CNEP group and 22 deaths 
(18%) in the standard group; mean difference 5% (95% C.I. -3 to 14). 
Cranial ultrasound abnormalities were identified in 15 babies (12%) in 
the CNEP group and in 10 babies (8%) in the standard group; mean 
difference 4% (95% C.I. -4 to 12). The higher number of deaths and 
cranial ultrasound abnormalities in the CNEP group led to public 
concern about its safety; this was in spite of the lack of significance in 
the difference between the groups in both measures. The use of a non-
validated clinical score as the primary outcome measure in the study 
has been criticised although the authors argue that it provided an 
ethical strategy to terminate the trial early if the use of CNEP was 
associated with significant benefit or harm. A significant limitation of the 
study, acknowledged by the authors, was the lack of planned long-term 
neurodevelopmental follow-up. 
1.4.4.2 Respiratory distress syndrome (long-term 
outcome)
Infants enrolled in the randomised trial of the use of CNEP for neonatal 
RDS (Samuels et al., 1996) have been re-evaluated in a study of long-
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term outcome, 9-15 years after their treatment (Telford et al., 2006, 
Telford et al., 2007). In the original trial, 259 children were randomised 
to receive standard care or standard care + CNEP; following exclusions 
244 children remained paired at the end of the study. Telford and 
colleagues were able to trace 198 of the 205 survivors of the original 
cohort (54 having died in the neonatal period or later) and 133 (65% of 
the survivors) consented to participate in the follow-up study (Telford et 
al., 2006). None of the follow-up authors had been involved in the 
original trial and all were blinded to the subjects’ original treatment. The 
primary outcome measure was death or severe disability and data to 
evaluate this were available for 187 of the original 259 children, 
including 65 of the original 122 pairs. There was no difference in death 
or severe disability between the CNEP group and controls in either 
paired (odds ratio for CNEP group 1.0; 95% C.I. 0.41 to 2.41) or 
unpaired analysis (odds ratio for CNEP group 1.05; 95% C.I. 0.54 to 
2.06). Secondary outcome measures assessed included behaviour, 
cognitive and neuropsychological function and health related quality of 
life. There was no significant difference in full IQ between the two 
groups - however mean performance IQ, language and visuospatial 
performance subscores of the neuropsychological tests were all 
significantly higher in the CNEP group whilst behaviour scores and 
health related quality of life assessed using the Health Utilities Index 
were not significantly different between the groups. The findings of this 
study suggest that the use of CNEP in treating neonatal RDS is not 
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associated with an increased risk of later disability or psychological 
problems.
The same survivor group was assessed for the effects of CNEP on 
respiratory outcome in late childhood (Telford et al., 2007). In the 
original trial the use of CNEP was associated with a shorter duration of 
oxygen therapy and a significantly lower incidence of chronic lung 
disease, which might lead one to speculate as to whether it could have 
beneficial effects persisting into late childhood (Samuels et al., 1996). 
Telford et al. (2007) assessed mean airway resistance (measured with 
an interrupter device), spirometric measurements and the prevalence 
of respiratory symptoms as secondary outcome measures in the 133 
survivors who consented to follow-up. No significant difference was 
found in any of these measures between the group treated with CNEP 
and controls managed with standard care. 
1.4.4.3 Pulmonary hypertension
Cvetnic et al. (1990) reported an uncontrolled trial in which CNEP was 
used as an adjunct to IPPV for 50 babies with RDS, pulmonary 
interstitial emphysema (PIE) or pulmonary hypertension. Those with 
pulmonary hypertension were sub-divided according to whether they 
had meconium aspiration syndrome (MAS) or some other cause (non-
MAS) making four groups for evaluation. Pulmonary hypertension was 
diagnosed by demonstrating right to left shunting at atrial level using 
echocardiography to visualise peripherally-injected saline shunting 
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across the foramen ovale; and by the finding of a difference in PaO2 > 
20 mm Hg in umbilical arterial blood compared to a simultaneously 
drawn radial artery sample. The response to CNEP was a rapid 
improvement in oxygenation in all groups, most marked in babies with 
non-MAS pulmonary hypertension whose mean PaO2 was 30 mm Hg 
before CNEP, rising to 140 mm Hg within 30 minutes of starting it. The 
authors found CNEP to be more effective than the equivalent amount 
of PEEP in improving PaO2 and were able to lower peak airway 
pressures in all groups to less than 50% of pre CNEP values by 12 
hours. Ten infants had intraventricular haemorrhage (IVH) before 
starting CNEP and 4 infants in the PIE group had significant extension 
of their IVH while receiving CNEP (p<0.01). In view or this, the authors 
cautioned that perhaps CNEP should not be used in babies at highest 
risk of IVH - but they also noted that the incidence of IVH after 
treatment with CNEP was no different from that in other babies in their 
unit needing maximal ventilatory support. 
In a later prospective randomised crossover study of 30 babies, 
Cvetnic and co-workers evaluated the use of CNEP as rescue 
treatment for severe hypoxaemia (Cvetnic et al., 1992). The study 
included 23 babies who met the criteria for extracorporeal membrane 
oxygenation (ECMO). Babies of 30-42 weeks gestation were recruited 
to the study if they needed intubation and PPV for hypoxaemia and if 
arterial PaO2 remained < 45 mm Hg for at least 2 hours despite 100% 
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oxygen and minimum mean airway pressures of 12-15 cm H2O 
(minimum values varied dependant on birth weight). The diagnoses of 
babies recruited included RDS, pneumonia and pulmonary 
hypertension due to meconium aspiration (MAS) or other causes (non-
MAS). Thirty babies were randomly assigned to either CNEP or PEEP 
and were crossed over to the other mode of support if PaO2 remained 
< 45 mm Hg after at least 2 hours of the initial treatment or an air leak 
developed. CNEP was substituted for the numerically equivalent 
amounts of PEEP whilst maintaining positive pressure ventilation in 
both groups of babies. Fifteen babies were initially randomised to 
receive PPV + PEEP and 15 to PPV + CNEP; mean time of 
randomisation was 23.5 +/- 19.1 hours. Two babies (13%) in the CNEP 
group crossed over to receive PEEP and 11 babies (73%) crossed over 
from PEEP to CNEP (p=0.003). Of five babies who died, 4 were 
originally assigned to receive PEEP; 2 of these died within 12 hours of 
randomisation without undergoing crossover, the other 2 babies died 
after crossover to CNEP. In the subset of 23 babies who met criteria for 
ECMO at the time of initial randomisation (11 PEEP, 12 CNEP), 1 
(8.3%) crossed over from CNEP to PEEP, 9 (81.8%) from PEEP to 
CNEP and just 3 (13.3%) babies were referred for ECMO. Thirty-six 
hours into the trial, only 5 of the original 30 babies remained in the 
PEEP group compared to 20 in the CNEP group. CNEP was 
associated with a significantly higher increase in PaO2 (69 + 17 mm Hg 
versus 48 + 27 mm Hg, p < 0.05) and in the arteriolar-alveolar (a/A) 
ratio of oxygen (0.098 + 0.070 versus 0.078 + 0.049, p < 0.05) 30 
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minutes after randomisation compared to PEEP. PaO2 and a/A ratio of 
O2 also increased significantly in those who crossed over from PEEP to 
CNEP (37 + 5 mm Hg and 0.058 + 0.009 versus 60 + 12 mm Hg and 
0.154 + 0.096, p < 0.05). There was no significant increase in PaO2 or 
a/A ratio following crossover from CNEP to PEEP (n=2). This study 
confirmed the groups earlier finding (Cvetnic et al., 1990) that CNEP 
was more effective than equivalent amounts of PEEP at improving 
oxygenation. It also showed that CNEP used as an adjunct to IMV was 
effective in severely hypoxic neonates and reduced the need for ECMO 
in this population. The authors surmised that CNEP may be more 
effective than equivalent amounts of PEEP by permitting more uniform 
alveolar recruitment. 
1.4.4.4 Post cardiac surgery
The haemodynamic benefits of cuirass-type NPV after cardiac surgery 
have been reported in studies by Shekerdemian et al. (1997) and 
Shekerdemian et al. (1999). NPV has also been used as respiratory 
support in patients with phrenic nerve palsy after cardiac surgery. 
Raine et al. (1992) conducted an uncontrolled trial in 14 patients aged 
1 week to 30 months with phrenic nerve palsy (bilateral in 4). One 
patient with bilateral nerve palsy and 4 with unilateral palsy had 
undergone diaphragmatic plication. All patients needed supplementary 
oxygen and 10 were receiving positive pressure ventilation before 
starting negative pressure ventilation. NPV was introduced in 
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spontaneously breathing patients with a persistent or increasing 
oxygen requirement and respiratory distress, and gradually substituted 
in those already having PPV. After initiation of NPV, 3 patients required 
diaphragmatic plication or re-plication and 3 died from non-respiratory 
causes including candida sepsis, intro-operatively during pulmonary 
artery banding and following a cardiac arrhythmia. Eleven patients 
survived after receiving NPV for 3 -241 days. At follow-up 2 - 22 
months later, all surviving patients were reported to have ‘normal 
respiratory function’ although no details are provided. The authors 
suggest that the use of NPV may have avoided plication or re-plication 
in 11 patients. This study suggests that NPV can usefully support 
patients with phrenic nerve palsy but a controlled trial is needed to test 
whether it has clear benefits over positive pressure ventilation in this 
disorder.
1.4.4.5 Cystic fibrosis
A case report of the use CNEP in 3 infants with cystic fibrosis found it 
was well tolerated and associated with clinical improvement (Klonin et 
al., 2000). One child received CNEP at home for several months. Non-
invasive respiratory support is preferable to intubation and IPPV in 
children with cystic fibrosis because clearance of airway secretions, of 
particular importance in this condition, is even more difficult after 
intubation. There are no controlled trials of the use of NPV for cystic 
fibrosis.
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1.4.4.6 Congenital diaphragmatic hernia 
Baglaj et al. (1998) reported an uncontrolled study of the use of CNEP 
in the management of babies after repair of congenital diaphragmatic 
hernia (CDH). Between 1981 and1995, 108 babies with CDH 
presented to the South West Regional Paediatric Surgical Unit in 
Bristol, UK. Fourteen died without surgery, as their condition could not 
be stabilised sufficiently. After 1990, CNEP was used as an adjunct to 
PPV in babies with CDH needing ventilatory support for more than 7 
days post-operatively. In the 9 years before the introduction of CNEP, 
17 babies were ventilated for more than 7 days; of these, 7 developed 
chronic lung disease and 6 died after 4 weeks, 5 from the chronic lung 
disease. Between 1990 -1995, CNEP was used in 11 out of 18 babies 
who were ventilated for longer than 7 days; there were no cases of 
chronic lung disease and just one late death in a child who received 
prolonged ECMO out of region. This study suggests that the use of 
CNEP may reduce the risk of developing chronic lung disease in 
babies requiring prolonged respiratory support; however, there are no 
controlled trials of the use of CNEP for CDH.
1.4.4.7 Central hypoventilation syndrome
Hartmann et al. (1994a) reported their use of CNEP in an uncontrolled 
trial in 9 children with central hypoventilation syndrome (CHS). The 
children were aged 22 days to 4 years 9 months at the onset of 
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treatment. With the introduction of CNEP, 7 children (78%) were 
successfully weaned from PPV and managed at home by their parents 
without the need for tracheostomy. Due to problems with upper airway 
obstruction, 3 needed CPAP in addition to NPV (2 for up to 2 weeks 
and 1 permanently). Two of the 7 patients treated with NPV were 
eventually weaned off all ventilatory support. Two of the original 9 could 
not be managed with NPV and required tracheostomy. The findings 
suggest that NPV may give useful non-invasive support to a majority of 
children with CHS but a controlled trial is needed to evaluate more fully 
its role in managing this condition.
79
Table 6: Studies of the physiological effects of continuous negative extrathoracic pressure
First author (Year) Study group Study protocol Findings Comments
Gappa et al. (1994)
18 infants, aged
10 -127 days, 
gestational age 24- 36 
weeks with RDS
Respiratory mechanics 
measured in atmospheric 
pressure and following the 
application of -6 cm H2O 
CNEP
CNEP resulted in a significant 
decrease in respiratory rate, 
increased compliance 
measured with the single 
breath technique but no 
change in respiratory 
resistance.
Benefits of CNEP may 
be explained by its effect 
on respiratory mechanics
Essa et al. (1994)
13 newborn piglets with 
induced lung injury 
following saline lavage
Piglets were randomly 
assigned to receive PEEP or 
CNEP at equivalent 
pressures of 3, 6, 9 and 
12cm H2O
No difference in lung 
compliance, resistance, 
arterial oxygen pressure or 
cardiac output. Lower end 
expiratory lung volume in the 
PEEP group
CNEP and PEEP may be 
physiologically equivalent
Raine et al. (1994)
8 babies aged 2-15 
days, gestational age 
25-36 weeks with RDS
All babies received both 
CNEP and IPPV initially; 
blood flow velocity was 
measured whilst receiving 
CNEP and repeated after 
discontinuation of CNEP.
No significant changes noted 
in cerebral blood flow velocity, 
heart rate, oxygen saturations 
and transcutaneous pCO2.
No adverse effect of 
CNEP on cerebral blood 
flow velocity 
demonstrated
Palmer et al. (1994)
10 infants, aged 3-62 
days, gestational age 
27-36 weeks with RDS
Cerebral blood volume 
measured with near infrared 
spectroscopy before and 
after discontinuation of 
CNEP and during removal of 
neck seal
Cerebral blood volume 
increased significantly on 
discontinuation of CNEP but 
there was no significant 
change on removal of the neck 
seal
CNEP may enhance 
cerebral venous 
drainage; no evidence of 
an effect by the neck 
seal 
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First author (Year) Study group Study protocol Findings Comments
Palmer et al. 
(1995)
29 infants (12-CNEP 
17-IPPV) aged 1-65 
days, gestational age 
26-37 weeks with RDS
Cerebral blood volume 
measured with near infrared 
spectroscopy whilst 
receiving CNEP or IPPV, 
following discontinuation and 
after resumption of CNEP or  
IPPV
The use of CNEP was 
associated with a median 
decrease in blood volume of 
0.14ml/100ml brain (95% C.I. 
0.035-0.280) compared with 
no respiratory support and 
IPPV with a median decrease 
of 0.06ml/10ml brain (95% C.I. 
0.010-0.115). Both oxygenated 
and deoxygenated Hb 
decreased in CNEP infants, 
deoxygenated Hb increased 
and deoxygenated Hb 
decreased in IPPV group 
Both CNEP and IPPV 
reduce cerebral blood 
flow velocity but CNEP 
probably causes 
increased cerebral 
venous drainage whilst 
IPPV reduces cerebral 
venous drainage but 
other factors may also be 
significant
Shekerdemian et al. 
(1997)
9 children, median age 
6.3 years  (post 
fontan’s  procedure)
9 children, median age 
5.8 years (during 
cardiac catheterisation 
5 mths-15 yrs later) 
Pulmonary blood flow
measured by the ‘Flick 
method’ during IPPV and 
NPV
Pulmonary blood flow 
increased during NPV from 
2.3±1.2 to 3.3± 1.9 L·min-1·m-2
(p=0.01) in acute patients and 
from 2.6±1.0 to 3.7±1.1 L·min-
1·m-2 (p=0.01) in convalescent 
patients.
Cuirass type negative 
pressure ventilation 
significantly increases 
pulmonary blood flow in 
children with a ‘Fontan 
circulation’
Shekerdemian et al. 
(1999)
23 children aged 0.5-
13years, post  tetralogy 
of fallot repair
Pulmonary blood flow 
measured by the ‘Flick 
method’ during IPPV and 
NPV, 4-18 hours after 
tetralogy of fallot repair
NPV increased pulmonary 
blood flow by 39% after 15 
minutes and by 67% after 45 
minutes. Increase most 
marked if restrictive right 
ventricular physiology (84%) 
Cuirass type negative 
pressure ventilation 
improves the pulmonary 
blood flow of patients 
after tetralogy of fallot 
repair
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Table 7: Summary of studies reporting outcome following the use of continuous negative extrathoracic pressure
First author (Year)
Number of 
subjects
Age at follow up Condition treated Type of study Findings
Fanaroff et al. (1973)
15 CNEP       
14 Controls
Newborns
Respiratory distress 
syndrome
Controlled
67% of CNEP vs 
14% of controls  
improved without 
further need for 
respiratory support
Monin et al. (1976)
57 CNEP       
58 IPPV
Newborns
Respiratory distress 
syndrome
Controlled       
(abstract)
Reduced BPD & 
pneumothoraces with 
CNEP
Alexander et al. (1979)
18 CNEP       
18 CPAP
Newborns
Respiratory distress 
syndrome
Randomised controlled
No significant 
difference
Samuels and Southall 
(1989)
88 1 day - 2 years Respiratory failure Uncontrolled
Reduced FiO2 after 2 
hrs and 48 hrs of 
CNEP
Cvetnic et al. (1990) 37 Newborns
Pulmonary 
hypertension
Uncontrolled
Rapid improvement 
in oxygenation 
following CNEP
Cvetnic et al. (1992) 30 Newborns
Pulmonary 
hypertension
Randomised controlled 
crossover
2 ‘CNEP’ babies 
crossed over to 
PEEP, 11 ‘PEEP’ 
babies crossed over 
to CNEP 
Raine et al. (1992) 14 1 wk -30 months Phrenic nerve palsy Uncontrolled
CNEP used to aid  
weaning from PPV
Hartmann et al. (1994a) 9 22 days - 4.75 yrs
Central 
hypoventilation 
syndrome
Uncontrolled
Effective long term 
respiratory support
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First author (Year)
Number of 
subjects
Age at follow up Condition treated Type of study Findings
Hartmann et al. (1994b)
15 CNEP       
18 Controls
40 -61 weeks 
post conceptual 
age
Bronchiolitis
Randomised controlled 
(abstract)
4 in the CNEP group 
had reduced FIO2 to 
≤30% within 1 hour 
compared to no 
controls. I control 
needed IPPV and 
another CPAP
Samuels et al. (1996) 244 Newborns
Respiratory distress 
syndrome
Randomised controlled
5% less intubations 
with CNEP, shorter 
duration of oxygen 
therapy
Linney et al. (1997) 56 13 -325 days Bronchiolitis
Retrospective review 
(abstract)
Reduced intubation 
with CNEP
Baglaj et al. (1998) 108 Newborns
Congenital 
diaphragmatic hernia
Retrospective review
Reduced chronic 
lung disease
Klonin et al. (2000) 3 4-8 months Cystic fibrosis Case reports
May be useful 
respiratory support
Al-balkhi et al. (2005)
31 NPV,         
21 controls
-
Bronchiolitis related 
apnoea
Retrospective review
Reduced intubation 
and shorter PICU 
stay in NPV group
Telford et al. (2006) 187 9 -15 years
Respiratory distress 
syndrome
(Long term outcome)
Randomised controlled
No difference in 
death or severe 
disability
Telford et al. (2007) 187 9 -15 years
Respiratory distress 
syndrome
(Long term outcome)
Randomised controlled
No difference in 
respiratory symptoms 
or respiratory 
function
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1.4.5 Advantages and disadvantages of negative 
pressure support
There are several advantages of negative pressure ventilation (both 
continuous and intermittent negative extrathoracic pressure) over 
positive pressure ventilation and a similar number of disadvantages 
that are summarised in Table 8. When CNEP is compared with nasal 
CPAP, however, there are fewer advantages to its use. It is relatively 
more difficult to deliver and access to patients is much more restricted. 
There is limited evidence though that CNEP may be more effective 
than equivalent levels of CPAP at improving oxygenation (Alexander et 
al., 1979). The option of using intermittent negative pressure support in 
addition to CNEP, make NPV a more effective mode of ventilatory 
support than CPAP alone. However, non-invasive positive pressure 
ventilation has become possible in recent years and is increasingly 
being used in paediatric intensive care units (Essouri et al., 2006).  
When the cuirass type device is used NPV has the advantage of 
improving venous return and stroke volume which may be especially 
beneficial in some cardiac patients. 
The use of CPAP in combination with NPV has been reported to be 
effective in overcoming the problems with upper airway obstruction 
which occasionally complicates the use of NPV alone (Hartmann et al., 
1994a). The combination of CNEP and IPPV may have significant 
advantages over IPPV alone. Because the equivalent amount of CNEP 
may be more effective than PEEP (Cvetnic et al., 1992), the use of 
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both ventilatory strategies together may offer the benefits of effective 
ventilatory support whilst minimising ventilator associated lung injury by 
using a lower peak inspiratory pressure. Another potential use of NPV 
in combination with IPPV is to facilitate weaning from positive pressure 
support in intubated patients (Corrado et al., 1996).
Table 8: Summary of advantages and disadvantages of NPV (Corrado et al., 
1996, Samuels and Boit, 2007)
Benefits of NPV over IPPV Problems associated with NPV 
Avoidance of intubation Unprotected airway
Better airway clearance  -
physiological cough; airway 
suctioning without interruption of 
ventilation
NPV may be associated with 
upper airway obstruction because 
of constriction by the neck seal 
Less likely to cause chronic lung 
disease
Less effective than IPPV in severe 
cases 
Haemodynamic benefits with 
cuirass devices
Limited access to patients and 
increased nursing care 
1.5 Summary of the literature 
Several studies have reported long-term outcome following bronchiolitis 
with particular reference to its association with reactive airway disease. 
There remains uncertainty as to whether host responses or the effect of 
the infecting organism (i.e. RSV) is the reason for this association.
Most studies following up children after bronchiolitis have used 
spirometry to assess lung function but a few have also assessed lung 
volumes and airway resistance by plethysmography. Two studies have 
been identified which provide limited data on neurological outcome 
following mechanical ventilation in children, including a small number 
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with bronchiolitis. Short-term outcome has been reported after the use 
of CNEP in infants with several conditions including neonatal 
respiratory distress syndrome, pulmonary hypertension, central 
hypoventilation syndrome, cystic fibrosis, congenital diaphragmatic 
hernia, and after cardiac surgery (including some with the complication 
of phrenic nerve palsy). Data on the use of NPV in bronchiolitis are 
provided by just four studies, one an uncontrolled study including a 
small number of children with bronchiolitis and 2 that were reported in 
abstract form only. There is no published study of long-term outcome 
following the use of CNEP for bronchiolitis. The following questions 
about the use of CNEP in bronchiolitis need to be addressed:
1. What are the short-term respiratory effects of CNEP? 
2. If CNEP is beneficial for use in bronchiolitis, is it best used as 
‘rescue therapy’ or at an earlier stage to pre-empt intubation? 
3. Are there long-term respiratory or neurological effects of CNEP? 
Ideally, these questions would be addressed by an adequately 
powered, prospective, randomised controlled trial but this would be 
difficult to carry out in light of the adverse publicity the treatment has 
received in the UK. However, much valuable information can be gained 
by a careful evaluation of past clinical experience. This thesis reports 
the retrospective evaluation of respiratory and functional outcome in 
children who were treated for bronchiolitis with NPV and provides new 
evidence to help answer the third question posed above.
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2 Aims and hypothesis
2.1 Study aim 
Using a matched cohort design this study aims to determine whether 
there are respiratory or neurological sequelae to the use of CNEP for
the treatment of bronchiolitis.
2.2 Primary hypothesis 
The null hypothesis is that there is no difference in airway resistance 
measured in later childhood between children who received CNEP for 
bronchiolitis and matched controls. 
2.3 Secondary hypotheses 
a) The use of CNEP for bronchiolitis does not result in an increase in 
respiratory symptoms in later childhood compared with matched 
controls.
b) The use of CNEP during bronchiolitis is not associated with an 
increase in disability or worse health related quality of life among 
surviving children compared to controls.
c) The use of CNEP is associated with short-term benefit, such as a 
reduced need for intubation, when compared to controls.
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2.4 Study design
This was a retrospective matched cohort study of children treated with 
CNEP for bronchiolitis at North Staffordshire Hospital (NSH). Matched 
controls were recruited from a cohort of children who were admitted to 
Queen’s Medical Centre (QMC) with bronchiolitis during the same 
period as the children treated with CNEP. The two hospitals are 50 
miles apart in the Midlands of England and provide tertiary paediatric 
intensive care to similar sized populations. A small number of children 
in whom CNEP was used to facilitate weaning from positive pressure 
ventilation were also evaluated; the outcome for these children is 
described separately without comparison to a control group.
88
3 Outcome measures
Outcome measures evaluated in the study are listed below:
1. Primary outcome:
a. Airway resistance measured using the interrupter 
technique (!int)
2. Secondary outcomes:
a. Other lung function tests:  Percentage change !int , 
FEV1, FVC, FEF25-75, percentage change FEV1
b. Frequency of respiratory symptoms
c. Need for respiratory medication
d. Prevalence of disability 
e. Health related quality of life (Health Utility Index 3)
3. Short term outcomes:  
a. Length of hospital stay 
b. Length of PICU admission 
c. Duration of oxygen therapy 
d. Rates of intubation
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3.1 Choice of primary outcome
An increased prevalence of respiratory symptoms is the commonest 
adverse outcome after bronchiolitis and so it is important to identify 
therapies that either worsen or ameliorate this effect. Most studies of 
long-term outcome following bronchiolitis have assessed the 
prevalence of respiratory morbidity by interview, use of questionnaires
or by measuring respiratory function. Several outcome studies following 
bronchiolitis have used the prevalence of respiratory symptoms as the 
primary outcome measure (Tables 2-5). It could be argued that these 
are more relevant than measures of lung function, also commonly 
used, but their disadvantage is that they tend to be subjective and 
liable to bias. A study by Cane et al. (2000) found only 45% agreement 
between parents’ (n=139) and clinicians’ reports of wheeze in children 
attending a chest clinic and the same investigators found that parents 
(n=190) identified wheeze with just 59% accuracy when shown a video 
of different respiratory signs (Cane and McKenzie, 2001).
Lung function tests, by contrast, are arguably a more objective way of 
assessing the prevalence of airway disease but they may correlate 
poorly with the prevalence of symptoms and so be of less relevance to 
subjects. However, some lung function tests do correlate well with 
clinical symptoms. McKenzie et al. (2000) found higher baseline Rint 
values in children with a history of wheeze compared to healthy 
controls. Bronchodilator responses were also significantly higher in 
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those who wheezed compared to controls with a median ratio of 
baseline to post-bronchodilator airway resistance (BDR) of 1.4 versus 
1.07. Children with chronic cough but no wheeze (presumed cough 
variant asthma) had an intermediate bronchodilator response ratio 
(BDR) of 1.27, also significantly higher than the controls. 
A lung function measure was selected as the primary outcome for this 
study because objectivity was considered to be crucial in determining 
any difference between the two groups. The frequency of respiratory 
symptoms was assessed as a secondary outcome measure.
The measurement of airway resistance and lung volumes by 
plethysmography (Raw) is considered to be the ‘gold standard’ method 
of assessing airway disease in children (Hammer and Eber, 2005). The 
technique for this involves a subject breathing against a closed valve 
whilst inside a perspex body box which children less than 8 years old 
find difficult.  With sedation plethysmography can be achieved 
successfully even in infants (Stokes et al., 1981). It was anticipated that 
most subjects would have difficulty cooperating with this technique or 
would require sedating, posing ethical difficulties and probably also 
deterring parents from consenting to the study.  A recent modification 
of the plethysmography technique involves the measurement of 
specific airways resistance (sRaw), which avoids the need to breathe 
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against a closed shutter, and can be done with a parent also inside the 
box, both factors improving the acceptability of the procedure. 
However, the plethysmography box is bulky and therefore not easily 
transported; it is also very expensive. To avoid subjects having to travel 
long distances to participate in the study; and to maximise recruitment, 
evaluations were planned to be carried out at two centres (one in each 
city), close to the subjects’ homes. Achieving this would have needed 
two plethysmography boxes and their high cost precluded this option.
Respiratory function has been assessed in most outcome studies of 
bronchiolitis by using spirometry. The flow volume curve produced by 
forced expiration is a widely used and well characterised test of 
respiratory function. It has the benefit of extensive normative data for 
both a wide age range and for different ethnic groups. With appropriate 
training and the use of incentive displays, some very young children 
can be coached to perform the test - however about half of 3 -6 year 
olds may not be able to do it adequately (Dundas and McKenzie, 
2003). This was considered to be a significant limitation to its use as 
the primary outcome measure in this study. With over a third of the 
CNEP cohort aged 4.5 - 6 years at the time of evaluation, it was 
anticipated that spirometry might not be possible in about 20% of 
subjects.
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The forced oscillation technique (FOT) and the impulse oscillation 
system (IOS) are two non-invasive methods that have recently been 
used in children and adults to assess airway resistance. They deduce 
the mechanical properties of the respiratory system by measuring 
impedance to airflow after applying externally-produced pressure 
waves (oscillation); resistance and reactance are then calculated from 
the measurements obtained (Hammer and Eber, 2005). Although this is 
a promising development in paediatric lung function testing, the 
measurements obtained using FOT are less reproducible than those 
from airway resistance measured with an interrupter device (!int) and 
specific airways resistance (sRaw) in children aged 4-6 years (Bisgaard 
and Klug, 1995, Klug and Bisgaard, 1998). They were also found to be 
unreliable in up to a third of 5 year olds undergoing bronchial challenge 
(Wilson et al., 1995). The equipment used for FOT is larger and more 
expensive than interrupter systems which are also easier to operate 
and have been standardised in children up to 13 years of age (Merkus 
et al., 2002, McKenzie et al., 2002).
3.2 Airway resistance - interrupter method (!int)
Assessment of airway resistance by the interrupter method (!int) 
involves measuring airflow and airway pressure at the mouth in tidal 
breathing just before and after transiently occluding the airway with a 
rapidly moving shutter. It is based on the assumption that transient 
occlusion of the airway at the mouth results in rapid equilibration of 
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alveolar pressure with mouth pressure. The difference between the 
pressure at interruption and the baseline pressure prior to interruption 
is thought to reflect resistance in the pulmonary airways and !int is the 
ratio of this difference in pressure to flow at the time of interruption 
(Bates et al., 1987, Chowienczyk et al., 1991). In the same way that 
alveolar pressure is not a single value, airway resistance measured by 
this technique represents an average resistance value of the airways. 
3.2.1 History of the interrupter technique (!int)
The interrupter technique for measuring airway resistance was first 
described by Von Neergaard and Wirz (1927) but failed to gain wide 
acceptance for many years. The values obtained were found to differ 
from the ‘gold standard’ values of airway resistance measured by 
plethysmography (Raw) and physiological interpretation of the method 
remained unclear (Dundas and McKenzie, 2003, Bridge et al., 1996).  
There has been renewed interest in the technique since the late 1980s 
following theoretical and animal work by Bates and co-workers (Bates 
et al., 1987, Bates et al., 1988b, Bates et al., 1988a, Bates et al., 
1989a, Bates et al., 1989b). Studies in anaesthetised open-chested 
dogs with tracheostomy showed !int to be an excellent approximation 
to Raw in that model (Bates et al., 1988b). In closed-chested dogs, !int 
was found to have a strong ()&&%/0$")# with Raw but, by including a 
contribution from the chest wall, tended to exceed it (Bates et al., 
1989b, Bates et al., 1989a). The authors also identified that upper 
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airway compliance may result in an underestimate of Raw which can 
be minimised by supporting the cheeks and pharynx (Bates et al., 
1987). Theoretical analysis of the technique by Bates and co-workers 
suggests that !int is a valid method of assessing airway resistance 
(Bates et al., 1988a). Chowienczyk et al. (1991) evaluated !int in 43 
adults with varying degrees of airflow obstruction and found a similarly 
good correlation with Raw (r=0.86); they also tried the technique in 10 
children aged 3 years and found that they were able to use it 
successfully. 
Since the early 1990’s !int has gained wide use in adults and children. 
Its main advantage over spirometry and plethysmography is that it 
involves a simple technique and requires only minimal cooperation, 
making it suitable for use even in preschool children. Bridge and 
McKenzie (2000) found that, of 100 children aged 5-10 years 
(consecutive referrals to a tertiary respiratory centre) who were tested 
with both spirometry and !int, 97% were able to complete the !int test 
compared to 53% able to complete spirometry. !int has also been 
shown to be of value in detecting bronchodilator responsiveness, a key 
diagnostic criterion for asthma. In a study by McKenzie et al. (2000), a 
pre- to post-bronchodilator !int ratio of 1.22 was found to be 80% 
specific and 76% sensitive for previous wheeze. Bridge et al. (1996) 
found !int to be as sensitive as spirometry at detecting bronchodilator 
responses in a study of 25 school-aged children with asthma. Its 
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usefulness for comparing treatment outcomes has been demonstrated 
in 2 studies evaluating the effect of inhaled corticosteroids in asthmatic 
preschool children. A randomised placebo-controlled study of inhaled 
budesonide in 38 children aged 2-5 years with asthma, found 
significantly lower Rint values in the treatment group after 8 weeks 
(Nielsen and Bisgaard, 2000).  Baseline !int and BDR were primary 
outcome measures in a study by Pao and McKenzie (2002) in which 
they evaluated the use of inhaled fluticasone in a randomised placebo-
controlled crossover trial in 61 children aged 2-5 years with asthma. 
After 6 weeks treatment !int was 7.6% lower than baseline in the 
group as a whole and 16% lower in 14 children who were skin prick test 
positive to one or more of the common aeroallergens. Similarly the 
BDR fell by 5.6% overall after 6 weeks of inhaled fluticasone and by 
10.6% in skin prick positive subjects. !int values returned to baseline 
16 weeks after stopping treatment. 
3.2.2 Technical aspects of performing !int
Bates and co-workers showed that !int values are an approximation of 
airways resistance. The flow just prior to interruption and the pressure 
change following interruption are both measured at the mouth and used 
to calculate airway resistance. The technique is based on the 
assumptions that the shutter closes instantaneously and is followed by 
an instantaneous equilibration of airway opening pressure with alveolar 
pressure. The exact pressure at interruption is obscured by a series of 
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oscillations, caused by the inertia of gas in the airway and compliance 
of the airway walls. A back-extrapolation method is most commonly 
used to estimate the alveolar pressure at the point of interruption. 
Several methods of analysing the mouth pressure/time curve to 
determine !int have been evaluated including a measurement of the 
pressure change after the post interruption oscillations have decayed 
or the pressure change at the end of the period of interruption (Phagoo 
et al., 1995). The two-point linear back extrapolation method for 
calculating !int resulted in the lowest baseline variability and was the 
most sensitive at detecting change following methacholine challenge 
when compared with other methods (Phagoo et al., 1995). It has been 
proposed as the accepted standard (Carter, 1997) and is currently the 
most widely used. 
To perform a !int measurement, the subject is asked to take normal 
tidal breaths through a mouthpiece attached to the interrupter device 
(Figure 5). Closure of the valve is actuated when airflow reaches a 
predetermined value and takes about 5 milliseconds (ms) 
(Chowienczyk et al., 1991). During the process of closure, some gas 
continues to flow through the valve so lung volume and alveolar 
pressure continues to change (Bates et al., 1987). The changes in 
volume and pressure that occur during the time it takes for valve 
closure have been found to be of little clinical importance provided 
complete occlusion occurs within 10 -20 ms (Sly and Lombardi, 2003).
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The valve remains closed for about 100 ms during which pressure is 
measured at 1ms intervals and the results stored in the computer 
memory (Chowienczyk et al., 1991)
Figure 5: A child aged 2 years and 10 months holding a Micro-Rint
TM
device
Factors that can affect its measurement include air leak around the 
mouthpiece, compliance of the cheeks, neck position, airflow rate and 
lung volume at interruption. The results obtained are also affected by 
both the type of device used and by the criteria chosen for selecting the 
Shutter
Nose clip!
Mouth piece
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post-occlusion pressure (Pao et al., 2004). All these factors may 
significantly affect the result of a single !int measurement (Phagoo et 
al., 1996) but reliability of results can be improved by standardising 
technique in the following ways:
1. The two-point linear back extrapolation method for 
calculating  airway resistance has been shown to have the                                                   
least baseline variability and the highest sensitivity for 
detecting a response to inhaled methacholine when 
compared with other methods (Phagoo et al., 1995).
2. Measurements taken in expiration are more sensitive at 
detecting differences in airway calibre than in inspiration
(Merkus et al., 2001).
3. Upper airway compliance can be minimised by supporting 
the cheeks and pharynx during testing (Bates et al., 1987).
4. Taking the median of at least six readings significantly 
increases reliability of results (Bridge and McKenzie, 2001). 
Figure 6 is an example of a typical pressure-time curve produced as a 
result of airway occlusion during the measurement of !int.
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Figure 6: Mouth Pressure-time curve showing back extrapolation of Rint
Ppre is the mouth pressure measured prior to occlusion, during tidal 
breathing. Valve closure during expiration results in a sharp increase in 
pressure within the mouth, a series of high-frequency oscillations and 
then a smooth increase in pressure. The time of airway occlusion (T0) 
is defined as the point at which 25% of the peak value of the first 
pressure upstroke is reached. The airway pressure at T0 is obtained by 
linear back extrapolation using 2 points from the curve at 30 and 70 ms 
post occlusion (T30 and T70). Mouth pressures pre occlusion (Ppre) and 
at time T0 (Pint) are used in the later calculations. The pressure at 
interruption (Pint) is an approximation of alveolar pressure and airway 
resistance (!int) is determined by the ratio of DPint (the difference 
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between Ppre and Pint) to the expiratory flow at the mouth immediately 
before interruption (Chowienczyk et al., 1991, Phagoo et al., 1996).
3.2.3 Summary of !int
The main advantage of !int over other methods of assessing airway 
resistance is the ease with which it can be performed, allowing its use 
in preschool children. It is portable, affordable and reproducible results 
can be obtained by relatively inexperienced personnel (Phagoo et al., 
1996). Several studies have found good correlation between !int 
values and airways resistance obtained by plethysmography (Raw) in 
both normal and asthmatic children (Merkus et al., 2001, Carter et al., 
1994, Chowienczyk et al., 1991) and there is good correlation between 
!int and spirometric measurements such as PEF and FEV1 (Carter et 
al., 1994). The reported ‘within-occasion’ reproducibility of !int is varied 
with some studies suggesting it is satisfactory and similar to Raw 
(Oswald-Mammosser et al., 1997, Merkus et al., 2001), whilst other 
studies suggest a high coefficient of variability particularly in patients 
with airway obstruction (Chan et al., 2003). The ‘between-occasion’ 
variability of !int is high limiting its usefulness for monitoring a child’s 
illness over time (Chan et al., 2003); an area of use where !int 
compares unfavourably with spirometry. Most lung function tests that 
assess airflow resistance, including !int, tend to underestimate airway 
disease in those with asthma because equilibration of mouth and 
alveolar pressure may occur more slowly in obstructed airways 
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(Bisgaard and Klug, 1995, Oswald-Mammosser et al., 2000). Despite 
these limitations, the interrupter technique remains useful in detecting 
airway disease and is particularly sensitive at determining a 
bronchodilator response (McKenzie et al., 2000, Bisgaard and Klug, 
1995). The determination of normal values for children aged 2-13 years 
has further increased its usefulness (Lombardi et al., 2001, Merkus et 
al., 2002, McKenzie et al., 2002). !int was chosen as the primary 
outcome measure for this study because, limitations notwithstanding, it 
offers a practical, sensitive, validated and objective tool for comparing 
the two cohorts of children. 
3.3 Secondary outcomes- Respiratory 
3.3.1 Respiratory function tests – Spirometry/ 
Reversibility studies 
The following respiratory function tests have been evaluated as 
secondary outcome measures: baseline and percentage change FEV1, 
FVC, FEF25-75, percentage change !int and !int bronchodilator 
response ratio (BDR ratio). Forced expiratory manoeuvres have been 
reported in several studies evaluating outcome in children following 
bronchiolitis (Table 5); their inclusion as outcome measures in this 
study allows for comparison of the findings with published data. The 
forced expiratory volume in 1 second (FEV1) and forced vital capacity 
(FVC) are the 2 most commonly reported spirometric measures and 
provide a useful assessment of airflow obstruction or restrictive lung 
disease respectively. The forced mid expiratory flow (FEF25-75) is 
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reported less often than FEV1 and FVC but is a more sensitive marker 
of small airway disease than FEV1 (Valletta et al., 1997). A minimum 
12% change in FEV1 following a bronchodilator is one of the standard 
criteria for diagnosing asthma (Miller et al., 2005). The !int 
bronchodilator response ratio has recently been identified as having 
high sensitivity and specificity for detecting children with a history of 
wheeze (McKenzie et al., 2000).
3.3.2 Respiratory symptoms and use of medication
A difference in the prevalence of symptoms between the groups, 
although potentially less objective, may arguably be of more relevance 
as an outcome measure than airway resistance. To improve the 
reliability of the data obtained, a questionnaire that has previously been 
validated for use in the International Study of Asthma and Allergies in 
childhood (ISAAC) was chosen to assess this secondary outcome 
measure. ISAAC is a large epidemiological study involving over 
700,000 children, which was designed to investigate the prevalence of 
asthma in different populations worldwide (The International Study of 
Asthma and Allergies in Childhood (ISAAC) Steering Committee, 1998). 
Other study aims were to obtain baseline measurement to allow 
assessment of future trends in the prevalence of asthma and to identify 
aetiological factors associated with its increasing incidence (Asher et
al., 1995). Questions that make up the core questionnaire were 
selected because they have been shown in previous studies to detect 
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differences between populations and have been assessed for validity 
(Table 9). The validity of the questions was further evaluated in a study 
of 168 children with previous wheeze who completed the questionnaire 
prior to assessment by a respiratory physician (Jenkins et al., 1996). 
The children also underwent a bronchial challenge with hypertonic 
saline; bronchial hyper-responsiveness (BHR) was confirmed if there 
was as a 15% reduction in FEV1 from baseline following inhaled saline. 
The physician was blinded to the subjects’ questionnaire responses 
and bronchial challenge results and made a diagnosis of asthma based 
on standard clinical criteria. Using physician diagnosed asthma as the 
gold standard, the ISAAC questionnaire had sensitivity of 0.85 (95% 
C.I. 0.73-0.93) and specificity of 0.81 (95% C.I. 0.76-0.86) for detecting 
physician diagnosed asthma in children, with a positive predictive value 
of 0.61 (95% C.I. 0.5-0.71) and negative predictive value of 0.94 (95% 
C.I. 0.88-0.98). BHR had a much lower sensitivity for detecting 
physician diagnosed asthma 0.54 (95% C.I. 0.48-0.67) but was more 
specific 0.89 (95% C.I. 0.83-0.94). These findings suggest the ISAAC 
questionnaire is a valid tool to use to compare the prevalence of 
wheezing symptoms in the groups evaluated in this study. Data on the 
use of bronchodilator therapy or inhaled corticosteroids have also been 
collected to identify whether an increased use of medication in one 
group may account for any difference in the prevalence or frequency of 
symptoms. 
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Table 9: ISAAC Study Core Questionnaire – wheezing (Asher et al., 1995)
1. Have you ever had wheezing or whistling in the chest at any time 
in the past?
2. Have you had wheezing or whistling in the chest in the last 12 
months?
3. How many attacks of wheezing have you had in the last 12 
months?
4. In the last 12 months, how often on average, has your sleep 
been disturbed due to wheezing? 
5. In the last 12 months has wheezing ever been severe enough to 
limit your speech to only one or two words at a time between 
breaths? 
6. Have you ever had asthma? 
7. In the last 12 months, has your chest sounded wheezy during or 
after exercise? 
8. In the last 12 months have you had a dry cough at night apart 
from a cough associated with a cold or a chest infection? 
3.4 Secondary outcomes- Functional 
Adverse neurological outcome following bronchiolitis is rare, however 
two reported uncontrolled studies suggest it may occasionally occur as 
a consequence of circulatory failure associated with severe 
bronchiolitis (Bray and Morrell, 1982, Wren et al., 1982). The study by 
Samuels et al. (1996) evaluating the use of CNEP in preterm babies 
with RDS, led to concern that it might be associated with later adverse 
neurological outcome in some children because of a non-significant 
increase in cranial ultrasound abnormalities associated with its use. A 
few parents expressed the view that the use of CNEP had been 
responsible for subsequent disability in their children at the time of a 
government enquiry into the conduct of research at NSH (Griffiths, 
2003). The study reported here is insufficiently powered to detect a 
small or subtle difference in neurological outcome due to the 
constraints of the original cohort size and the rarity of adverse 
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neurological outcome - a large difference, however, should be 
detectable and has therefore been evaluated as a secondary outcome 
measure.
3.4.1 Disability 
In assessing the level of disability in the two cohorts of children, it was 
first necessary to define disability for each domain to be studied. The 
World Health Organisation (WHO) has established criteria for defining 
disability (World Health Organisation, 1980) and an adaptation of these 
was published by the National Perinatal Epidemiology Unit and Oxford 
Health Authority (1995). These more detailed criteria were originally 
described for assessing disability in ex-preterm children at 2 years of 
age but, with appropriate modifications, they have been shown to be of 
value in the assessment of older children (Marlow et al., 2005). 
Using criteria described in the NPEU/ Oxford HA report, the categories 
of impaired/ mild and moderate/ severe disability have been defined for 
6 domains of disability. Table 9 below lists the definitions of disability 
used in this study. Children were deemed to have an impairment or 
mild disability if they had abnormal clinical signs with normal motor 
function or mild clumsiness but were able to function independently; if 
they were receiving extra support in a mainstream school and if they 
had near normal hearing or vision with or without the use of aids. 
Disability was deemed moderate/severe if a child required aids for 
mobility, placement in a special needs school, persistent defects of 
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hearing or vision despite aids or required a high degree of supervision 
or dependence on their carer. Behavioural disability was determined by 
parent responses to the ‘Strengths and Difficulties questionnaire’ and 
the impact of any behaviour problems by the ‘impact score’. Children 
were also specifically assessed for the presence of cerebral palsy.
3.4.1.1 Cognitive disability
An assessment of cognitive disability in children would ideally include 
psychometric testing by a trained psychologist. However, because 
cognitive disability is a rare outcome following bronchiolitis and in view 
of the limited power of this study to detect small differences in this 
outcome measure, the use of psychometric tests was considered 
inappropriate. Instead it was decided to simply record whether or not 
children had been identified at school as having special educational 
needs. The two categories of disability described are: (1) Impaired or 
mild disability – children receiving additional educational support in a 
mainstream school and (2) moderate or severe disability – children 
placed in a ‘special needs school’. All children placed in ‘special needs 
schools’ will have had a ‘statement of educational needs’. This involves 
a multi-disciplinary assessment process by the health professionals 
involved in the child’s care and educational psychologists. Many 
children in mainstream school also have a ‘statement of educational 
needs’ and will be offered additional support without the need to be 
placed in special needs schools. Others will not have a ‘Statement’ but 
are acknowledged by their teachers to have difficulties and so receive 
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extra attention. Children are generally only considered for placement in 
special needs schools after going through the process of assessment 
for a ‘statement’ and if their needs cannot be met in mainstream 
schools. The effect of this is that children placed in special needs 
schools are generally those with a cognitive or learning disability more 
severe than children who receive additional support in a mainstream 
school. For this reason there is likely to be good correlation between a 
child’s degree of cognitive disability and the level of special educational 
needs they receive or type of school they attend. It is probable that 
some children with mild cognitive disability will not be identified using 
these criteria because the school will not have identified their problems. 
Children with significant disabilities, however, should be identified with 
these criteria and are arguably the group most important to identify. 
3.4.1.2 Neuromotor disability 
The assessment of neuromotor disability was based on a combination 
of the gross motor function classification system (GMFCS) (Palisano et 
al., 1997) and clinical examination techniques described by Amiel-
Tison and Stewart (1989). The GMFCS was originally devised and 
validated for the assessment of children with cerebral palsy (CP) but is 
useful for the classification of gross motor disability of other causes. It 
is a five-level classification system based on a child’s usual 
performance in which level 1 grades the least disability and level 5 the 
most (Table 10).
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Table 10: Gross Motor Function Classification System (Palisano et al., 1997)
Level 1
Walks without restrictions; limitations in more advanced gross 
motor skills -reduced speed, balance and coordination.
Level 2
Walks without assistive devices, limitations on uneven surfaces, 
inclines, crowds or confined spaces. Minimal ability (at best) to 
perform gross motor skills such as running and jumping.
Level 3
Walks with assistive mobility devices; limitations walking outdoors 
and in the community. Depending on upper limb function can 
propel a wheelchair manually or is transported when travelling for 
long distances or on uneven terrain outdoors. Able to sit 
independently.
Level 4
Self-mobility with limitations. Needs adaptive seating for head 
control and to maximise hand function. Walks only short distances 
with assistive devices. Difficulty turning. Difficulty on uneven 
surfaces. May rely on wheeled mobility. Self-mobility using 
powered wheelchair.
Level 5
No means of independent mobility or self-mobility using powered 
wheelchair with extensive adaptations. Lack independence even 
in antigravity postural control.
3.4.1.3 Behavioural disability
Behavioural disability was defined using scores generated from the 
strength and difficulties questionnaire (SDQ) which was completed by 
parents (Goodman, 1997). The SDQ is a behavioural screening 
questionnaire that may be completed by parents and teachers of 4 -16 
year olds. A self-report version is available for children aged between 
11-16 years (Goodman et al., 1998). The questionnaire has been 
validated for use as a screening tool in a nationwide sample of over 
10,000 British children (Goodman et al., 2000). It is used to screen for 
behavioural symptoms in 5 different categories namely: conduct 
problems, hyperactivity-inattention, emotional symptoms, peer 
problems and prosocial behaviour. An extended version of the 
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questionnaire which includes an impact supplement has been found to 
discriminate more effectively between children with psychiatric 
symptoms and children with a psychiatric disorder (Goodman, 1999). 
Used on its own the SDQ has been shown to have a negative 
predictive value of about 95% but a positive predictive value of only 
35% (Goodman, 2001). The sensitivity of the questionnaire is 
significantly improved with the use of a computer algorithm that 
combines responses from ‘multi-informants’ (parents, teachers, older 
children), identifying individuals with a psychiatric diagnosis with 95% 
specificity and 63% sensitivity (Goodman et al., 2000). Because 
behavioural disability was assessed as a secondary outcome measure 
and the testing done in a clinic setting, the increased sensitivity 
achieved by obtaining the teachers’ responses was considered to be 
unnecessary. Children in the study were not old enough to complete 
the self-report version of the questionnaire and so parent responses to 
the extended questionnaire are reported.
3.4.1.4 Visual / Hearing / Other disability
The criteria for defining disability in the domains of vision, hearing and 
‘other disability’ were selected for the same pragmatic reasons as were 
those for cognition. The levels of disability in each domain are defined 
in Table 11 and were assessed by a parent questionnaire. 
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Table 11: Definitions of 6 domains of disability
Definitions Cognitive Neuromotor Vision Hearing Behaviour
Other,
e.g. medical condition, 
communication problem
Impairment 
or mild
disability
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Learning 
difficulties 
requiring 
extra support 
in a 
mainstream 
school
Abnormal signs 
with normal 
function
OR
GMFCS level 1
Upper Limbs: 
Clumsiness of fine 
movements but 
independent
Normal or 
near normal 
vision with 
correction 
despite the 
presence of 
an eye defect
Hearing 
impairment 
not sufficient 
to require 
aids 
OR
Hearing loss 
fully 
corrected 
with aids
SDQ:
One or more 
abnormal 
sub-scores 
with a normal 
impact score 
on parent 
report
1. Medical condition that 
requires medication most 
days   OR
2. Chronic medical 
condition requiring >2 
admission /year, causing 
growth problems, or 
requiring special diet OR
3. Epilepsy with >1 
generalised fit /month OR
4. Stoma   OR
5. Uses sign language, 
communicates effectively
Moderate 
or
severe 
disability
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Learning 
difficulties 
requiring 
placement in 
a special 
needs school
GMFCS level 2-5
Upper Limbs: 
Requires aids or 
assistance to feed 
and dress
Blind or 
impaired 
vision not 
fully 
corrected
Hearing loss 
not fully 
corrected 
with aids
SDQ: 
Abnormal 
total 
difficulties 
score with an 
abnormal 
impact score
1. Medical condition 
requires supervision most 
of the time (includes 
continuous home O2)
OR
2. Communication 
severely limited
GMF= Gross Motor Function, SDQ= Strengths and Difficulties Questionnaire
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3.4.2 Health-related quality of life- HUI3
Most research on outcome following ventilation has focused on 
physiological and clinical end points such as oxygenation, extubation 
rates and survival. Increasingly, researchers have become interested in 
patient-assessed outcomes including quality of life, functional health 
status and symptoms. Functional health status is used to describe an 
individual’s ability to perform tasks of daily living and may be 
categorised for ambulatory, manual, cognitive, hearing and visual 
disabilities. Although these are inherently subjective, it is argued that 
they are no less valid as measurable physiological outcomes are only 
important to patients if they affect the quality or quantity of their life 
(Randall Curtis, 2002).
A number of questionnaires have been devised to assess a patient’s 
subjective experience of the effect of health and illness on their quality 
of life. The Health Utilities Index (HUI) is one such validated 
questionnaire that has been used extensively in clinical studies; the 
third version (HUI3) has evolved from the first and second versions and 
is the most detailed descriptive classification of the 3 systems (Feeny 
et al., 1996). The HUI has two components, a multi-attribute health 
status classification system that may be used to describe health status 
and a multi-attribute utility function that is used to value health status by 
way of a utility score. The utility score is computed from a mathematical 
formula and represents the mean community preference for a particular 
health status on a scale where dead =0.00 and perfect health =1.00. It 
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is based on preference measurements obtained from a survey of a 
random sample of 504 adults from Hamilton, Ontario. HUI was initially 
developed to evaluate outcomes in very low birth weight infants and 
comprised of four attributes: physical function, role function, social-
emotional function and health problem. Following its inception, a core 
set of the most important attributes was determined and used in a 
second version (HUI2) to specifically assess morbidity associated with 
childhood cancer. HUI3 has evolved from HUI2 primarily to address 
concerns about the applicability of HUI2 to a general population. The 
attributes have been selected to be structurally independent, each 
contributing unique information, thus making the HUI3 classification 
system more efficient than the earlier versions. HUI3 has 8 attributes: 
Vision, Hearing, Speech, Ambulation, Dexterity, Emotion, Cognition 
and Pain, with 5 or 6 levels of function for each. It can be used to 
describe almost a million (972,000) unique health states. 
The HUI3 has been shown to distinguish between health states in 
paediatric populations known to have clinically important differences. In 
a study of 156 extremely low birth weight (ELBW) survivors assessed 
at 8 years of age, Saigal et al. (1994) found the mean multi-attribute 
HUI2 score (0.82, SD 0.21) to be significantly lower than 145 normal 
birth weight children (0.95, SD 0.07; p< 0.0001) who were matched for 
age, sex and socio-economic status. The authors found that 50% of 
ELBW children had scores below 0.88 compared to 10% of the controls 
and only 17% of the ELBW scores were 1.00 compared with 50% of 
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controls. These results provide a perspective from the general 
population that ELBW children have an increased long-term health 
burden compared to the normal birth weight controls. An increased 
health burden was similarly identified in 126 children or young people 
(aged 6-21 years) with ‘fetal alcohol spectrum disorder’ in a prospective 
cross sectional study by (Stade et al., 2006). Mean HUI scores of 0.47 
were measured in this group compared with a mean of 0.95 in the 
reference population of healthy Canadian children. The HUI was 
selected to assess functional health status in this study because it has 
been shown to be a valid tool with the ability to identify important 
differences in different paediatric populations.
3.5 Short-term outcomes
Most of clinical practice is about the risk-benefit ratio of treatment. It is 
important to ascertain whether the use of CNEP for bronchiolitis has 
beneficial short-term effects over conventional management; adverse 
long-term effects of any treatment can only be properly interpreted if 
the beneficial effects of the treatment are known. The published data 
on short-term outcome after the use of CNEP for bronchiolitis are 
limited so the short-term outcome findings of this study may be 
particularly relevant (Samuels and Southall, 1989, Hartmann et al., 
1994b, Linney et al., 1997, Al-balkhi et al., 2005). The measures that 
could be reasonably assessed in a retrospective study such as this 
were: rates of intubation, length of PICU/ hospital stay and duration of 
oxygen therapy.  
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3.6 Matching
The following variables were used in the selection of matched controls: 
q Sex (male/ female)
q Gestational age (<32 weeks, 32-36 weeks, >36 weeks)
q Oxygen dependency as an index of illness severity
Gestational age and sex were chosen because they are the two factors 
that most influence the outcomes of airway disease and disability. 
Airway disease is more common in ex-preterm infants (compared with 
those born at term) because of their increased incidence of neonatal 
lung disease (Korhonen et al., 2004) whilst disability has consistently 
been found to be more common in males (Wood et al., 2000, Kraemer, 
2000). Oxygen dependency was chosen as the criterion for matching 
illness severity after it became clear, following a review of the medical 
notes of index cases, that an illness severity score could not be used. 
3.7 Assessment of illness severity 
Illness severity scores, used since the early 1980’s, have proved to be 
particularly useful when assessing differences in outcome between 
intensive care units (Pollack et al., 1987). They were developed as 
probability models to predict the mortality risk in patients with serious 
illness requiring intensive care but have also proved useful for 
comparing outcomes from different units by accounting for differences 
in illness severity of admissions. A variety of scores have been used for 
different age groups and different types of intensive care provision. 
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Several scores have been validated for use in neonatal intensive care 
including Score for Neonatal Acute Physiology (SNAP) / SNAP with 
Perinatal Extension (SNAPE)  (Richardson et al., 2001), Clinical Risk 
Index for Babies (CRIB) (Fowlie et al., 1998) and Neonatal Acute 
Physiology Parameters Index (NAPPI)(Corcoran et al., 1998). Fewer 
scores are validated for use in children needing paediatric intensive 
care; the most widely used is the Pediatric Risk of Mortality (PRISM) III 
score (Pollack et al., 1996), a third generation physiology-based 
predictor of mortality risk, which was initially derived from the 
Physiologic Stability Index (Pollack et al., 1987). It is based on 17 
physiological variables measured 12 hours and 24 hours after 
admission. Other scores in common use tend to be illness-specific 
such as the Glasgow Meningococcal Septicaemia Prognostic Score 
(Riordan et al., 2002) or Clinical Asthma Score (Wood et al., 1972).
The use of such scores was considered for this study as a way of 
accurately matching cases and controls for illness severity. The PRISM 
and clinical asthma scores would have been suitable but the 
parameters needed to calculate them (blood gas, blood chemistry and 
mental status scores) were not recorded in all cases of interest. A 
significant proportion of children in the study were not admitted to an 
intensive care unit where such parameters might have been routinely 
recorded. Thus for pragmatic reasons the oxygen requirement just prior 
to ventilation (or maximum FiO2 if not ventilated) was selected because 
116
it was the one parameter of illness severity that was consistently 
recorded in all the medical notes. To further ensure appropriate 
matching without the option of a validated illness severity score, clinical 
guidelines for the assessment of illness severity in children with 
bronchiolitis were used (Table 12). Children were matched within 
categories of mild, moderate or severe illness. 
Table 12: Guidelines for the clinical assessment of children with bronchiolitis 
(Hodge and Chetcuti, 2000)
Mild Moderate Severe
SaO2 in air > 93% 86-92% < 85%
Apnoea No No Yes
Cyanosis No Yes Yes
Recession Mild Moderate Severe
Respirations/ minute < 50 50-70 > 70
FiO2 to keep SaO2 >93% Air 21% - 40% > 40%
Heart rate/ minute <140 140 -160 >160
Feeding Feeding well Not feeding Not feeding
Two or more criteria must be met to justify a given category  
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4 Methods
4.1 Study Population - Index cases
CNEP was used routinely for ventilatory support of children with 
bronchiolitis at the NSH and no record was kept of which children 
received this therapy. Therefore, identification of the study population 
first required a detailed search of computer records and ward diaries to 
determine all children diagnosed with bronchiolitis during the period 
when CNEP was known to have been used (January 1993 - March 
1999). A search was then undertaken of the medical notes of children 
identified with bronchiolitis in the relevant period, to determine all those 
who received CNEP. If evidence of CNEP use was found, details of the 
admission with bronchiolitis and neonatal history were recorded. 
4.1.1 Computer records
Children admitted to NSH with bronchiolitis between April 1996 and 
March 1999 were identified using computer records; they numbered 
nearly 1200. It was not feasible to search this number of notes in the 
time available and it was decided to examine only those of children 
who had a hospital stay of longer than 4 days. This was based on the 
pragmatic assumption that children requiring CNEP would have 
moderate or severe bronchiolitis and so would almost certainly have 
stayed in hospital for longer than the median length of stay for 
bronchiolitis admissions, which in the UK is 4 days (Behrendt et al., 
1998). In this way the number of notes to be searched was reduced to 
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257 from the total of 1194. Data on length of hospital stay was obtained 
from Patient Administration System (PAS) records. 
4.1.2 Ward admission diaries
In NSH there were no computer records of admission diagnosis before 
April 1996 and so to identify admissions for bronchiolitis between 
January 1993 and April 1996 the ward diaries were used. All children 
with bronchiolitis who needed respiratory support were admitted to 
either the Paediatric Intensive Care Unit (PICU) or the children’s 
respiratory ward, which also served as a High Dependency Unit (HDU). 
The diaries were searched both for children whose admission 
diagnosis was recorded as ‘bronchiolitis’ or ‘RSV positive’, and for 
those (the majority) in whom no diagnosis was stated but instead had 
recorded admission symptoms deemed to be suggestive of 
bronchiolitis (cough, wheeze, shortness of breath or ‘chestiness’ in 
infants admitted during the months of October- April i.e. the RSV 
bronchiolitis season). The medical notes were examined for all those 
children whose admission lasted more than 4 days for the reasons 
explained in section 4.1.1, above. The length of hospital stay was 
determined from the patient administration system (PAS) records of 
admission, which was in use from March 1994 onwards. The notes 
were sought for all children admitted to the PICU with a diagnosis of 
bronchiolitis, regardless of their length of hospital stay. All the notes 
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obtained were searched for evidence of treatment with CNEP during 
the admission with bronchiolitis. 
The HDU ward admission diaries for January 1993-May 1994 could not 
be found. An attempt was made to identify the children admitted with 
bronchiolitis and treated with CNEP during this period, by searching 
through the diaries of the ‘short-stay’ ward. This was an assessment 
ward where children referred to hospital by family practitioners were 
first seen before being admitted to other wards or being discharged 
home again. As before, the diaries were searched for children with 
respiratory symptoms during the months of the RSV season (October-
April). The recorded symptoms that were considered significant
included: ‘difficulty breathing’, ‘cough’, ‘wheeze’, ‘chesty’, ‘bad chest’, 
‘cyanosed’, or ‘poor feeding’. The length of hospital stay could not be 
determined for most of these patients, as PAS records did not exist 
before March 1994. A total of 360 children were identified and only 54 
(admitted after March 1994) could be excluded because their hospital 
stay was less than 4 days. The medical notes were sought for the 
remaining 306 children with a view to searching through them all for 
evidence of CNEP use; however, only 191 notes could be traced. A 
search  of these 191 notes identified 5 children as having received 
CNEP,  but all 5 children were also identified from other sources. 
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4.1.3 Physiology study
Eighteen children had participated in a study of ‘The physiological 
effects of CNEP ventilation in infants with bronchiolitis’ and were 
identified from the relevant study records. The study records included 9 
children who received CNEP for bronchiolitis as well as 9 controls who 
did not receive CNEP. The notes were sought to ascertain which 
children were in the CNEP arm but four sets could not be traced. From 
the 14 sets of notes obtained, 8 children who had received CNEP were 
identified, 5 of whom had already been identified through the PICU and 
HDU ward diaries.
4.1.4 Self referral
Two children who had received CNEP were identified because their 
parents became aware of this study and contacted us to enquire about 
their eligibility to take part. Their notes were traced and the use of 
CNEP for bronchiolitis was confirmed.
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Figure 7: Identification of the study population
Queen’s Medical Centre (QMC) North Staffordshire Hospital (NSH)
Sources:
Computer records -1164 
Ward diaries - 19
→
1183
cases
Diagnosis of 
Bronchiolitis
1469 
cases
←
Sources:
Computer records -1194
Ward diaries - 260
Other sources -15
↓ ↓
413 Stay ≥ 4 days 474 ←
Computer records -257
Ward diaries - 202
Other sources - 15
↓ ↓
23 exclusions
7 deaths, 1 untraceable
← 336 Notes traced 465 →
20 received CNEP for 
weaning†
→
19 traced
1 death
↓ ↓ ↓
305 potential 
controls
110  
received 
CNEP
→
11 exclusions
1 death
1 untraceable
19 contacted
↓ ↓ ↓
61 non-responders
7 refusals
1 non-attendee*
3 post hoc exclusions
←
122 
contacted
97  
contacted
→
40 non-responders
7 refusals
6 non-responders
↓ ↓ ↓
50 Matched 
Controls*
Evaluated 50 CNEP 13 PPV + CNEP
* One of the controls who was the only match for an index child did not have a clinical assessment. † Children who received CNEP for the 
purpose of weaning from mechanical ventilation were evaluated separately without controls. 
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4.1.5 Exclusion criteria
Children were excluded from the study if they had any of the following:
1. Congenital cyanotic heart disease or non cyanotic heart disease 
requiring medication or associated with pulmonary hypertension.
2. Cystic fibrosis or other congenital anomaly involving the airway 
3. Neuromuscular disease
4. Primary or secondary immune deficiency
4.1.6 Summary of study population - Index cases
q A total of 649 notes were searched and 130 children identified 
who had received treatment with CNEP.
q 7 children were excluded using the criteria above and another 4 
because their notes revealed the diagnosis was not bronchiolitis.
q 99 children had received CNEP as primary treatment and 20 as 
an aid to weaning from conventional ventilation.
q 2 children had died after recovering from the bronchiolitis illness.
q A total of 50 children who had received CNEP as their primary 
treatment made up the final study population of index cases.
q 13 children who received CNEP to aid weaning from 
conventional ventilation are described as a separate group 
without controls.
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4.2 Study Population – Comparison group
Computer records were available for children admitted to the Queen’s 
Medical Centre (QMC) with a diagnosis of bronchiolitis between 
January 1993 and March 1999. As with the index cases the selection of 
notes to review was limited to those whose hospital stay was longer 
than 4 days. A further 19 children were found by searching a separate 
database of admissions to the PICU and by examining the PICU 
admission diaries; the notes were requested on all of these children. A 
total of 413 patients with a diagnosis of bronchiolitis and length of stay 
> 4 days were identified for the specified period. The notes of 336 
children were traced and details recorded of their admission for 
bronchiolitis and of their neonatal history. Thirty one were excluded 
(exclusion criteria as in 4.1.5, above), had died or were untraceable, 
leaving 305 children as potential controls. 
A matched control was selected for each index case with parental 
consent to participate in the study. When consent was withheld for a 
control child or no response was obtained after 2 letters, the next 
matching child was selected from the group of potential controls. 
Parents were given up to 6 weeks to respond to the first invitation letter 
before a second was sent. To improve recruitment and avoid delay in 
the final stages of the study, invitations were sent simultaneously to two 
controls for each index case. For one index case this resulted in two 
consented controls so the most closely matching was selected. Two 
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controls were replaced because subsequent to their recruitment, 2 
others were identified who matched more closely. There were thus 3 
controls at the end of the study who were unpaired and not included in 
the final analysis.
One of the controls failed to attend a follow up assessment despite 
written consent from a parent agreeing to participation in the study. As 
the only suitable match for a consented index case, this child was 
included in the study and their neonatal and bronchiolitis admission 
data (short term outcome data) were used in paired analysis.
4.3 Patient tracing and invitation letters
A study administrator used hospital records, the central NHS register 
and general practitioners as sources to trace the identified population.  
General practitioners were contacted to ensure that no child had died. 
A letter, originating from the lead consultant at each hospital, was sent 
to the parents of the identified children inviting them to participate in the 
study. Included with the invitation letters were information sheets 
(Appendices A, B and C) which explained the purpose and nature of 
the study in detail. Written informed consent was obtained from parents 
agreeing to participate in the study. The invitation letters, parent 
information leaflets and consent forms were designed by myself and 
revised by my supervisor. Ethical approval was obtained from the Local 
Research Ethics Committees in Stoke on Trent and Nottingham.
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4.4 Matching
Cases were matched using the following criteria:
q Sex (male/female)
q Gestational age (<32 weeks, 32-36 weeks, >36 weeks)
q Illness severity (mild, moderate, severe) - Table 12
q Fraction of inspired oxygen (FiO2) prior to ventilation 
The FiO2 just prior to starting CNEP was determined for all the index 
cases. Controls matching the first 3 criteria were then selected from the 
group of potential controls and matched for oxygen dependency. For 
those needing ventilation, FiO2 just before ventilation was used for 
matching; for those admitted to PICU but not ventilated, FiO2 just 
before admission to PICU was used; for controls treated on the general 
paediatric ward, the maximum FiO2 given was used for matching. 
4.5 Assessments 
Children in the index group taking part in the study were assessed in a 
clinic setting adjacent to the North Staffordshire Hospital (NSH). 
Children in the control group were assessed in the Paediatric 
Respiratory Laboratory at the Queen’s Medical Centre (QMC). Nine 
children (4 index cases, 5 controls) who had moved out of area, or 
whose parents were unable to attend either of these 2 centres, were 
visited at home. The parents of 2 children, who were recruited to a 
concurrent study of long-term outcome following the use of CNEP for 
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respiratory distress syndrome (RDS-CNEP study), gave consent to 
their participation in this study as well as they met the inclusion criteria 
for both. To avoid duplicating assessments, data acquired from these 2 
children for the RDS-CNEP study were used in this study as well. 
Assessments for the RDS-CNEP study were carried out by a colleague 
(KT) and included an identical data-set to that needed for this study. I 
carried out all the other assessments with the assistance of a 
respiratory nurse (AS) for subjects seen at the QMC. The study nurse 
measured children’s height, weight and blood pressure and assisted 
with the lung function testing. 
4.5.1 Examination
Height was measured with the child wearing socks but no shoes. A 
calibrated wall fixed stadiometer (Holtain Ltd., Dyfed, UK) was used at 
the QMC whilst a portable, temporarily fixed stadiometer (Raven 
Equipment Ltd, Essex, UK) was used for home visits and at the NSH. 
Weight was measured in light clothing using @90/$%&A weighing scales 
(Jessops Ltd, Nottingham, UK). Head circumference was measured 
with a ‘lasso’ tape measure (Child Growth Foundation) or a standard 
tape measure. Height, weight and head circumference standard 
deviation scores (z-scores) were calculated using data provided by the 
Child Growth Foundation in a ‘Microsoft Excel worksheet’. Blood 
pressure was measured with a mercury sphygmomanometer using an 
appropriately sized cuff. A respiratory examination was carried out to 
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identify any signs of acute or chronic respiratory disease and to 
measure the respiratory rate at rest. Neurological clinical examination 
was performed and documented in accordance with techniques 
described by Amiel-Tison and Stewart (1989). Examination findings 
were recorded in an assessment form (Appendix D). Criteria used to 
assess disability are detailed in Table 11.
4.5.2 Lung function tests
4.5.2.1 Airway resistance pre and post bronchodilator
Airway resistance (!int) was measured using a ‘Microlab 4000’ Micro-
RintTM device (Micro Medical Ltd, Gillingham, UK). Two identical Micro-
RintTM devices were shared between this study and another which was 
running concurrently (RDS-CNEP study). To minimise the chance of 
any small differences between devices, the same Micro-RintTM device 
was used whenever possible. It was necessary to use the second 
device to test 4 children in the control group because the first device 
was in use at the time. Subjects were seated in a comfortable position 
and were distracted with a puzzle book during the procedure. They 
were encouraged to breathe quietly through a plastic mouthpiece with a 
nose-clip in place and their cheeks supported from behind. If a nose 
clip was not tolerated, the child’s nose was occluded by the 
investigator’s fingers whilst also supporting their cheeks. Ten 
consecutive measurements were taken at random intervals during 
expiration and the median value of at least 6 acceptable measurements 
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was taken. Values were considered acceptable when both the ‘flow-
time curves’ and ‘pressure-time curves’ were of consistent shape 
(Phagoo et al., 1996); examples of acceptable and non-acceptable 
curves are shown in Figure 8. Airway resistance was repeated after the 
administration of 500 micrograms of salbutamol administered through a 
spacer device (Volumatic; Allen & Hanburys, UK) in all children who 
were able to perform adequate baseline lung function testing.
4.5.2.2 Spirometry including reversibility studies
Spirometry was performed using a Fleisch Pneumotachograph 
Spirometer 2120 (Vitalograph Ltd., Buckingham, UK) on all index cases 
and all but 4 of the controls. A second Fleisch Pneumotachograph 
Spirometer (Vitalograph Ltd., Buckingham, UK) was used on 4 children 
in the control group due to the first device being in use. Both devices 
were connected to a personal computer with spirotrac 4.20 software, 
which includes an incentive display. The spirometer was calibrated at 
the beginning of each test day with a 1-litre syringe (Vitalograph Ltd.) 
after adjusting for room temperature. Children were coached, by me or 
the study nurse, to perform the test in a standing position; the best of 3 
acceptable attempts was chosen in accordance with standardised 
criteria (Miller et al., 2005). The FEV1, FVC and FEF25-75 were recorded 
and spirometric measurements were repeated after inhalation of 
salbutamol 500 micrograms through a spacer device (Volumatic; Allen 
& Hanburys, UK) in all children who were able to perform adequate 
baseline lung function testing. 
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Figure 8: Examples of Rint Flow/Time and Pressure/Time curves obtained
ü - Accepted ü - Accepted
ü - Appears acceptable X - Not accepted
X – Not accepted X- Not accepted
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4.5.3 Data collected from medical notes
Details of the admission for bronchiolitis and neonatal history were 
mostly obtained from the medical notes. In a few cases, however, data 
were incomplete because of prior or subsequent treatment in a district 
general hospital (DGH); in these cases a letter was sent to the General 
Practitioner or DGH consultant to request the missing data. 
4.5.4 Data collected using questionnaires
Parents completed questionnaires (Appendices E and F) detailing 
disability, demographics, current health, family history, prior respiratory 
or neurological morbidity; they also completed the Strengths and 
Difficulties Questionnaire to quantify behaviour problems (Goodman, 
1999) and the Health Utilities Index (HUI-3) to assess health related 
quality of life (Feeny et al., 1996). An assessment of disability was 
made partly by clinical examination (Appendix D) and partly from 
information recorded in the parent and medical history questionnaires. 
The medical history questionnaire (Appendix E) was completed by 
interview of the parents whilst the parent questionnaire (Appendix F) 
was completed independently.
4.6 Statistical analysis
Data were entered into SPSS v11.5 and encoded for further analyses.
In view of the matched-pairs design, statistical methods appropriate for 
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paired data were used throughout the analyses unless the number of 
pairs where insufficient to justify its use. The sign test was used to 
compare matched pairs of continuous data (Armitage, 2002). Although 
this test has low statistical power, no assumptions are made on the 
shape of the probability distribution the observations are from. For 
paired categorical data with binary outcomes the Mantel-Haenszel 
statistic with 95% confidence intervals has been used (Rothman and 
Greenland, 1998) and for more than two categories the marginal 
symmetry of the outcomes was tested using the Stuart-Maxwell test.  
For outcomes in which there were insufficient pairs, a Mann Witney U 
test was used for continuous data and relative risk or a chi-squared for 
categorical data. 
4.7 Ethical issues
Ethical approval was obtained from the Local Regional Ethics 
Committees in Stoke on Trent and Nottingham prior to starting the 
study (Appendix G). Written informed consent was obtained from the 
parents or guardians of all children participating in the study.
4.8 Funding
The study was funded by the West Midlands Regional Health Authority, 
through the University Hospital of North Staffordshire NHS Trust, by a 
grant to the University of Nottingham. 
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5 Results
A comprehensive search of NSH records for patients admitted with 
bronchiolitis and treated with CNEP identified 130 children who received 
this mode of respiratory support. Twenty children received CNEP as an aid 
to weaning from PPV whilst 110 received CNEP as primary treatment. One 
hundred and sixteen children who were traced and found to be eligible for 
the study (97 treated primarily with CNEP, 19 who had CNEP for weaning 
from PPV) were invited to participate. Parental consent was obtained for 
63 children (54%). Fifty of the 97 children (51%) who received CNEP as 
their primary treatment were evaluated with an equal number of matched 
controls; 13 of the 19 children (68%) who received CNEP to aid weaning 
from PPV were evaluated without controls. Data for the children who 
received ‘CNEP for weaning’ are shown alongside those of children in the 
matched cohort study in Table 13 and in Figures 9-35. Other data for the 
children in the ‘CNEP for weaning’ group are listed in section 5.2.
5.1 Matched cohort study 
5.1.1 Non-responders or refusals
Audit data collected on all children who received CNEP as primary 
treatment during the period of interest shows that the median FiO2 prior to 
ventilation in those not recruited was 0.37, median gestation at birth was 
36 weeks and 83% were RSV positive. These factors do not differ 
significantly from those of children who were recruited to the study 
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(p=0.23, p=0.76, p=0.23 respectively; Mann-Whitney U test). Children 
recruited to the study were more likely than the non-responders or refusals 
to be male (32 v 20; p=0.035) and to have a severe illness (78% v 49%); 
they were less likely to have a moderate illness (22% v 51%; χ2 p=0.003).  
5.1.2 Matching details
  
Table 13: Population characteristics 
CNEP        
(n=50)
Controls
(n=50)
CNEP for 
weaning  
(n=13)
Non-responders 
or refusals 
(n=47)*
Matching Criteria
Male
32      
(64%)
32      
(64%)
5          
(39%)
20                
(43%)
Median gestational 
age at  birth (weeks)
37 37.5 36 36
Gestation age bands
< 32 weeks
32-36 weeks
 ≥ 37 weeks
9
15
26
9
15
26
2
5
6
11
13
22
Illness severity
Mild
Moderate
Severe
0
11
39
0
11
39
0
0
13
0
24
23
Median Fi02 0.28 0.40 0.41 0.37
(n=50) (n=49) (n=13) (n=47)
Median age at study 
evaluation (years)
(Range)
6.4
(4.5 -11.0)
7.7
(5.2 -11.5)
6.7
(5.2 - 10.8)
-
 
RSV positive
45     
(90%)
44       
(90%)
11         
(85%)
39                
(83%)
Ethnic Group
 White
 Mixed
 Asian
 Black
47
1
2
0
44
3
1
1
10
3
0
0
-
-
-
-
* The gestational age at birth was not recorded in the medical notes for a child 
who was a refusal.
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Details of the matching criteria and characteristics of the non responders 
or refusals are listed in Table 13 above. Fourteen children in the CNEP 
cohort (28%) received both intermittent (INEP) and continuous negative 
extrathoracic pressure (CNEP); 36 (72%) received CNEP alone. Thirty 
three children treated with CNEP and 27 controls had evidence of 
respiratory failure defined using criteria reported by Outwater and Crone 
(1984); this was not significantly different between the groups (p=0.35). 
The criteria included: hypercarbia (paCO2 ≥ 8.0 kPa) with or without 
respiratory acidosis, persistent hypoxia (paO2 ≤ 8.0 kPa despite FiO2 ≥
40%), metabolic acidosis, apnoea or bradycardia. The median pCO2 in the 
CNEP group was 8.5 kPa, (IQR 7.0 - 9.8) [n=28] prior to starting 
respiratory support and in the controls was 8.8 kPa, (IQR 8.03 -11.7) 
[n=19]; p=1.00. The pCO2 measurement used in analysis was that 
recorded just prior to respiratory support if the child was ventilated, 
otherwise it was the measurement prior to admission to PICU or at the 
point of maximum oxygen dependency. A child in the control group with a 
pCO2 measurement of 25.2kPa (outlier) had a corresponding pH of 6.9 
and from the records appears to have required immediate intubation and 
ventilation. The result has therefore been included in the analysis as a true 
measurement. Figure 9 is a scatter plot of pCO2 measurements.
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Figure 9: Scatter plot of ‘pre-ventilation’ capillary or arterial pCo2 with median 
values and interquartile ranges showing no significant difference between the 
CNEP cohort and their controls. The diamond shaped data points represent 
controls who received positive pressure respiratory support. Data for the children 
who received ‘CNEP for weaning’ are displayed without a comparison group.
Children in the control group were on average 1.25 years older than 
children in the CNEP cohort at the time of assessment. Age was partly 
controlled for by matching from a cohort of children treated at a similar 
time as those receiving CNEP. The groups were well matched in respect 
to the stipulated criteria other than for the pre-ventilation FiO2. Thirty-six 
cases were matched with controls within a FIO2 range of +/- 10% and 45 
cases were matched within a range of +/- 15% (1 SD). Each of the 5 
CNEP cases that could not be matched within this range had FIO2
136 136
between 0.24 - 0.28 before commencing ventilation. They were matched 
with controls whose FIO2 ranged from 0.40 - 0.47 (FIO2 differences: +0.16, 
+0.16, +0.18, +0.19 and + 0.21, respectively). Just over half of infants 
treated with CNEP were receiving nasal cannula oxygen prior to starting 
respiratory support compared to just 14% of the controls. Almost 75% of 
controls were receiving headbox oxygen (Table 14). 
Table 14. Different modes of oxygen delivery in the CNEP and control cohorts
Nasal prongs Head box Face mask
CNEP 27 18 5
Controls 7 37 6
5.1.3 Demographic and neonatal variables
Demographic details of the 2 groups are shown in Table 15. There were 
no significant differences in birth weight, parental age, social class or other 
demographic information. There was a trend towards increased prenatal 
smoking amongst mothers in the CNEP group; parents who were current 
smokers were not significantly different between the groups. One child in 
the CNEP cohort was a smoker; none of the children in the control group 
reported being a smoker. 
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A range of demographic details and neonatal variables were evaluated in 
the 2 groups and are shown in Tables 15 and 16. Equal numbers of 
children in the CNEP and control cohorts were admitted to the neonatal 
intensive care unit. The rates of intubation at birth and subsequent 
ventilation on NICU were not significantly different between the groups. 
Four children in the CNEP group compared to none of the controls had 
had intraventricular haemorrhages in the neonatal period; this was not 
significantly different between the groups.
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Table 15: Demographic information of children in the CNEP and control cohorts; comparisons made with Sign tests or Mantel-Haenszel 
statistic as appropriate
CNEP Range Controls Range Number of pairs ‘p’
Median birth weight (grams) 2597 [n=50] 975 - 4479 2800 [n=49] 820 - 4479 49 0.15
Median maternal age (years) 34 [n=48] 22 - 48 36 [n=48] 25 - 51 46 0.46
Median paternal age (years) 39 [n=44] 23 - 53 39 [n=44] 29 - 64 39 0.14
Median  aovercrowding index                      1.20 [n=50] 0.5 - 2.7 1.25 [n=45] 0.7 - 2.3 45 0.11
CNEP Controls
Number of 
pairs
Mantel-
Haenszel 
statistic
95% confidence 
intervals
‘p’
Maternal social class
Manual
Non-manual
[n=49]
32
17
[n=48]
24
24
47 1.25 0.93 to 1.67 0.13
Paternal social class
Manual
Non-manual
[n=44]
28
16
[n=42]
23
19
39 1.25 0.89 to 1.76 0.20
Current smokers in household 28 [n=50] 19 [n=49] 49 1.42 0.86 to 2.35 0.17
Maternal smoking in pregnancy 23 [n=50] 14 [n=50] 50 1.64 0.95 to 2.84 0.07
Receiving benefits 36 [n=50] 34 [n=48] 48 1.03 0.87 to 1.22 0.74
Maternal use of a car 35 [n=49] 37 [n=48] 47 0.92 0.71 to 1.19 0.51
Paternal use of a car 26 [n=45] 29 [n=45] 40 0.89 0.66 to 1.21 0.47
a
Overcrowding index = (Number of adults + children in the household)/ Number of rooms
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Table 16: Neonatal information of children in CNEP and control cohorts; comparisons made using Mantel-Haenszel statistic or Mann 
Whitney U test
CNEP
[n=50]
Controls
[n=50]
Mantel-Haenszel 
statistic
95% C.I. ‘p’
NICU admission 22 22 1.00 0.75 to 1.33 1.00
Intubated at birth 8 6 1.33 0.60 to 2.97 0.48
Ventilated in NICU 7 [n=22] 12 [n=22] 0.58 0.29 to 1.19 0.13
Intraventricular haemorrhage 4 [n=6]* 0 [n=6]* - - 0.16
Postnatal steroids for chronic lung disease 2 1 0.00 - 0.32
Neurological abnormality suspected at birth 4 2 2.00 0.50 to 8.00 0.32
CNEP Range Controls Range ‘p’
Median number of days ventilated (NICU) 4 [n=7] 1 - 38 3.5 [n=12] 1 - 33 0.27
Median number of days in oxygen  (NICU) 4 [n=15] 1 - 301 5  [n=10] 1 - 75 0.33
* There were 3 children in both cohorts who were preterm (<32weeks) but had no recorded cranial ultrasound findings
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5.1.4 Outcome evaluations
5.1.4.1 Primary outcome measure
Nine children (6 CNEP, 3 controls) were unable to cooperate 
sufficiently with testing for !int due to their young age or developmental 
problems. Median baseline !int (% predicted) was significantly higher 
in the CNEP group compared to controls: CNEP 99.5%, Controls 83%; 
p<0.001 (Figure 10, Table 17) but there was no significant difference in 
the percentage (%) change !int after bronchodilator treatment (Figure 
11, Table 17). This showed a median 31.8% fall in the CNEP group and 
a 29.6% fall in controls; p=0.43 (Table 17). The median bronchodilator 
response ratio (BDR ratio) was1.47 (Range 0.89 - 2.48) for children 
treated with CNEP and 1.42 (Range 0.92 - 2.56) for controls; p=0.43, 
[n= 40 pairs]. Thirty three children treated with CNEP [n=44] and 31 
controls [n=46] had a BDR ratio ≥ 1.22; in paired analysis the relative 
risk of CNEP being associated with a BDR ratio ≥ 1.22 was 1.07, 95% 
C.I. 0.80 -1.43, n=40 pairs; p=0.64. The effect of tobacco smoke 
exposure on the observed difference in !int has been further explored 
by stratifying the data to evaluate pairs in the CNEP and control cohorts 
where the exposure was similar. For the 6 pairs of children who had 
smoking parents in the home the median !int value was 93% - CNEP 
group (range 80-113%) and 83% - Control group (range 66 - 103%; 
p=0.031). For 8 pairs of children whose parents were non smokers the 
median !int value was 93.5% - CNEP group (range 75 - 159%) and 
75% - Control group (range 44% - 112%; p=0.07).
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5.1.4.2 Other respiratory outcome measures  
Thirteen children (9 CNEP, 4 controls) were unable to perform 
spirometry. All lung function tests were adequately performed by 39 
children in the CNEP cohort [n=50] and 45 children in the control group 
[n=49]; this was not significantly different between the two groups 
although there was a trend towards more success in controls (Mantel-
Haenszel statistic 0.87, 95% CI: 0.74 -1.02; p= 0.08). FEV1 and FVC 
were not significantly different in the two groups and showed similar 
change after bronchodilator treatment (Figures 12-15). In contrast 
median FEF25-75 was significantly lower in the CNEP group - 77.5% 
predicted compared to controls - 86.8% predicted; p=0.029 (Figure 16). 
The percentage change FEF25-75 was not significantly different between 
the groups (Figure 17). The significant difference found in baseline 
FEF25-75 supports the finding of higher airway resistance in the CNEP 
cohort. 
The frequency of wheeze and inhaled medication use was similar in the 
two groups (Table 19, Figures 21 and 22) and there were no 
differences in the number of intrinsic or extrinsic risk factors for asthma. 
No child was admitted to hospital with a respiratory illness in the 12 
months before being assessed. 
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5.1.4.3 Short term outcome measures
Short term outcome measures are shown in Table 18. Children in the 
CNEP cohort spent an average of 2 days longer in supplemental 
oxygen; p=0.037 (Table 18, Figure 19) and stayed in hospital an extra 
1.8 days compared to controls; p=0.087 (Table 18, Figure 18). In 
contrast they received PPV less frequently (6 versus 18; p=0.005) and 
if ventilated, spent a shorter period receiving IPPV; p=0.004 (Table 18, 
Figure 20) compared to their matched controls. Twenty six children 
treated with CNEP and 23 controls were admitted to PICU (p=0.49).
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Table 17: Results of lung function testing of children in the CNEP and control cohorts; comparisons made with Sign test.
CNEP Range Controls Range
Number 
of pairs
‘p’
Baseline Airway Resistance (kPaL-1s-1) 0.71 [44] 0.31 to 1.19 0.56 [47] 0.27 to 1.53 41 0.003
(% predicted) 99.5  [44] 54.0 to 160.0 83.0  [47] 44.0 to 225.0 41 <0.001
Airway Resistance post bronchodilator (kPaL-1s-1) 0.48 [44] 0.21 to 1.00 0.41 [46] 0.18 to 0.92 40 0.025
(% predicted) 68.0   [44] 40.0 to  118.0 59.5  [46] 29.0 to 139.0 40 0.025
% change in Airway Resistance -31.8  [44] -60.0 to 13.0 -29.6 [46] -61.0 to 9.0 40 0.43
FEV1  (% predicted) 86.3   [41] 48.3 to 112.1 88.5  [46] 56.9 to 119.3 39 0.52
FEV1 post bronchodilator (% predicted) 98.0   [39] 60.6 to 114.9 97.2  [43] 73.5 to 124.5 36 0.62
% change in FEV1 11.7   [39] -7.2 to 58.6 10.7  [43] -6.8 to 32.2 36 0.13
FVC  (% predicted) 96.9   [41] 69.8 to 121.5 93.9  [48] 61.4 to 123.2 40 0.08
FVC post bronchodilator (% predicted) 102.7 [40] 84.1 to 121.7 100.1  [47] 55.9 to 122.3 38 0.63
% change in FVC 6.0     [40] -11.6 to 38.5 5.9   [47] -9.9 to 24.3 39 0.63
FEF25-75                                                                   (% predicted) 77.5   [42] 13.7 to 196.6 86.8  [48] 33.9 to 127.5 40 0.029
FEF25-75 post bronchodilator             (% predicted) 93.9   [41] 26.6 to 192.7 102.4 [47] 57.5 to 173.7 39 0.34
% change in FEF25-75 23.3   [41] -13.3 to 173.8 27.2   [47] -10.6 to 83.2 39 1.00
[n]= number of children who successfully completed the test, FEV1 = Forced expiratory volume in 1 second, FVC = Forced vital capacity, 
FEF25-75 = Forced expiratory flow between 25% and 75% of forced vital capacity.
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Figure 10: Scatter plot of baseline Rint with median values and 
interquartile ranges showing a significant difference in baseline 
Rint between the CNEP cohort and their controls. Data for the 
children who received ‘CNEP for weaning’ are displayed without a 
comparison group.
Figure 11: Scatter plot of % change Rint with median values and 
interquartile ranges showing no significant difference in the % 
change Rint following a bronchodilator. Data for the children who 
received ‘CNEP for weaning’ are displayed without a comparison 
group.
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Figure 12: Scatter plot of baseline forced expiratory volume in 1 
second with median values and interquartile ranges showing no 
significant difference between the CNEP cohort and their controls. 
Data for the children who received ‘CNEP for weaning’ are 
displayed without a comparison group.
Figure 13: Scatter plot of % change forced expiratory volume in 1 
second with median values and interquartile ranges showing no 
significant difference between the CNEP cohort and their controls. 
Data for the children who received ‘CNEP for weaning’ are displayed 
without a comparison group.
146
Figure 14: Scatter plot of baseline forced vital capacity with 
median values and interquartile ranges showing no significant 
difference between the CNEP cohort and their controls. Data for 
the children who received ‘CNEP for weaning’ are displayed 
without a comparison group.
Figure 15: Scatter plot of % change forced vital capacity with median 
values and interquartile ranges showing no significant difference 
between the CNEP cohort and their controls. Data for the children 
who received ‘CNEP for weaning’ are displayed without a 
comparison group.
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Figure 16: Scatter plot of baseline FEF25-75 with median values and 
interquartile ranges, showing a significant difference between the 
CNEP cohort and their controls. Data for the children who received 
‘CNEP for weaning’ are displayed without a comparison group.
Figure 17: Scatter plot of %change FEF25-75 with median values and 
interquartile ranges, showing no significant difference between the 
CNEP cohort and their controls. Data for the children who received 
‘CNEP for weaning’ are displayed without a comparison group.
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Table 18: Variables associated with the index bronchiolitic illness in the CNEP and control cohorts; comparisons made with the Sign test or 
Mann-Whitney U test as appropriate.
CNEP
[n=50]
Range
Controls
[n=50]
Range
No of 
pairs
‘p’
Median age at admission with 
bronchiolitis (weeks)
9.3 1 -71 8.0 2 -54 50 0.89
Median time to ventilation, to PICU 
admission or to maximum FiO2 (hours) 24.5 1 -138 18.5 1 -127 39 0.87
Median length of stay in hospital with 
bronchiolitis (days)
9 [n=46] 5 -26 8 [n=50] 4 - 25 46 0.017
Median duration of oxygen therapy with 
bronchiolitis illness (days) 
8 [n=45] 4 -23 5 [n=48] 1 -23 43 0.035
Median duration of nasogastric or 
intravenous feeding (days) 
4.5 0 -20 4.5 0 -21 50 0.56
Median duration of CNEP (days) 3.5 1 -15 N/A - - -
CNEP Range Controls Range ‘p’*
Median length of stay on PICU (days) 2  [n=26] 1 - 10 4   [n=23] 1 - 18 - 0.80
Median duration of  IPPV/ CPAP (days) 4.5 [n=6] 1 - 9 5.5 [n=18] 1 - 15 - 0.004
* Mann-Whitney U test
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Figure 18: Scatter plot of days hospital stay with median values and 
interquartile ranges showing significantly longer hospital stay in the 
CNEP cohort compared to their controls. Data for the children who 
received ‘CNEP for weaning’ are displayed without a comparison group.
Figure 19: Scatter plot of days of supplementary oxygen therapy with 
median values and interquartile ranges showing significantly more days 
of oxygen therapy in the CNEP cohort compared to their controls. Data 
for the children who received ‘CNEP for weaning’ are displayed without 
a comparison group.
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Figure 20: Scatter plot of days of positive pressure ventilation with median 
values and interquartile ranges showing significantly fewer days of PPV in the 
CNEP cohort compared with their controls. Data for the children who received 
‘CNEP for weaning’ are displayed without a comparison group.
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Table 19: Respiratory outcomes reported by parents showing no significant difference between the CNEP and control cohorts; comparisons 
made using Mantel-Haenszel statistic
CNEP 
[n=50]
Control 
[n=49]
Mantel-Haenszel 
statistic
95% C.I. ’p’
Any wheezing in previous 12 months 15 13 1.15 0.66 to 2.02 0.62
Ever diagnosed asthma 18 19 0.95 0.58 to 1.54 0.83
Follow up by a paediatrician for respiratory  disorder 4 2 2.00 0.37 to10.92 0.41
Current use of bronchodilators 11 16 0.94 0.85 to 1.03 0.18
Current use of steroid inhalers 7 11 0.64 0.26 to 1.55 0.32
Frequency of wheeze in previous 12 months‡
No wheeze
Occasional wheeze (1-3 episodes)
Moderate wheeze (4 -12 episodes)
Frequent wheeze (> 12 episodes)
35
7
8
0
36
10
0
3
- - 0.30
No. of extrinsic* factors  
None
1
2
3
24
22
3
1
22
22
3
2
- - 0.95
No. of intrinsic† factors   
None
1
2
 ≥3
12
9
7
22
4
10
7
28
- - 0.24
* Extrinsic factors = Damp, mould, long haired or feathered pets, †Intrinsic factors = Family history of asthma, hay fever or chronic chest 
problem, ‡ assessed with the Stuart Maxwell Statistic
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Figure 21: Stacked bar graph of the frequency of wheezing in the 
12 months prior to assessment; no significant difference was found 
between the CNEP cohort and their controls. Data for the children 
who received ‘CNEP for weaning’ are displayed without a 
comparison group.
Figure 22: Stacked bar graph showing whether or not a diagnosis 
of asthma had been made at any time previously; no significant 
difference was found between the CNEP cohort and their controls. 
Data for the children who received ‘CNEP for weaning’ are 
displayed without a comparison group.
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5.1.4.4 Functional outcome measures 
One child in the control group did not have a clinical or respiratory 
assessment and so their paired CNEP child, who was assessed to 
have a moderate or severe disability, was removed from this analysis, 
leaving 49 sets of paired data (Table 20). Of the remaining children, 14 
in the CNEP group had moderate or severe disability compared to 10 in 
the control group (Figure 23); this was not significantly different 
between the groups, Mantel-Haenszel statistic 1.40 (95%CI: 0.64 to 
3.04). An unexpectedly high proportion of children in both groups were 
identified as having a moderate or severe disability because of high 
behavioural scores. Without this domain, 7 children had moderate or 
severe disability in the CNEP group compared to 5 in the control group 
(Figure 24); this also was not significantly different between the groups, 
Mantel-Haenszel statistic 1.40 (95%CI: 0.49 to 3.99). No significant 
difference was found between the groups in any of the individual 
disability domains (Figures 25-30, Table 20). Figure 31 and Table 22 
show the frequency and types of diagnoses known to be associated 
with disability which parents were aware of prior to their childrens’ 
treatment for bronchiolitis. At assessment 1 child in the CNEP group 
and 2 children in the control group had cerebral palsy (CP). The CNEP 
child had ataxic type CP; one of the controls had unilateral spastic CP 
and the other had bilateral spastic CP. A possible association between 
the use of CNEP and upper limb coordination problems has previously 
been reported; no significant difference was found between the groups 
for this outcome measure (Table 21).
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Table 20: Disability by pair within 6 domains showing no significant differences between the CNEP and control cohorts; comparisons made 
using Mantel-Haenszel statistic.
CNEP 
*[n=49]
Controls 
* [n=49]
Mantel-
Haenszel 
statistic
95% C.I. ‘p’ value
Moderate or severe cognitive disability 5 2 2.5 0.5 to 12.9 0.26
Moderate or severe neuromotor disability 4 4 1.0 0.3 to 3.3 1.00
Moderate or severe visual disability 1 1 1.0 0.1 to 16.0 1.00
Moderate or severe hearing disability 0 0 - - -
Moderate or severe behaviour disability 11 6 1.8 0.7 to 5.0 0.23
Moderate or severe other disability 6 3 2.0 0.6 to 6.8 0.26
Any moderate or severe disability 14 10 1.40 0.64 to 3.04 0.39
Any moderate or severe disability 
(excluding behaviour)
7 5 1.40 0.49 to 3.99 0.53
* One child in the control group did not have a clinical assessment and so their paired CNEP child, who was assessed to have a
moderate or severe disability was removed from this analysis leaving 49 sets of paired data.
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Table 21: Upper limb function in CNEP and control cohorts; comparisons made using Stuart-Maxwell test.
Normal Impairment
Mild 
clumsiness
Able to feed and 
dress but
requires aids or 
assistance
for some tasks
Severe difficulty 
with fine 
movements, 
requires aids or 
assistance
Total
Controls 45 0 3 1 0 49
91.8% 0% 6.1% 2.0% 0% 100.0%
CNEP 43 0 3 3 1 50
86.0% 0% 6.0% 6.0% 2.0% 100.0%
Stuart-Maxwell test for a 4x4 table performed; χ2 test statistic 1.36, p=0.71
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Figure 23: Stacked bar graph of worst disability scores; no 
significant difference was found between the CNEP cohort and 
their controls. Data for the children who received ‘CNEP for 
weaning’ are displayed without a comparison group.
Figure 24: Stacked bar graph of worst disability scores without 
behavioural domain; no significant difference was found between 
the CNEP cohort and their controls. Data for the children who 
received ‘CNEP for weaning’ are displayed without a comparison 
group.
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Figure 25: Stacked bar graph of cognitive disability; no significant 
difference was found between the CNEP cohort and their controls. 
Data for the children who received ‘CNEP for weaning’ are 
displayed without a comparison group.
Figure 26: Stacked bar graph of motor disability; no significant 
difference was found between the CNEP cohort and their 
controls. Data for the children who received ‘CNEP for weaning’ 
are displayed without a comparison group.
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Figure 27: Stacked bar graph of hearing disability; no significant 
difference was found between the CNEP cohort and their controls. 
Data for the children who received ‘CNEP for weaning’ are displayed 
without a comparison group.
Figure 28: Stacked bar graph of visual disability; no significant 
difference was found between the CNEP cohort and their 
controls. Data for the children who received ‘CNEP for weaning’ 
are displayed without a comparison group.
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Figure 29: Stacked bar graph of behavioural disability; no significant 
difference was found between the CNEP cohort and their controls. 
Data for the children who received ‘CNEP for weaning’ are displayed 
without a comparison group. 
Figure 30: Stacked bar graph of other disability; no significant 
difference was found between the CNEP cohort and their 
controls. Data for the children who received ‘CNEP for weaning’ 
are displayed without a comparison group. 
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Figure 31: Stacked bar graph showing whether or not a diagnosis associated 
with disability was suspected before admission with bronchiolitis; no significant 
difference was found between the CNEP cohort and their controls. Data for the 
children who received ‘CNEP for weaning’ are displayed without a comparison 
group.
Table 22: Known or suspected diagnoses associated with disability in children 
in the CNEP and control cohorts at the time of assessment
CNEP Controls
Down Syndrome 2 1
Haemorrhagic hydrocephalus 1 0
Severe learning difficulties 1 0
Suspected Cornelia De Lange 1 0
Peter’s Plus Syndrome 0 1
Cerebral Palsy 1 2
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5.1.4.5 Parent reported health related quality of life 
This was assessed using the HUI3 multi-attribute scores. The median 
HUI score for the CNEP group was 1.00 (IQR: 0.85 -1.00) and did not 
differ significantly from that of the controls 0.99 (IQR: 0.81 -1.00), n=48 
pairs; p=0.37 (Figure 32).
Figure 32: Scatter plot of the Health Utilities Index 3 multi-attribute scores 
showing no significant difference between the CNEP cohort and their controls. 
Data for the children who received ‘CNEP for weaning’ are displayed without a 
comparison group.
162
5.1.4.6 Growth measures
The CNEP group were heavier and taller than controls although this 
was not statistically significant. Median weight z-score was 0.53 (Range 
-2.79 to 3.13) for the CNEP cohort [n=50] and -0.02 (Range -3.96 to 
3.39) for controls [n=49]. The median height z-score was 0.02 (Range -
3.14 to 2.10) for the CNEP cohort [n=50] and -0.09 (Range -4.66 to 
1.77) for controls [n=49]. The median head circumference z-score was 
0.53 (Range - 5.9 to 3.53) for the CNEP cohort [n=50] and -0.36 
(Range -3.9 to 2.74) for controls [n=48]. A child in the ‘CNEP for 
weaning’ group had a rare syndrome which resulted in profound growth 
restriction (‘CINCA Syndrome’). The data for this child are included as 
they are true measurements. Weight, height and head circumference z-
scores are depicted in Figures 33-35. 
Figure 33 : Scatter plot of weight z-scores showing no significant difference 
between the CNEP cohort and their controls. Data for the children who received 
‘CNEP for weaning’ are displayed without a comparison group.
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Figure 34: Scatter plot of height z-scores showing no significant 
difference between the CNEP cohort and their controls. Data for the 
children who received ‘CNEP for weaning’ are displayed without a 
comparison group
Figure 35: Scatter plot of head circumference z-scores showing no 
significant difference between the CNEP cohort and their controls. Data 
for the children who received ‘CNEP for weaning’ are displayed without  
a comparison group
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5.2 Uncontrolled study of CNEP used to 
facilitate weaning from PPV
The data of 13 children who had PPV as their primary treatment but 
received CNEP to help aid weaning from respiratory support are 
provided in this section. These children were identified as a group that 
needed separate evaluation to those in whom CNEP was the primary 
treatment. No suitable control group was identified for these children; 
however, data obtained from their evaluation has been included in this
thesis for completeness and to allow any important trends or patterns 
to be identified. Without a control group it is not possible to determine 
the effect of either treatment modality (CNEP and PPV) on the outcome 
measures evaluated as both modalities could be contributing to the 
measurement being investigated. Analysis of the data obtained from 
this group is limited to descriptive statistics and general comparisons 
with the CNEP and control groups. Data have also been illustrated 
graphically in Figures 9-35 alongside those of the children evaluated as 
part of the matched cohort study and listed separately in Tables 23-29. 
5.2.1 Matching criteria
Children who received CNEP for weaning from PPV were evaluated 
against matching criteria (Table 13) to determine how this group differs 
from children evaluated in the matched cohort study. There were fewer 
males (39%) and they had significantly higher pre-ventilation FiO2
(0.48) compared to the CNEP group (p=0.012) but not the controls 
(p=0.32). There was also a trend towards more severe illness in this 
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group (Table 13) compared to those in the matched cohort study (χ2; 
p=0.06). Their median gestational age was 36 weeks and 85% were 
RSV positive, both similar to the other groups. Their median age at 
study evaluation was 6.7 years, which was not significantly different to 
the CNEP group but was younger than the controls.
5.2.2 Demographic and neonatal variables
Demographic data for the children who received ‘CNEP for weaning’ 
are listed in Table 23 and are similar to those of children in the 
matched cohort study.
Table 23: Demographic information of children who received CNEP for weaning 
from PPV
 Mean [n]
Mean birth weight (grams) 2450 [13]
Mean maternal age (years) 36.7 [13]
Mean paternal age (years) 36.2 [11]
aOvercrowding index 1.00 [12]
Maternal social class 
Non-manual
Manual
7[13]
6[13]
Paternal social class
Non-manual
Manual
6[10]
4[10]
Current smokers in household 8 [13]
Maternal smoking in pregnancy 5 [12]
Receiving benefits 8 [13]
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None of the children who received CNEP for weaning from PPV were 
intubated at birth. The neonatal data of these children is otherwise 
similar to those of the children in the matched cohort group (Table 24). 
Table 24: Neonatal information of children who received CNEP for weaning 
from PPV
 Frequency [n]
NICU admission 8 [13]
Intubated at birth 0 [12]
Ventilated in NICU 2 [13]
Intraventricular haemorrhage 1 [11]
Postnatal steroids for chronic lung disease 0 [11]
Neurological abnormality suspected at birth 0 [12]
Median (Range) [n]
Median number of days ventilated (NICU) 0 (0 -11)    [13]
Median number of days in 02  (NICU) 0 (0 -154 ) [12]
5.2.3 Outcome evaluations
Lung function results of children who received CNEP for weaning from 
PPV are listed in Table 25. These results do not differ significantly from 
those of children in the CNEP or control cohorts.
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Table 25: Lung function tests of children who received CNEP for weaning from PPV
Median 
values 
[n=11]
Range
Baseline Airway Resistance      (kPaL-1s-1) 0.80 [12] 0.4 to 2.45
(% predicted) 103.0 65.0 to 137.0
Airway Resistance post bronchodilator (kPaL-1s-1) 0.49 0.3 to 1.57
(% predicted) 62.0 44.0 to 161.0
% change in Airway Resistance -29.5 -56.0 to 20.0
FEV1  (% predicted) 87.1 56.6 to 110.1
FEV1 post bronchodilator        (% predicted) 97.2 59.8 to 120.0
% change in FEV1 6.2 -2.2 to 40.1
FVC (% predicted) 91.2 63.4 to 119.1
FVC post bronchodilator         (% predicted) 103.5 62.0 to 120.9
% change in FVC 2.0 -5.0 to 18.7
FEF25-75                                                      (% predicted) 82.7 48.3 to 117.3
FEF25-75 post bronchodilator   (% predicted) 101.4 69.9 to 132.8
% change in FEF25-75 15.5 -6.6 to 109.9
Parent reported respiratory outcomes in children receiving CNEP for 
weaning are listed in Table 26. There are no major differences in these 
measures when compared to CNEP or control cohorts other than the 
frequency of wheezing which was more likely to be moderate or 
frequent than the other two groups.
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Table 26: Respiratory outcomes reported by parents for children who received 
CNEP for weaning from PPV
Frequency 
[n=13]
Any wheezing in previous 12 months 8
Ever diagnosed asthma 7
Follow up by a paediatrician for respiratory disorder 4
Current use of bronchodilators 8
Current use of steroid inhalers 6
5
1
5
Frequency of wheeze in previous 12 months
No wheeze
Occasional wheeze (1-3 episodes)
Moderate wheeze (4 -12 episodes)
Frequent wheeze (> 12 episodes) 2
No. of extrinsic*factors  
None
1
2
3
[n=12]
4
6
0
2
No. of intrinsic† factors   
None
1
2
 ≥3
[n=13]
2
2
4
5
Mean [n=13]
No of days off school with respiratory illness 8.2
No of days off school with any illness 13.9
*Extrinsic factors = Damp, mould, long haired or feathered pets †Intrinsic factors = 
Family history of asthma or wheezing, hay fever or chronic chest problem. 
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There were no major differences in the prevalence of disability in 
children receiving CNEP for weaning compared to the CNEP cohort or 
controls (Table 27 and 28). The health related quality of life assessed 
with the health utilities index 3 multi-attribute score does not differ 
significantly from that of children in the CNEP and control cohorts 
(median HUI score 0.78 IQR: 0.40 - 1.00). 
Table 27: Disability within 6 domains in children who received CNEP for 
weaning from PPV
Frequency 
[n=13]
Moderate or severe cognitive disability 1
Moderate or severe neuromotor disability 1
Moderate or severe visual disability 2
Moderate or severe hearing disability 0
Moderate or severe behaviour disability 3
Moderate or severe other disability 3
Any moderate or severe disability 6
Any moderate or severe disability  
(excluding behaviour)
4
Table 28: Worst disability in children who received CNEP for weaning from PPV
Worst disability Worst disability 
(excluding behaviour)
No disability 4 4
Impaired / mild 3 5
Moderate / severe 6 4
5.2.3.1 Short term outcome measures
Short term outcome measures are shown in Table 29. Children in 
whom CNEP was used for weaning spent longer ventilated overall and 
were admitted to PICU for longer periods than children in both the 
CNEP and control cohorts (p=0.005 and p<0.001 respectively). They 
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also spent significantly longer receiving oxygen therapy (p=0.003) and 
in hospital (p=0.001) than children in the control groups (Figures 18 
and 19). 
Table 29: Bronchiolitis illness variables in children who received CNEP for 
weaning from PPV
Range [n]
Median length of stay on PICU (days)  6 (4 -28) [13]
Median length of stay in hospital with 
bronchiolitis (days)
15 (7-37) [11]
Median duration of 02 therapy with 
bronchiolitis illness (days) 
11 (6-32) [9]
Median duration of nasogastric or 
intravenous  feeding (days) 
8 (3 - 32) [13]
Median duration of  IPPV/ CPAP  4 (1 -24) [13]
Median time from admission to hospital to 
ventilation (hours)
7 (0-119) [10]
Median duration of CNEP (days) 3 (1- 9) [13]
5.2.3.2 Growth measures
Children in whom CNEP was used for weaning were shorter and lighter 
than children in the CNEP cohort but not the controls. The median 
weight z-score was -0.58 (range -4.99 to 1.77) and the median height 
z-score was -0.83 (range -5.97 to 1.06). The median head 
circumference z-score was -1.23 (range -2.35 to 0.57) and not 
significantly different to the other two groups (Figures 33-35). 
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6 Discussion
6.1 Summary of findings
The study aim was to determine whether there are respiratory or 
neurological consequences to the use of CNEP for the treatment of 
bronchiolitis. The primary hypothesis was that there is no difference in 
airway resistance measured in later childhood between infants who 
received CNEP for bronchiolitis and matched controls. The secondary 
hypotheses were that there were short term benefits associated with the 
use of CNEP but no difference in respiratory symptoms, disability or health 
related quality of life in children receiving this treatment compared to 
controls treated with conventional methods. The findings from this study 
do not support the primary hypothesis and instead show significantly 
increased airway resistance in children treated with CNEP when assessed 
at a median age of 6.4 years. The forced mid-expiratory flow (FEF25-75)
was also significantly lower in children treated with CNEP in keeping with 
the finding of increased airway resistance. There were no differences in 
any of the other spirometric measures, including FEV1 and FVC, and no 
difference in the frequency of reported respiratory symptoms such as 
wheeze. Disability (defined in Table 11) and health related quality of life 
assessed with the Health Utilities Index were not significantly different 
between the groups. 
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The finding of a significant difference in airway resistance raises a number 
of questions including:
1. If CNEP is associated with higher airway resistance is the 
difference observed of any clinical significance?
2. Are there factors other than the mode of respiratory support 
received which differ between the groups and contribute to the 
difference in airway resistance?
3. If the use of CNEP is truly associated with higher airway resistance, 
what is the mechanism involved?
6.2 Difference in airway resistance
In the next sections I will discuss potential confounding factors and other 
possible explanations for the difference in airway resistance observed.  
These will be considered under the headings: “is the difference of clinical 
significance?”; “population differences” and “effect of CNEP on airway 
resistance”.
6.2.1 Is the difference of clinical significance?
Although the difference in baseline !int between the groups is statistically 
significant it is important to ascertain if it has clinical significance. !int has 
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been shown to have a high coefficient of variability particularly in children 
with RAD (Chan et al., 2003). The within-occasion variability of !int in a 
healthy individual is of the order of 20% and is much higher than that of 
other spirometric measurements. In an individual, a change in !int of this 
magnitude between 2 measurements taken on the same occasion may 
therefore reflect natural variability. For the comparison of 2 groups, 
however, this difference still has clinical significance as the co-efficient of 
variability relates to an individual and not a group. A randomised controlled 
crossover trial of the use of fluticasone in preschool children with 
intermittent wheeze found a mean reduction in !int of 16% after 6 weeks 
of treatment in children sensitised to aeroallergens. The mean !int 
returned to baseline 16 weeks after stopping treatment. The difference in 
median !int observed in this study of 16.5% is of a similar magnitude and
must also be considered clinically significant. However, this degree of 
change in !int is comparable to a difference in FEV1 of less than 5% 
which is only a small change in respiratory function. In a randomised study 
of the effects of anti-asthma treatment on lung function in children, 
Stelmach et al. (2007) evaluated 150 children with a range of lung 
function tests following treatment with budesonide, montelukast, 
budesonide + formoterol, budesonide + montelukast or placebo. The lung 
function tests included the spirometric measures: FEV1 and FEF25-75; 
specific airway resistance measured using plethysmography (SRaw) and 
!int. All four measures were tested in the 5 groups before and after 4 
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weeks of active treatment or placebo. !int, SRaw, and FEV1 improved 
significantly in all active treatment groups, whilst FEF25-75 only increased 
significantly in the 2 groups treated with montelukast and budesonide + 
montelukast. A change in !int of 18-20% corresponded to a change in 
FEV1 of 5% and a change in FEF25-75 of 8%. Interestingly, !int performed 
better than SRaw in discriminating responses to treatment, confirming the 
view that it is a sensitive tool for assessing airway reactivity. The lack of a 
significant difference in other spirometric measures such as FEV1 and 
FVC or in other clinical outcome measures, suggests the difference found 
in baseline !int between the CNEP and control groups represents a small 
difference in respiratory function. It is, however, of sufficient significance to 
require a plausible explanation.
6.2.2 Population differences 
Differing degrees of prenatal or environmental cigarette smoke exposure 
could account for some of the observed difference in airway resistance 
between the groups. Kooi et al. (2004) evaluated the effect of parental 
smoking on !int measurements in 557 children aged 4 -12 years and 
found that !int values were 7% higher in children (n=84) who had 1 or 2 
parents smoking ≥ 3 cigarettes/ day in their presence, compared to those 
of children (n= 473) whose parents smoked less or not at all. In a 
subgroup of 180 pre-school children aged 4-6 years, the mean !int values 
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were 13% higher in the children exposed to cigarette smoke (n=20) 
compared to those in children (n=160) exposed to none. 
There was a trend towards increased reporting of maternal smoking in 
pregnancy in the CNEP group in this study (23 CNEP, 14 Controls; 
p=0.07) and a higher proportion of parents of CNEP children smoked at 
home although the difference was not significant (28 CNEP, 19 controls; 
p=0.17). Despite the lack of significance in the difference in reported 
smoking, it remains possible that the degree of cigarette exposure was 
further different between the groups as the numbers of cigarettes smoked 
by parents was not quantified but could well have differed.
Another potential confounder was the use of inhaled corticosteroids. 
Eleven control children were prescribed inhaled steroids compared with 7 
from the CNEP-treated group, which is not statistically significant (p = 
0.32). However, the drug dose, effectiveness of technique and compliance 
have not been assessed and so it is not possible to say with confidence 
whether one group received more inhaled steroid than the other; published 
data by Nielsen and Bisgaard (2000) suggest this may be important. The 
authors conducted a randomised placebo-controlled study of inhaled 
budesonide 400 micrograms twice daily in 38 children (19 cases, 19 
controls) aged 2-5 years with asthma. There were no significant 
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differences in passive smoking exposure or atopic disposition between the 
groups and baseline !int values were not significantly different; after 8 
weeks, however, the budesonide-treated group had significantly lower !int 
values (median 1.10 kPa.L-1.s-1 [95% C.I. 0.98 -1.22]), compared with 
controls (1.26 kPa.L-1.s-1 [95% C.I. 1.14 -1.38]; p=0.01).
Children were not specifically matched for age but this was indirectly 
controlled for by selecting controls from a cohort of children treated at a 
similar time to the CNEP group. Seventy six percent of controls were 
matched within an age range of +/-2 years of their CNEP pair and 88% 
were within +/- 3 years (Range -3.76 to + 4.87 years). The median age of 
children treated with CNEP was 6.4 years and the median age of controls 
was 7.7 years. The potential effect of this age difference is highlighted by 
the Tuscon Children’s study which evaluated the incidence of reactive 
airway disease (RAD) in an original cohort of 207 children with RSV lower 
respiratory tract illness at 3, 6, 11 and 13 years (Stein et al., 1999). The 
authors showed that the prevalence of RAD declined steadily until children 
were aged 13 years when it was similar to that of the background 
population. The effect of this decline in prevalence of RAD on a cohort of 
children following bronchiolitis is that older children will have less RAD 
than younger ones. The controls were on average 1.3 years older than 
children in the CNEP cohort by the time they were assessed due to slower 
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recruitment to this group resulting in later assessments. Percentage 
predicted !int values have been used to allow for any difference in age 
when comparing airway resistance in children of different of ages-
however, this simply allows for age related changes in !int in a healthy 
population and does not take account of the changing prevalence of RAD 
over time. The older age of controls may therefore have an effect on their 
airway resistance measurements, reflecting a declining prevalence of RAD 
with time.
Apart from the older age of controls, no other population variables differed 
significantly between the groups; however, a few measures have been 
identified (prenatal or current parental smoking and prescription of inhaled 
corticosteroids) which differed in controls compared with the CNEP cohort 
in ways that would favour a lower !int value. It is conceivable that the 
collective effects of these variables could have contributed to a 
significantly lower Rint measurement. 
Children in the CNEP cohort were well matched with controls for all the 
matching criteria except the median pre-ventilation FiO2, which was 12% 
higher among the controls. Seventy two percent of subjects were matched 
within a FiO2 range of +/-10% and 18% within +/-15% but in the remaining 
10% the matching was only possible within a FiO2 range of +/-21%. This 
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reflects the fact that 54% of children in the CNEP group were receiving 
nasal cannula oxygen at rates of 0.5-2.5 litres/ minute when intervention 
was deemed necessary, because of recurrent apnoea or because 
clinicians believed they were ‘tiring’. This compares with just 14% of 
controls receiving nasal cannula oxygen at rates of 0.5-2 litres/ minute. 
Apnoea was recorded as the reason for starting respiratory support in 7 
children treated with CNEP and in 5 controls. Matching children in the 
CNEP group with controls receiving similarly low oxygen concentrations 
may have resulted in CNEP cases being paired with controls with a less 
severe illness, as the matching criteria did not take account of measures 
of type II respiratory failure. An alternative explanation is that intervention 
with respiratory support in the CNEP group was at an earlier stage than it 
was in the control group, resulting in a longer period of exposure to the 
unwanted effects of ventilatory support. Matching was done on the basis 
of FiO2 irrespective of whether controls received respiratory support or not, 
because published data from NSH indicates that CNEP was started early 
in some cases with the aim of avoiding later intubation. In the study by 
Hartmann et al. (1994b) indications for starting CNEP included any infant 
with bronchiolitis requiring FiO2 ≥ 0.4, so it is likely that some children 
treated with CNEP who are included in this study would not, in other 
centres, have received any respiratory support. 
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Recognised features of respiratory failure and indications for respiratory 
support include: signs of clinical deterioration (see below), hypercarbia 
(pCO2 ≥ 8.0 kPa) with or without respiratory acidosis, persistent hypoxia 
(paO2 ≤ 8.0 kPa despite FiO2 ≥ 40%), metabolic acidosis, apnoea or 
bradycardia (Outwater and Crone, 1984). Clinical deterioration is judged 
by worsening respiratory distress (defined as severe recession, 
hyperinflation, diminished breath sounds, increasing tachypnoea or 
tachycardia), heart rate > 200 beats per minute, listlessness or impaired 
peripheral perfusion. It was not possible, from a retrospective review of 
medical notes, to assess reliably for clinical deterioration but one or more 
of the remaining criteria for respiratory support (i.e. hypercarbia, hypoxia 
despite FiO2 ≥ 40%, metabolic acidosis, apnoea or bradycardia) were met 
by 33 children treated with CNEP and 27 controls. Of the 27 matched 
controls with signs of respiratory failure, 18 received IPPV, 4 were 
admitted to PICU but managed conservatively and 5 were managed 
conservatively on a general paediatric ward. Twenty six CNEP cases and 
23 controls were admitted to PICU. The similar numbers of children in 
each group with respiratory failure or requiring PICU admission suggest 
that appropriate matching for illness severity was achieved. 
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6.2.3 Effect of CNEP on airway resistance
Another theoretical explanation for the observed difference in airway 
resistance between children treated with CNEP and controls might be the 
differing effects of ventilator associated lung injury on each group. 
Negative pressure ventilation could theoretically be associated with lung 
injury in a similar way to positive pressure ventilation by causing alveolar 
overdistension (volutrauma) (Slutsky, 1999). Positive pressure ventilation 
in neonates with respiratory distress syndrome has been reported to be 
associated with subsequent increase in airway resistance (Stocks and 
Godfrey, 1976). Fourteen of the 50 children (28%) treated with CNEP also 
received intermittent negative pressure ventilation (with pressures up to –
30 cm H2O). Because the volutrauma effects of PPV and NPV are likely to 
be similar, one might surmise that lung function abnormalities, including 
airway resistance, observed after PPV may also occur after treatment with 
NPV- however, there are no reported studies investigating this hypothesis 
to the author’s knowledge. Therefore the observed difference in airway 
resistance between the groups may result from the differing numbers of 
children receiving ventilatory support in each group. Half of the control 
group in this study received no ventilatory support and so fewer controls 
would have been exposed to the effects of ventilator associated lung injury 
compared to the CNEP treated group. To the author’s knowledge there 
are no long term studies comparing lung function measures in children 
previously treated for bronchiolitis with or without ventilation. 
181 181
6.3 CNEP used for weaning from PPV
Children who received CNEP for the purpose of weaning from PPV were 
evaluated in addition to those who received CNEP as primary treatment, in 
view of recommendations made in the Griffiths report that all children who 
received CNEP were assessed for evidence of significant benefit or harm.  
Unlike the group who received CNEP as primary treatment, a suitable 
control group could not be identified for this group of children thereby 
limiting the interpretation of the data obtained. Although the data on these 
children have been depicted graphically alongside those of children in the 
matched cohort study, the ‘CNEP for weaning’ group is not directly 
comparable to either the CNEP or control cohorts. These children were 
either deemed to be so unwell at presentation to NSH that they required 
immediate intubation and ventilation or they were transferred from another 
centre to NSH already receiving PPV. In both cases they only received 
CNEP in the recovery phase of their illness to speed up the process of 
weaning from PPV. As a group they are likely to represent children with a 
more severe illness than those recruited to the matched cohort study; this
is evident by the matching criteria showing that all of these children had a 
severe bronchiolitis illness at presentation compared to 78% of children in 
the CNEP and control cohorts. The outcome measures evaluated in this 
study are likely to have been influenced as much (if not more) by the 
positive pressure ventilation as the negative pressure support which these 
children received. The closest available comparison group to the children 
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who received ‘CNEP for weaning’ is a subgroup of the control cohort who 
received PPV (n=17). These children would not have been matched by 
any of the stipulated criteria. However, no significant difference was found 
in any of the primary or secondary outcome measures in a comparison of 
the two groups (i.e. ‘CNEP for weaning group’ and ‘children in the control 
cohort who received PPV’).  
6.4 Comparison with published work
6.4.1 Respiratory outcome after bronchiolitis
Parents in this study reported ‘current wheeze’ (wheezing in the previous 
12 months) in 30% of children treated with CNEP and 27% of controls; this 
is similar to that reported by Noble et al. (1997) who found wheeze in 34% 
of a cohort of 61 children assessed 10 years after bronchiolitis. Murray et 
al., (1992) found current wheeze in 42.5% [n=73] of the same cohort 
assessed by Noble et al. when they were assessed at 5½ years. Parent 
reports of children who had ever been diagnosed with asthma was 36% in 
those treated with CNEP and 39% in controls and is in keeping with the 
findings of previous studies reporting ‘any wheeze’ (wheezing at any time 
following the bronchiolitic illness) (Pullan and Hey, 1982, Mok and 
Simpson, 1984). 
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Mean FEV1 values of 90.7% and 91% were reported by Mok and Simpson 
(1984) and Noble et al. (1997) respectively in cohort studies of children 
following bronchiolitis. Similar measurements were obtained in children in 
this study: median FEV1 was 86.3% in the CNEP group and 88.5% in the 
controls. Mok and Simpson (1984) reported a mean FEF25-75 value of 
89.1% in a cohort of 102 children evaluated at a mean age of 7 years 
following bronchiolitis. This finding is similar to the median FEF25-75 
measurement of 86.8% found in the controls in this study. Significantly 
lower median measurements of 77.5% were obtained in the CNEP group, 
reasons for which are unclear. It is likely that the lower median FEF25-75 
measurement in the CNEP group is caused by the same factor(s) resulting 
in a significantly lower !int measurement in this group as both are affected 
by small airways disease; possible reasons for this have been discussed 
earlier. A bronchodilator response ratio (BDR) > 1.22 was found to be 
associated with previous ‘doctor confirmed recurrent wheezing’ in a study 
of 82 children with recurrent wheeze and 48 with no symptoms with 76% 
sensitivity and 80% specificity (McKenzie et al., 2000). Baseline !int > 
1.45 kPa.L-1.s-1 likewise had 80% specificity but only 60% sensitivity. Thirty 
three children (75%) treated with CNEP and 31 controls (67%) able to 
perform Rint measurements had a BDR ≥ 1.22. This measure has not 
previously been reported in cohort studies of children treated for 
bronchiolitis to the author’s knowledge. 
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6.4.2 The use of CNEP for bronchiolitis
Previous studies of the use of CNEP for bronchiolitis have tended to be 
uncontrolled trials involving small numbers of children (Samuels and 
Southall, 1989, Linney et al., 1997). There are two reported controlled 
trials one of which was published in abstract form only (Hartmann et al., 
1994b). The other controlled study by Al-balkhi et al. (2005) was a 
retrospective review of hospital case-notes and unlike this study did not 
involve any clinical assessments. The limited evidence from all of these 
studies suggests that the use of CNEP may reduce the need for intubation 
in children with bronchiolitis associated respiratory failure. The study by Al-
balkhi et al. (2005) found no difference in the duration of oxygen therapy 
but observed a reduced duration of intensive care stay in children treated 
with CNEP. A possible confounding factor in the study was the trend 
towards an increased use of methylxanthines in the CNEP group (17 
treated with NPV vs 6 in the standard group; p=0.06). Historically, 
methylxanthines were used more commonly for the purpose of reducing 
bronchiolitis related apnoea despite limited data to support its use 
(Ramesh and Samuels, 2005). Methylxanthines are rarely used in 
bronchiolitis now with clinicians tending to use CPAP more readily for such 
children. A randomised trial is currently underway to evaluate the role of 
aminophylline in reducing the need for respiratory support in severe 
bronchiolitis (Royal Children's Hospital Website). 
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This study supports the findings of others in showing a reduced need for 
intubation in the CNEP cohort but found duration of oxygen therapy to be 
increased and no difference in the mean length of stay in hospital or 
intensive care.
6.4.3 Disability and functional outcome following 
bronchiolitis
Disability and functional outcome are rarely reported following 
bronchiolitis; only two uncontrolled studies have been identified which 
report on this (Wren et al., 1982, Bray and Morrell, 1982). This outcome is, 
nevertheless, of particular concern to some parents whose children were 
treated with CNEP and was one of the main reasons for the 
recommendation that its use was discontinued pending further evaluation 
of the children who had been treated with it. Concerns about the possible 
risks of IVH associated with CNEP were suggested by Cvetnic et al. 
(1990) who noted that 4 infants with IVH had extensions of the bleeding 
after treatment with CNEP, leading the authors to recommend its use was 
avoided in babies most at risk of IVH. Further concerns about adverse 
neurological outcome following CNEP have stemmed from the randomised 
study of its use in preterm neonates by Samuels et al. (1996) which found 
a non-significant difference in the frequency of intraventricular 
haemorrhage (IVH) and death in a group treated with CNEP compared to 
controls. One of the concerns associated with earlier models of the CNEP 
186 186
tank was the possible effect of the neck seal in obstructing jugular venous 
drainage. This concern was addressed with the use of a latex neck seal in 
the newer model of CNEP tank, following work reported by Palmer et al. 
(1994) which found no significant effects on jugular venous drainage.
In a recent follow-up study by Telford et al. (2006) of children treated in the 
original randomised trial of CNEP for neonatal RDS, a careful evaluation 
was conducted of survivors for any evidence of adverse neurological 
outcome. The primary outcome of death or severe disability did not differ 
significantly between the CNEP and control groups and no evidence was 
found of adverse outcome on detailed assessment of cognition, 
neuropsychological function; behaviour and health related quality of life. 
The findings of this study are in keeping with those of Telford et al. (2006) 
in that no significant difference was found between CNEP treated children 
and controls in the prevalence of moderate or severe disability or in the 
parent reported health-related quality of life. Most children identified with a 
significant motor or cognitive disability in this study had a relevant 
diagnosis which was known before the admission with bronchiolitis. Two
children in the CNEP group (1 haemorrhagic hydrocephalus, 1 cerebral 
palsy) and two in the control group (2 cerebral palsy) have been found to 
have significant neurological disorders following their admission with 
bronchiolitis. It is unclear whether predominantly perinatal factors or the 
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bronchiolitis illness have contributed to these diagnoses and it  is clearly 
beyond the scope of this study to determine causation in any of these 
cases. A non-significant increase in the prevalence of moderate or severe 
cognitive disability amongst children in the CNEP cohort is explained by 
the higher prevalence of diagnoses associated with neurodisability, which 
were known before they were admitted with bronchiolitis. It would appear, 
therefore that the use of CNEP is not associated with an excess of major 
neurological diagnosis such as cerebral palsy in this study. Interestingly, 
parents own evaluation of their children’s health related quality of life was 
remarkably similar in both cohorts with similar median Health Utility Index 
multi-attribute scores (CNEP 1.00, Controls 0.99; p=0.83). 
An unexpectedly high prevalence of moderate or severe behavioural 
disability was observed in both the CNEP cohort (28%) and controls 
(20%). The ‘Strength and Difficulties Questionnaire’ which was used to 
assess this outcome is well validated and has a high degree of sensitivity 
for screening behavioural problems in children. Its limitation, however, is a 
low positive predictive value of 35% when completed by a single informant 
(Goodman, 2001). The positive predictive value may be improved by use 
of multi-informants i.e. parents and school teachers. The use of multi-
informants was considered during the planning of the study design but 
deemed unnecessary because behavioural disability was to be assessed 
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as a secondary outcome measure and the testing done in a clinic setting. 
It is likely that the criteria for determining a moderate or severe disability 
based solely on parents’ perceived impact of their child’s behaviour 
problems (and not on convergence of parents and teacher’s ratings) 
overestimates the degree of disability within this domain. In retrospect 
information provided by school teachers would have been helpful and 
potentially would have improved the reliability of these data.
6.5 Methodology of this study
6.5.1 Study strengths
This is one of only three reported controlled studies which have evaluated 
outcome following the use of CNEP in infants with bronchiolitis (including a 
study reported in abstract form only). It is the first to evaluate long-term 
outcome, with a median age at follow-up of 6.4 years and represents the 
largest cohort of children treated with CNEP for bronchiolitis. A 
prospective randomised study would be the ideal way to evaluate the use 
of CNEP for bronchiolitis, however, in view of some of the prevailing 
perceptions about its impact on later disability (Griffiths, 2003), it is most 
unlikely that it would be possible to recruit patients to such a study, even if 
ethical approval were granted, without a more thorough assessment of its 
safety first. A matched cohort design, on the other hand, allows a detailed 
evaluation of the previous experience with CNEP in infants with 
bronchiolitis, without exposing subjects to any potential harmful effects in 
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the process. Given the prevailing concerns, it is the most appropriate way 
to first evaluate this technique and to determine which outcome measures 
need to be considered in any future prospective controlled trial.  
The study evaluates important respiratory outcomes which are known to 
occur frequently after bronchiolitis but is also the first to report specifically 
on disability and functional outcome measures after this illness. All other 
reports of these outcomes in cases of bronchiolitis have been case series 
and have not been evaluated in a systematic and controlled manner. The 
use of a combination of lung function testing and parent reported 
symptoms using a validated respiratory questionnaire has allowed for a 
detailed and objective assessment of respiratory outcome measures. 
Similarly, disability and functional outcome measures have been assessed 
objectively using validated questionnaires where available or disability 
criteria (based on WHO definitions) that are widely accepted. 
Demographic and neonatal data were collected in sufficient detail to 
evaluate for possible confounding variables that may have biased the 
outcome measures in favour of one of the groups. 
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6.5.2 Study limitations
A major limitation of any retrospective matched cohort study is the 
difficulty achieving adequate matching of all the important variables. An 
important demonstration of this is to do with the matching of illness 
severity which was undertaken in this study with the use of bronchiolitis 
clinical criteria in conjunction with a measure of oxygen dependency 
instead of a more robust illness severity score. In a prospective study one 
could stipulate that an arterial pCO2 measurement or ‘PRISM’ score was 
an essential inclusion criteria allowing for more reliable matching. Such 
data cannot obviously be obtained retrospectively if not collected 
systematically in a prospective manner. Equally, the measurement of a 
variable such as oxygen dependency can vary in respect to what target 
saturation one is aiming for. The target saturation can be clearly stipulated 
in a prospective trial but may have varied in a way that is not possible to 
ascertain when evaluated retrospectively. The effect of both of these 
examples would be to introduce bias or inadequate matching in a 
retrospective cohort study but could have been avoided in a prospective 
randomised study.  
The relatively small number of subjects studied means this study lacks 
power to detect small differences in some of the secondary outcome 
measures. There were difficulties recruiting to both arms of the study with 
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just over 50% of children who received CNEP and eligible to be included 
agreeing to participate. Recruitment to retrospective cohort studies is 
generally recognised to be difficult, reported rates ranging between 40 and 
97% (Rogers et al., 2004). Every attempt was made to maximise response 
rates by adopting measures shown to have an impact (Edwards et al., 
2002). The measures used included carefully-worded invitation letters to 
avoid any ambiguity about the purpose for the study, reimbursement of 
travel costs, pre-paid stamped reply envelopes and up to 3 letters of 
invitation if the first brought no response. Another limitation of the small 
numbers and low percentage of potential subjects recruited (51% of the 
children receiving CNEP as primary treatment) is that the study findings 
may not be representative of all children treated with CNEP. Mean FiO2 
was not significantly different between children recruited to the study and 
those who were not, but children enrolled in the study were significantly 
more likely  to have had severe bronchiolitis and so perhaps were more 
likely to suffer severe disability as a result (Bray and Morrell, 1982, Wren 
et al., 1982). The findings of this study are therefore likely to overestimate 
the prevalence of disability among all children treated with CNEP for a 
variety of conditions. The use of matched controls, however, has made it 
possible to ascertain if children with severe bronchiolitis treated with 
CNEP differ from children of similar illness severity who received standard 
treatment. Other parameters including frequency of RSV infection and 
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median gestation at birth were not significantly different between those 
recruited and those who were not. 
The use of subjects from two different centres may have introduced bias 
despite the attempt to match subjects as closely as possible, due to 
differences in practice not identified or not measurable. It was not feasible 
to recruit controls from NSH because CNEP was used as standard 
treatment for all children requiring respiratory support with bronchiolitis.  
The matched cohort design would usually require an increased number of 
controls to allow a 2:1 or 3:1 ratio of controls to index cases to improve 
reliability of the findings. However, within the pool of potential controls 
there were insufficient numbers in certain categories to allow any more 
than 1:1 matching e.g. gestational age < 32 weeks. It also proved difficult 
to recruit subjects to both arms of the study, particularly so to the control 
cohort which took considerably longer than recruitment of index cases 
adding to the impracticality of increased matching. Concerns about 
possible risks associated with CNEP may have served as an increased 
motivational factor for recruitment to the index cohort which was lacking in 
the controls. This phenomenon may have in itself introduced bias but 
every effort has been made to match the index cases and controls closely 
to avoid any such effect.  
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It was not possible to conduct a blinded study because, to aid recruitment 
and to minimise their travel costs, participating children had to be 
evaluated as close to their homes as possible, which in turn meant they 
were evaluated where they received their treatment for bronchiolitis. Thus 
children who received CNEP were evaluated in premises near to the NSH 
in Stoke on Trent, whilst the control children, who generally came from 
Nottingham, were assessed at QMC, thereby precluding the possibility of 
blinding. 
The chosen primary outcome measure required minimal cooperation from 
subjects and the effect of the investigator on the measurement is likely to 
be minimal. Most other outcome measures evaluated were based on 
parent report and unlikely to be influenced by the investigator.   
As discussed in section 6.2.1 above, the difference in median FiO2
between the groups may suggest that matching for illness severity was not 
optimal. The use of a validated illness severity score such as the ‘PRISM’ 
would have minimised inconsistencies in matching, but this proved 
impossible because a previous audit of the medical notes of potential 
recruits to the study had revealed inconsistent recording of the data 
necessary for such scoring. Instead a pragmatic decision was made to 
match for illness severity using clinical criteria (Table 12), widely recorded 
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in UK paediatric units (Hodge and Chetcuti, 2000) as well as a measure of 
oxygen dependency. The FiO2 pre-ventilation (FiO2 pre-admission to PICU 
or maximum FiO2 if not ventilated) was the chosen measure of oxygen 
dependency because it was recorded in all cases. There was no 
difference in bronchiolitis illness criteria between the groups (Table 13).
6.5.3 What could have been done differently?
The primary outcome measure was selected to assess whether the 
prevalence of RAD differs between children treated with CNEP and their 
matched controls. Airway resistance measured by the interrupter 
technique (!int) has recently become available and offers an opportunity 
to perform lung function tests on young children who would not normally 
be able to cooperate sufficiently with more standard tests such as 
spirometry or plethysmography; these are frequently used in association 
with a bronchial challenge or bronchodilator response to assess reactive 
airways disease. Two previous studies have used baseline !int as a 
primary outcome measure to evaluate the effect of inhaled corticosteroids 
in preschool children with asthma (Nielsen and Bisgaard, 2000, Pao and 
McKenzie, 2002). In the study by Pao and McKenzie (2002) baseline Rint 
and bronchodilator response ratios were both assessed as primary 
outcome measures and found to be significantly lower in the treatment 
group. Earlier studies which evaluated the repeatability of !int in healthy 
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children found acceptable ‘within subject’ coefficient of variability; 8.1% in 
a study by Klug and Bisgaard (1998). However, subsequent work in 
symptomatic children with cough or wheeze has found high variability 
(Chan et al. (2003). Baseline !int may therefore not be as useful for 
comparison of outcomes in children with possible reactive airways 
disease. The percentage change in !int or BDR, however, remains useful 
and has significantly less variability than the baseline !int. 
Previous studies have found greater difficulty in recruitment if the study 
protocol included the administration of a drug; McKenzie et al. (2000) 
found that up to 25% of the recruits in their study refused a bronchodilator 
but were willing to perform baseline !int. In this study the percentage 
change in !int after a bronchodilator was evaluated as a secondary 
outcome measure and was achieved in 99% of the children who were able 
to undertake baseline Rint. An alternative measurement of RAD, the 
bronchodilator response ratio (BDR) characterised by the ratio of !int 
before and after bronchodilator, was also evaluated. !int was chosen 
primarily because it offered the opportunity to evaluate the prevalence of 
RAD objectively in the maximum number of children in the age range of 4-
10 years. The successful testing of 92% of children recruited to the 
matched cohort study confirms this as an appropriate choice. However, in 
retrospect, the BDR rather than baseline Rint would have been a more 
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preferable choice as the primary outcome measure to compare the 
prevalence of RAD between the 2 groups. Both percentage change Rint 
and BDR were found to be not significantly different between the groups. 
The data collected on the use of supplementary fluids was not recorded in 
sufficient detail to distinguish between the proportions of children in either 
cohort receiving nasogastric feeding as opposed to intravenous fluids. 
These data would be relevant for the reason that nasal obstruction is 
potentially more likely to occur with nasogastric feeding and if significantly 
different between the groups may be a confounding factor that has not 
been adequately evaluated (Sporik, 1994).
Earlier discussion about the possible overestimation of behavioural 
disability (section 6.4.3) highlights the fact that it would have been helpful 
to have included data on teacher responses to the ‘strengths and 
difficulties’ questionnaire in the study protocol, which was not obtained. 
6.6 Implications for future research and use of 
CNEP for bronchiolitis
The results of this study suggest that the use of CNEP for bronchiolitis 
may be associated with a reduced need for endotracheal intubation and 
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has not been shown to be associated with an increased incidence of later 
respiratory symptoms or neurodisability. However, before CNEP is used 
routinely in the management of children with bronchiolitis there is a need 
to assess outcomes associated with its use more fully in a prospective 
randomised study. As well as assessing short term measures it will be 
important for any future studies to undertake longer term follow up to 
assess the later outcomes evaluated in this study. Areas that need 
particular focus are the possible advantages that CNEP use might have 
over standard treatment such as the reduced need for endotracheal 
intubation but also to assess whether this comes at the cost of a longer 
duration of oxygen therapy or hospital stay. It would be helpful to evaluate 
if CNEP has any advantages over CPAP which is currently the most 
commonly used mode of non-invasive respiratory support in children with 
bronchiolitis. In longer term follow up it would be especially important to 
assess later outcomes such as prevalence of respiratory symptoms, 
respiratory function and functional outcomes including assessments of 
disability and health related quality of life. A randomised study would 
hopefully reduce the likelihood of inappropriate matching of illness severity 
but given its importance it may be appropriate to stratify study groups to 
ensure this was adequately addressed.
198 198
7 Conclusions 
This study was devised to determine if there are respiratory or 
neurological sequelae to the use of CNEP for bronchiolitis associated 
respiratory failure. This has been evaluated by assessing children who 
received CNEP at a median age of 6.4 years and comparing them with 
matched controls who received standard bronchiolitis treatment. Short 
term outcome measures have also been evaluated in the two groups. The 
findings of the study in relation to the study aim and the stated primary and 
secondary hypotheses have been reviewed and the conclusions that may 
be drawn from these findings are outlined below.
7.1 Primary hypothesis
The stated primary hypothesis was that: #$%&'& () *+ ,(--&'&*.& (* 
/('0/1 '&)()2/*.& 3&/)4'&, (* 5/2&' .%(5,%++, 6&20&&* .%(5,'&* 0%+ 
'&.&(7&, 89:; -+' 6'+*.%(+5(2() /*, 3/2.%&, .+*2'+5)<. The findings 
of this study suggest the primary hypothesis must be rejected as a 
significant difference was found in airway resistance when measured in 
later childhood. The reason for this difference, however, is most likely to 
be population differences which could not be adequately controlled for with 
the matched cohort study design. Another possible explanation is that 
PPV and CNEP have similar effects on airway resistance and that the 
difference in airways resistance observed is a reflection of the earlier use 
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and increased number of children receiving respiratory support in the 
CNEP group compared to the matched controls. It would seem unlikely 
that the observed difference reflects a specific adverse effect of CNEP on 
later airway resistance which is different to that observed with PPV, given 
the other possible causes identified which could explain the findings. 
However, the possibility of a specific adverse effect of CNEP on later 
airway resistance cannot be excluded. 
The use of baseline !int as the primary outcome measure in this study 
has highlighted difficulties associated with interpretation of the 
measurements obtained when it is used to compare cohort groups. The 
secondary outcome measures of percentage change !int and 
bronchodilator response ratios (BDR) were not significantly different 
between the groups and provide a more reliable objective comparison of 
the prevalence of reactive airway disease in the CNEP and control groups.
7.2 Secondary hypotheses
The secondary hypotheses evaluated were as follows:
1) #$%& 4)& +- 89:; -+' 6'+*.%(+5(2() ,+&) *+2 '&)452 (* /* 
(*.'&/)& (* '&)=('/2+'1 )13=2+3) (* 5/2&' .%(5,%++, .+3=/'&, 
0(2% 3/2.%&, .+*2'+5)<. 
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The findings from this study suggest this null hypothesis cannot be 
rejected as no significant difference was found in the frequency of 
wheezing episodes, in the numbers in whom asthma had been 
previously diagnosed and in the use of inhaled medication for reactive 
airways disease. There was also no difference in the reported number 
of days off school with a respiratory illness in the two groups. 
2) #$%& 4)& +- 89:; ,4'(*> 6'+*.%(+5(2() () *+2 /))+.(/2&, 0(2% 
/* (*.'&/)& (* ,()/6(5(21 +' 0+')& %&/52% '&5/2&, ?4/5(21 +- 5(-& 
/3+*> )4'7(7(*> .%(5,'&* .+3=/'&, 2+ .+*2'+5)<.
The study findings suggest this null hypothesis also cannot be rejected as 
no significant difference was found in the prevalence of disability defined 
using specific criteria. The wide confidence intervals, however, reflect the 
reduced power of this study to evaluate this hypothesis due partly to the 
fixed size of the original cohort and the difficulties encountered with 
recruitment. There was no significant difference in the health related 
quality of life assessed with the Health Utilities Index (HUI) multi-attribute 
score, a well validated measure for evaluating this outcome in the study 
population. The HUI findings could be considered to support those of the 
disability assessments as both measures evaluate similar domains of 
disability.    
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3) #$%& 4)& +- 89:; () /))+.(/2&, 0(2% )%+'2@2&'3 6&*&-(2A )4.% 
/) / '&,4.&, *&&, -+' (*246/2(+*A 0%&* .+3=/'&, 2+ .+*2'+5)<.
This hypothesis was supported by the study findings in respect to the 
reduced need for endotracheal intubation and duration of PPV if 
ventilated, which were observed significantly less frequently or for a 
shorter duration respectively in the children treated with CNEP. Other 
short term outcome measures such as length of hospital stay were found 
to be no different in the CNEP and control cohorts and the duration of 
oxygen therapy was found to be increased in those treated with CNEP.
7.3 Summary
Bronchiolitis is the commonest cause of acute respiratory failure in infancy 
and results in several hundred admissions to UK paediatric intensive care 
units for respiratory support each year. Most children receive invasive PPV 
but non-invasive respiratory support is increasingly being used as more 
experience is gained in the newer non-invasive techniques. Non-invasive 
respiratory support is mostly provided with positive pressure devices and 
very little is known about the use of negative pressure respiratory support 
for children with bronchiolitis. A cohort of children treated with CNEP for 
bronchiolitis at a UK centre were the focus of a government enquiry which 
identified parental concern about the possibility that children receiving this 
treatment may have suffered significant harm. This study has been 
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conducted in an attempt to evaluate these concerns using a matched 
cohort design. Difficulties were encountered in recruitment, which meant 
that just over half of the original cohort agreed to participate in the study. 
Despite its limitations this is the only study to date to have evaluated 
longer term outcomes in children treated with CNEP for bronchiolitis and 
has provided new evidence to address the expressed concerns and stated 
benefits of its use for this illness. Careful evaluation of this cohort of 
children treated with CNEP has found no evidence to suggest that children 
receiving this treatment have suffered significant harm. The finding of 
higher airway resistance (!int) in the CNEP group although highly 
statistically significant, reflects a small clinical difference and is not 
associated with any increase in respiratory symptoms, need for 
medication, disability or parent reported quality of life. The higher !int in 
children treated with CNEP is most likely to reflect a difference in cigarette 
smoke exposure between the two groups. The study findings do suggest 
that the use of CNEP may be associated with a reduced need for 
intubation in children with bronchiolitis although it is unclear if it results in a 
longer duration of oxygen therapy and hospital stay. Further work is 
required to assess whether CNEP has advantages over other modes of 
non-invasive respiratory support for bronchiolitis (i.e. CPAP) and to 
evaluate the long and short term effects associated with its use more fully. 
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9 Appendices
9.1 Appendix A: Invitation letter - CNEP cases
Letter to parent
NSH notepaper
Dear [Parent]
There has been a lot of publicity about doctors at the North Staffordshire Hospital using a 
technique called CNEP (continuous negative extrathoracic pressure) to help small babies 
with their breathing. Doctors and members of the public asked many questions, so an 
independent research team in Nottingham are hoping to find the answers.
The researchers need to meet lots of children who have had bronchiolitis to see how healthy 
they are long after they were treated. They will assess the present health of children treated 
originally in Stoke with CNEP and children who were treated in Nottingham without CNEP. 
They will then compare the health of the two groups.
Our records show that your child [Rupert] was treated for bronchiolitis at the North 
Staffordshire Hospital and had CNEP as part of [his] treatment.  The researchers would very 
much like to meet [Rupert] and many other children like [him].
The research team is based at the University of Nottingham with Professor Neil Marlow in 
charge. The leaflet with this letter tells you all about Professor Marlow’s work and asks for 
your help. You are being asked to help with a formal research study, but you will see that for 
[Rupert] it is only a check-up and it will help you find out more about him and CNEP.
Professor Marlow’s team want to be sure that the public and the medical profession know 
about any benefits or problems that came from this use of CNEP, and they hope their work 
will answer the questions independently and without bias.
You don’t have to help Professor Marlow, but we would be grateful if you could tell us 
whether or not you would like to help. The information leaflet has been written to help you 
decide. If we do not hear from you, we will write again in a few weeks because we would like 
to hear from as many people as possible, whatever your views.
Thank you in advance for your reply.
Yours sincerely
[WL]
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9.2 Appendix B: Invitation letter - Controls
Letter to parent
QMC notepaper
Dear [Parent]
There has been a lot of publicity about doctors using a technique called CNEP (continuous 
negative extrathoracic pressure) to help small babies with their breathing. Many doctors and 
members of the public asked questions – and an independent research team in Nottingham 
are asking for your help to find some answers.
Doctors at the North Staffordshire Hospital in Stoke used CNEP to help babies with 
bronchiolitis, the same condition your child [Rupert] was treated for in Nottingham when [he] 
was a baby. The researchers need to meet lots of children who had bronchiolitis to see how 
healthy they are long after they were treated. They will assess the present health of children 
treated originally in Stoke with CNEP and children who were treated in Nottingham without 
CNEP. They will then compare the health of the two groups.
The research team is based at the University of Nottingham with Professor Neil Marlow in 
charge. The leaflet with this letter tells you all about Professor Marlow’s work and asks for 
your help. You are being asked to help with a formal research study, but you will see that for 
[Rupert] it is only a check-up and it will help you find out more about him and CNEP.
Professor Marlow’s team want to be sure that the public and the medical profession know 
about any benefits or problems that came from this use of CNEP, and they hope their work 
will answer many questions independently and without bias.
You don’t have to help Professor Marlow, but we would be grateful if you could tell us 
whether or not you would like to help. The information leaflet has been written to help you 
decide. If we do not hear from you, we will write again in a few weeks because we would like 
to hear from as many people as possible, whatever your views.
Thank you.
Yours sincerely
[HV]
219
9.3 Appendix C: Parent information leaflet
Helping you decide 
whether you
would like to help us.
We are asking you to take part in our research study, so it 
is important that you understand why the research is being 
done and what you would be asked to do. That’s what this 
leaflet is for.
Please read this leaflet carefully. Show it to your friends or 
family if that helps, or talk it over with your doctor. You can 
call us if you want to know more or if something we’ve 
written isn’t clear.
Take your time deciding. You don’t have to help us if you 
don’t want to – and even if you decide to help us, you can 
change your mind at any time and leave our study.
If you don’t want to help, or if you change your mind about 
helping, you will never have to say why.
Whatever you decide, you and your child will always get 
the best health care possible.
Professor Neil Marlow
Study Director
The B-CNEP Study
Academic Division of Child Health
Level E
Queen’s Medical Centre
Nottingham  NG7 2UH
Phone  0115  970  9924  extension  44257
Fax  0115  970  9382
!"#$ $%&'( #$ $)*+$*,-' .( / 0,/+% 1,*2 345 67-8&%#9- :;-$% <#'=/+'$>? 
!"- 0,/+% 8*9-,$ %"- -7)-+$-$ *1 %"- ),*@-8% /+' %"- $/=/,#-$ *1 %"- ,-$-/,8" %-/2?
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The B-CNEP Study
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Many babies get a lung infection called bronchiolitis, and some of these babies either 
find it difficult to breathe or may even stop breathing altogether. When this happens, 
doctors have to choose which way to help the baby breathe. One method is to put a 
tube into the baby’s throat to make it possible to blow air in. This is called intubation. 
If a machine is connected to this tube and the machine breathes for the baby, this is 
called ventilation. Even with this help, bronchiolitis often leaves a baby with a wheezy 
chest. In some this lasts into adult life.
Intubation and ventilation are uncomfortable and can cause problems for the baby. 
Because of this, doctors at the North Staffordshire Hospital have used another 
method of helping these babies breathe. They put the baby in a machine that makes 
a slight vacuum around the baby’s chest. The negative pressure of the vacuum takes 
the pressure off the baby’s chest, making it easier for them to breathe. This is called 
continuous negative extrathoracic pressure, or CNEP. This method is not widely 
used to help babies with bronchiolitis, in the UK or anywhere else.
Of course everyone wants to know which method is best for the baby, not only while 
they are in hospital with bronchiolitis but also long after the original treatment. That’s 
why this is called a long-term study – we want to find out which method gives babies 
the best chance of growing up without breathing troubles. Every new method of 
helping babies breathe gets a long-term study.
That’s why we would like your help. We want to see how well [Rupert] is doing, to 
see how healthy [he] is compared with lots of other children who also needed help 
with their breathing. Some of those children were helped by CNEP, some by the 
other methods. This study will tell us whether CNEP gives babies with bronchiolitis a 
better chance of growing up strong and healthy.
!"#$ /%00 1 "#2' $, ), %+ /' #3-'' $, $#4' 5#-$.
We will ask you to bring [Rupert] to either Grindley Hill Court (next to the City General 
Hospital in Stoke on Trent) or the Queen’s Medical Centre in Nottingham, so that our 
paediatrician Dr Yanney can meet [Rupert] and see how well [he] is doing. This will 
be a medical check-up. We won’t be taking blood, giving injections, or doing anything 
else that hurts.
While you are there, we will ask you to complete a questionnaire. This will ask you 
what you have noticed about [Rupert]’s general health and behaviour. It will also ask 
about [Rupert]’s family background, your home and your work, in case this is relevant 
to [Rupert]’s health.  All this will take about 1 hour.
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Our paediatrician Dr Yanney will do the medical check up which includes measuring 
[Rupert's] height and weight. Dr Yanney may also perform an examination on 
[Rupert] which would include testing [his] movements, coordination and muscle 
strength– in other words, how well [he] controls [his] arms and legs.  Dr Yanney will 
also listen to [Rupert]’s chest and he will want to see how well [Rupert]’s lungs are 
working. To do this he will ask [Rupert] to do two breathing tests, one where [he] will 
be asked to blow hard into a tube and another where [he] will breathe normally 
through a tube. Then he will give [Rupert] a standard dose of an asthma inhaler 
called salbutamol. This is given to [Rupert] by asking [him] to breathe in from the 
inhaler.  Afterwards, Dr Yanney will ask [Rupert] to do the breathing tests again to 
see if the measurements have improved. 
<-' $"'-' #6* &%)' '++':$& +-,= $"%& )-(3.
It is rare for a standard inhaled dose of salbutamol to cause any side effects. Side 
effects can occur if salbutamol is used too often or too much is taken in one go.  
Because we would be giving [Rupert] a standard dose, we believe the risk of side 
effects is very low. 
Salbutamol is a very common drug for asthma that helps people breathe by opening 
up their airways. It is often supplied under the brand name Ventolin.
>#& #6*,6' '0&' 0,,4') #$ $"' 5,&&%?0' -%&4&.
Ethics committees are an independent group of people (doctors and non-medical 
people) who think carefully about planned research projects. The ethics committees 
of the two Regional Health Authorities involved with our study have looked at our 
plans. They agree that the study is acceptable.
If you would like to know more about medical research, a leaflet called 'Medical 
Research and You' (published by CERES) is available from North Staffordshire Local 
Research Ethics Office. We can provide you with a copy of this if you would like one.
<-' $"'-' #6* ?'6'+%$& +,- (& %+ /' )':%)' $, "'05.
After the check-up you will get a report that tells you how well [Rupert] has done and 
when the study is finished you can have a copy of either the main research report or 
a summary, whichever you prefer. You will be helping parents like yourself and 
children like [Rupert] in the future, because we will know more about how best to help 
children with bronchiolitis. We hope that you and [Rupert] will find your time with us 
interesting and fun. We offer an inconvenience allowance in recognition of the time 
given to help in our study.
!", /%00 5#* +,- $"' $-#2'0. 
We will also refund all reasonable travel costs. 
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The information about you and [Rupert] will be seen only by our study team in 
Nottingham, and we will remove all names before we put anything into a computer. 
Once we have analysed the information, we will destroy all the original paperwork. 
When we publish what we have found, we won’t mention any child by name.
!"#$ ), 1 ), 6'@$.
If you want to know more, please call us on the number at the bottom of the page.
If you decide not to take part, please send back the form to say so in the envelope 
provided. Even doing that will be helpful for the study. 
If you feel you would like to help us, please fill in and sign the consent form and post 
it to us in the pre-paid envelope. Our administrator Mrs Heather Palmer will contact 
you and arrange a date for [Rupert]’s check-up.
A"#64 *,( +,- *,(- %6$'-'&$ %6 ,(- /,-4
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9.4 Appendix D: Assessment record
B- CNEP Assessment Record
Office Use Only
Child No. Date of Birth
Chronological Age Years Months
Male Female Decimal Age . Years
To Be Completed By Paediatrician
Date of Assessment
Time Assessment Started Time Assessment Finished
Others present:   Mother   Father Sibling(s) Adult friend/Relative
Psychologist Other children
G4 #)? 80+ 0 +%()#1 ;*%+$")##0"&%
6"7%# 8"$5 0 4&%%.)+$ %#7%/).%Z
Yes No Yes No
Parental questionnaire received?
History completed by interview?
If ‘No’, history received?
Growth
Lung function Form Attached
Salbutamol
Clinical examination
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B. Growth and Blood Pressure
 
[2/%0+% $0<% )44 -)*& +5)%+=\
Weight Y6 To nearest kilogram Z- score
Height C' To nearest cm Z- score
Head circumference C' To nearest cm
Normal=0, 
<C5=1 >C95=2
Blood pressure (Sitting) )7%& ,' U6 I) #%0&%+$ S '' U6
+-+$)/"( 1"0+$)/"(
Other – Comment
A. Testers Rating of Child Behaviour
EH 2)"#$ Q $) 3% +()&%1 "''%1"0$%/-] S^V $) 3% +()&%1 0$ $5% %#1 )4 $5% 0++%++'%#$= 
2/%0+% ("&(/% $5% 0..&).&"0$% #*'3%&=
1. Approach / Withdrawal (Initial reaction)
How wary was the child of the 
tester? N/A
1 2 3 4 5 6 7 8 9
Very accepting/ 
actively approaching 10
Very 
withdrawn 
and shy
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C. Respiratory Examination
On clinical examination did you observe?
Chronic Signs:
Is the trachea deviated?                               (No=0; Yes=1)    
Does the child have any chest deformity?             (No=0; Yes=1)    
Harrison’s sulci (No=0; Yes=1)    
Hyperinflation (No=0; Yes=1)    
Number of chronic signs? (0-4)
 Acute Signs:
 Recession (No=0; Yes=1)  
Use of accessory muscles (No=0; Yes=1)    
Auscultation:  crackles (No=0; Yes=1)    
Wheezes (No=0; Yes=1)    
Number of acute signs? (0-4)
What was the resting respiratory rate? (over 30 seconds) H&%0$5+N'"#
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D. Lung Function Tests
1. Rint 
9"$$"#6? R '%0+*&%'%#$+ "# %J."&0$")#? 0$ $"10/ 7)/*'%
2. Spirometry
Standing, 
Use incentive, 
Encourage maximum effort
Record best of 3 
Record:
q PRE
Ø M-Rint median
Ø FEV1
Ø FEV1 % predicted
Ø FVC
Ø FVC  % predicted
Ø FEF25-75
• 90/3*$0')/ 7"0 
+.0(%&M 
QR '"#*$% 3&%0<
q POST
Ø M-Rint median
Ø FEV1
Ø FEV1 % predicted
Ø FVC
Ø FVC % predicted
Ø FEF25-75
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Salbutamol:  
Dose:  ______ puffs (100mg per puff) of salbutamol via spacer 
Prescribed by ____________ Given by _______________ Date _________ 
Time_________
Was lung function adequately performed          Yes1 No0
Was lung function repeated after salbutamol          Yes1 No0
If unable to perform lung function tests, please state why:
Tracheostomy1 Unable to cooperate2
Parent request3 Other4
Other, please state
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Attatch micro-Rint and spirometry data sheets to this page.
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E. Neurological Examination
1. Axis
Normal axis control?
Yes1 No0
G4 -%+? 6) $) ;*%+$")# S=  G4 #)? ()'./%$% $5"+ +%($")#=
Head control
_:3#)&'0/ 3*$ 5%01 *. 4)& %J$%#1%1 .%&")1+`Q] 
2))&? 5)/1+ 5%01 *. )#/- 4)& +5)&$ .%&")1+`S] E) ()#$&)/`ab
Truncal tone _FJ$%#+)& .&%1)'"#0#$`Q] )."+$5)$)#*+`S] 5-.)$)#"0`ab
Sitting
_C0# +"$ 3*$ /%++ +%(*&% $50# #)&'0/`Q] C0##)$ 3% /%4$ 
*#+*..)&$%1`S] D"44"(*/$ $) ./0(% "# +"$$"#6 .)+"$")# _0#- &%0+)#b`ab
Other –comment
2. Abnormal movements on observation
Movements observed (most prominent sign) :$ &%+$ c"$5 6)0/ 1"&%($")# )& %J("$%'%#$
None O
Incoordination Q
Tremor S
Short and jerky a
Slow and writhing P
Flexor/Extensor spasms R
Comment
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3. Upper Limb
Left Right
A Tone G#(&%0+%1`Q]
D%(&%0+%1`S]
d0&"03/%`a
:3+%#$`Q]
G#(&%0+%1`S]
ea 3%0$+ (/)#*+`a
Tendon Jerks
Biceps, Triceps, Supinator
(Record the worst score)
9$0$% 8)&+$ $%#1)#
9*.`Q? HC`S? IC`a
B Asymmetry I"(< $5% +"1% 8"$5 5"65%+$ $)#%
≥Q 6&01% )& ≥ QO° .0++"7% $)#% 1"44%&%#(% OR
T`Q? 
!`S
G4 $5% 03)7% 0&% 0// #)&'0/ ()#$"#*% $) /)8%& /"'3= G4 0#- 03#)&'0/"$- ()'./%$% +%($")# C=
C
Scarf _::T^,T`Q] f::T`Sb
Adducted thumb _2&%+%#$`Qb
Wasting _2&%+%#$`Qb
Fisting _2&%+%#$`Qb
Abnormalities in section A (no=0, 1=1, >1=2)
Abnormalities in section C (no=0, yes=1)
Comment
Upper Limb Function
_(/0&"4- 8"$5 (0&%& "4 #%(%++0&-b
Normal function, no impairment
0
Impairment, e.g. loss of a digit, but normal function
1
Mild clumsiness, but independent
2
3Able to feed and dress self but requires aids or assistance for some 
tasks, eg feeding and dressing
4Severe difficulty with fine movements, requires aids or assistance
for feeding and dressing 
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4. Lower Limb
/%4$ &"65$
A Tone "#(&%0+%1`Q
1%(&%0+%1`S
70&"03/%`a
Ankle stretch 250+"(`Q    
$)#"( )& (/)#*+` S
Tendon jerks 
(record the  worst score)
03+%#$`Q
"#(&%0+%1`S
ea 3%0$+ (/)#*+`a
9$0$% 85"(5 $%#1)#
_YB`Q? :B`Sb
Plantar response #)&'0/`O
%;*"7)(0/`Q   
.%&+"+$%#$/- *.`S
B Asymmetry _eQ 6&01% )&  eQO) .0++"7% $)#% 1"44%&%#(%b
I"(< $5% +"1% 8"$5 $5% 5"65%+$ $)#%
T`Q? 
!`S
G4 $5% 03)7% 0&% 0// #)&'0/ 6) $) 6&)++ ')$)& (/0++"4"(0$")#= G4 0#- 03#)&'0/"$-? ()'./%$% 
+%($")# C=
C Heel ear angle 
(angle between bed & 
>100
)
`O
gO^QOO
)
`Q
fgO
)
`S
Popliteal angle
(flex knees and hips, straighten knee)
eQQO`O
)
QOO^QQO`Q
)
fQOO`S
)
Ankle angle
(angle between foot and shin)
fVO
)
`O
VO^gO
)
`Q
egO
)
`S
Adductor angle
“Pretend to be a pair of scissors”
eQQO
)
`O
PO^QQO
)
`Q
fPO
)
`S
Wasting
E)#%`O?
2&%+%#$`Q
Abnormalities in section A (no=0, 1=1, >1=2)
Abnormalities in section C (no=0, yes=1)
Comment 
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5. Rombergs
Abnormal movements already noted Yes1 No0
G4 E)? 1) !)'3%&6+= G4 h%+? ()#$"#*% $) +%($")# U=
G#+$&*($")#+M E)8 +$0#1 *. 0#1 +$0#1 0+ +$"// 0+ -)* (0# 8"$5 -)*& %-%+ (/)+%1 0#1 -)*& 0&'+ )*$ /"<% $5"+M 
_0&'+ )*$ "# 4&)#$? .0/'+ 1)8#b?
Normal
0
Eyes closed; proximal involuntary movements
1
Eyes closed; distal involuntary movements
2
Eyes open; proximal involuntary movements
3
Eyes open; distal involuntary movements
4
Cannot stand 
5
Other/Reason for being unable to stand 
Gross motor function classification system
Level 0 Normal O
Level 1 Walk without restrictions, climb stairs without limitations, can run and 
jump but with reduced speed, balance, coordination.
Q
Level 2 Can walk on flat surfaces, climb stairs with rail, limitations on uneven 
surfaces, inclines, in crowds or confined spaces. Minimal ability in 
running, jumping.
S
Level 3 Walk on level surface with assistive mobility device. 
Climb stairs using railing. Depending on upper limb function may propel 
wheelchair manually. 
a
Level 4 PAdaptive seating for trunk control and to maximise hand function.  
Require assistance or stable surface to move out of chair.  Walk short 
distances with assistance. Self mobility using powered wheelchair.
RLevel 5 No independence in basic antigravity postural control. Independent 
mobility only by power wheelchair with extensive adaptations. 
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Neurology Summary
Abnormality
:J"+M 0#- 03#)&'0/"$- ` 03#)&'0/=
T"'3+M +"#6/% 3)J 03#)&'0/ "# +%($")# :? _%"$5%& >T )& TTb`+*+.%($?  
')&% $50# )#% 3)J 03#)&'0/ "# +%($")# : _>T )& TTb )& 0#- 03#)&'0/"$- "# +%($")# C`03#)&'0/=
Normal=0, suspect=1, abnormal=2 G4 #)&'0/ )& +*+.%($? 6) $) +%($")# UM U>G
Distribution
Lower limbs worse than upper
Q
Upper limbs worse than lower limbs 
S
All limbs equally impaired
a
Asymmetry? 2&%+%#$`Q? #)$`O
Dyskinesia? 2&%+%#$`Q? #)$`O
Type of movement disorder:
Cerebral Palsy Q Generalised Hypotonia Other 
a
C%&%3&0/ 20/+-M 1%4"#"$")#+ "# ()1"#6 +5%%$=
If cerebral palsy present, classify:
Bilateral Spastic1 Dystonic3 Ataxic5
Spastic Hemi2 Choreoathetotic4
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F. Vision
Is there a visual or eye defect of any type present?
No abnormality 
0
Yes- Right eye only 
1
Yes- Left eye only 
2
Yes- Both eyes 
3
Usual vision (with spectacles if worn)
Normal or near normal 
0
Impaired but appears to have useful vision   
1
Sees light or gross movement only 2
No useful vision (blind).
3
Is there a squint present (manifest) Yes
1
No
0
Are there abnormal eye movements present Yes
1
No
0
Does the child have a problem with fixation Yes
1
No
0
Does the child have a problem with tracking Yes
1
No
0
Abnormality of any of the above? (Y=1, N=0)
Other – Comment
G. Hearing
Is there a hearing impairment of any type Yes 
1
No 
0
Usual hearing (with aids if worn)
Normal or near normal 0
Hearing loss corrected with aids 1
Some hearing but loss not corrected with aids
2
No useful hearing even with aids
3
Other – Comment
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H. HUI-3
I5%+% 0&% ;*%+$")#+ 03)*$ $5% (5"/1A+ *+*0/ 5%0/$5 0#1 *+*0/ 03"/"$- $) 1) $5"#6+= 2/%0+% 1) #)$ &%.)&$ 
$%'.)&0&- )& )((0+")#0/ .&)3/%'+= 
1. Which one of the following best describes the child’s usual ability to see well enough to read 
ordinary newsprint?
Able to see well enough without glasses or contact lenses
Able to see well enough with glasses or contact lenses
Unable to see well enough even with glasses or contact lenses
Unable to see at all
2. Which one of the following best describes the child’s usual ability to see well enough to 
recognise a friend on the other side of the street?
Able to see well enough without glasses or contact lenses
Able to see well enough with glasses or contact lenses
Unable to see well enough even with glasses or contact lenses
Unable to see at all
3. Which one of the following best describes the child’s usual ability to hear what is said in a 
group conversation with at least three other people?
Able to hear what is said without a hearing aid
Able to hear what is said with a hearing aid
Unable to hear what is said even with a hearing aid
Unable to hear what is said, but doesn’t wear a 
hearing aid
Unable to hear at all
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4. Which one of the following best describes the child’s usual ability to hear what is said in a 
conversation with one other person in a quiet room?
Able to hear what is said without a hearing aid
Able to hear what is said with a hearing aid
Unable to hear what is said even with a hearing aid
Unable to hear what is said, but doesn’t wear a
hearing aid
Unable to hear at all
5. Which one of the following best describes the child’s usual ability to be understood when 
speaking his/her own language with people who do not know him/her?
Able to be understood completely
Able to be understood partially
Unable to be understood
Unable to speak at all
6. Which one of the following best describes the child’s usual ability to be understood when 
speaking with people who know him/her well?
Able to be understood completely
Able to be understood partially
Unable to be understood
Unable to speak at all
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7. Which one of the following best describes how the child usually feels?
Happy and interested in life
Somewhat happy
Somewhat unhappy
Very unhappy
So unhappy that life is not worthwhile
8. Which one of the following best describes the child’s usual level of pain and discomfort?
Free of pain and discomfort
Mild to moderate pain or discomfort that prevents no activities
Moderate pain or discomfort that prevents some activities
Moderate to severe pain or discomfort that prevents some 
activities
Severe pain or discomfort that prevents most activities
 
9. Which one of the following best describes the child’s usual ability to walk?
E)$%M 80/<"#6 %;*".'%#$ &%4%&+ $) '%(50#"(0/ +*..)&$+ +*(5 0+ 3&0(%+? (&*$(5%+ )& 0 80/<%&=
Able to walk around the neighbourhood without difficulty, and without 
 
walking equipment
Able to walk around the neighbourhood with difficulty, but does not 
 
require walking equipment or the help of another person
Able to walk around the neighbourhood with walking equipment, but 
without the help of another person
Able to walk only short distances with walking equipment, and
 
requires a wheelchair to get around the neighbourhood
Unable to walk alone, even with walking equipment. Able to walk short 
 
distances with the help of another person, and requires a 
wheelchair to get around the neighbourhood
Unable to walk at all
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10. Which one of the following best describes the child’s usual ability to use his/her hands and 
fingers?
E)$%M 9.%("0/ $))/+ &%4%&+ $) 5))<+ 4)& 3*$$)#"#6 (/)$5%+? 6&".."#6 1%7"(%+ 4)& ).%#"#6 i0&+ )& /"4$"#6 
+'0// "$%'+? 0#1 )$5%& 1%7"(%+ $) ()'.%#+0$% 4)& /"'"$0$")#+ )4 50#1+ )& 4"#6%&+=
Full use of two hands and ten fingers
Limitations in the use of hands or fingers, but does not require 
 
special tools or the help of another person
Limitations in the use of hands or fingers, independent with use 
 
of special tools (does not require the help of another person)
Limitations in the use of hands or fingers, requires the help of another
person for some tasks (not independent even with use of special tools)
Limitations in use of hands or fingers, requires the help of another person
for most tasks (not independent even with the use of special tools)
Limitations in use of hands or fingers, requires the help of another 
person for all tasks (not independent even with use of special tools)
11. Which one of the following best describes the child’s usual ability to remember things?
Able to remember most things
Somewhat forgetful
Very forgetful
Unable to remember anything at all
12. Which one of the following best describes the child’s usual ability to think and solve day to 
day problems?
Able to think clearly and solve day to day problems
Has a little difficulty when trying to think and solve day to day problems
Has some difficulty when trying to think and solve day to day problems
Has great difficulty when trying to think and solve day to day problems
Unable to think or solve day to day problems
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13. Which one of the following best describes the child’s usual ability to perform basic activities?
Eats, bathes, dresses and uses the toilet normally
Eats, bathes, dresses or uses the toilet independently with difficulty
Requires mechanical equipment to eat, bathe, dress or use the toilet 
independently
Requires the help of another person to eat, bathe, dress or use the toilet 
14. Which one of the following best describes how the child usually feels?
Generally happy and free from worry
Occasionally fretful, angry, irritable, anxious or depressed
Often fretful, angry, irritable, anxious or depressed
Almost always fretful, angry, irritable, anxious or depressed
Extremely fretful, angry, irritable or depressed, to the point of
needing professional help
15. Which one of the following best describes the child’s usual level of pain or discomfort?
Free of pain and discomfort
Occasional pain or discomfort.  Discomfort relieved by non-prescription drugs
or self-control activity without disruption of normal activities
Frequent pain or discomfort.  Discomfort relieved by oral medicines with 
occasional disruption of normal activities
Frequent pain or discomfort. Frequent disruption of normal activities. 
Discomfort requires prescription narcotics (eg morphine) for relief.
Severe pain or discomfort. Pain not relieved by drugs and constantly disrupts
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A(2). Tester’s Ratings of Child Behaviour
Complete at the end of the assessment.  Please circle the appropriate 
number.
Attention Span  
!"# $"%& '"() *+( ,+-$' ,"%*-%.( /%' 0(1)-)* -% )"$2-%& *+( */)34
1 2 3 4 5 6 7 8 9 10
V. brief periods/v. 
short attention 
span/no directed 
effort or absorption
V. long periods/long 
attention span / v. 
persistent and 
absorbed
Robustness and Endurance  
Energy resource available to the child during the testing period.
V. fragile / v. little 
energy / tires easily
1 2 3 4 5 6 7 8 9
V. robust, good energy 
sources
10
Social Attractiveness  
How appealing is the child to interact with?
1 2 3 4 5 6 7 8 9 10
V. little initiating 
social interaction, 
tester glad to be 
finished
V. rewarding social 
partner. Enjoyable to 
“take home”
Demandingness (Need for facilitation)
How much encouragement does the child require?
1 2 3 4 5 6 7 8 9 10
Little need for 
facilitation. Child 
well organised. 
Little work for tester
Great need for 
facilitation. V. hard 
work for examiner, 
demanding
General Emotional Tone (Mood)
Very unhappy 
throughout
1 2 3 4 5 6 7 8 9
Very happy / never 
upset
10
Cooperativeness
Cooperation with the tester and complies with requests
1 2 3 4 5 6 7 8 9 10
Very resisting / 
uncooperative
V. cooperative/ readily 
enthusiastically enters 
suggested tasks / 
games
Difficultness
Overall impression of the difficultness of the child
Very easy 1 2 3 4 5 6 7 8 9 Very difficult 10
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I.  Classification of Disability
Cognitive
(I)
Motor 
(M)
Vision 
(V)
Hearing
(H)
Behaviour 
(B)
Other 
(O)
Normal 0 0 0 0 0 0
Impairment/
Mild 
1 1 1 1 1 1
Moderate/
Severe
2 2 2 2 2 2
Cognitive Motor Vision Hearing Behaviour Other 
Domain 
Number
1 2 3 4 5 6
Score (0-2)
Worst Score Domain Number
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Lung function Normal Below normal
Blood Pressure Normal Raised
c% 8"// 6"7% -)* 0 /%$$%& $) 6"7% $) -)*& 1)($)& Tick if applicable
Physical Disabilities (2/%0+% 1%+(&"3% %=6= (%&%3&0/ .0/+-? 7"+*0/ N5%0&"#6 /)++b
Any other comments:
Feedback Letter
We will translate this form into a letter for the parents/carers.
CHILD’S NAME: 
General comment:  
We found [child’s name] to be a………..…………………. participant.
_G#+%&$ +5)&$? .)+"$"7% +$0$%'%#$ %=6= U0..-? 4&"%#1/- %$(=b
  
Weight: kgs Centiles
Height: Cm Centiles
Head Circumference: Cm Centiles
_9$0$% "4 0 '%0+*&%'%#$ "+ )#? 3%/)8 )& 03)7% 0 (%#$"/%b
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Check list
5%).1( *+/* 6". +/2( ,"70$(*(' /$$ 0/1*) /%' 
/**/,+(' $.%& 8.%,*-"% 8"17)9
1. Parental questionnaire 
2. Medical history sheet 
3. Child QoL questionnaire
P= Assessment (this form)
Ø Growth
Ø Clinical examination and impairments
Ø Lung function*
Ø Parent feedback form 
*Attach record sheet
Completed By
Signed
Date
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9.5 Appendix E: Medical history questionnaire
The B-CNEP Study
Medical History Interview Record
Office Use Only:
Name
Study Number
Date
Entry 1
Entry 2
In this questionnaire we ask you for some important details about the health of your child, 
and a few questions about your home. 
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B. Hospital admissions 
1a. NoIn the last 12 months, has your child been admitted for breathing 
difficulties? (E.g. asthma, wheezing, respiratory infections).
Yes
1b. If yes:
Age Condition Hospital Approx stay (Days)
N
T
2a. In the last 12 months, has he/she been admitted for surgery? No
Yes
2b. If yes:
Age Condition Hospital Approx stay (Days)
N
T
A. Long-term Illness
1. Does your child have /*1 long-term illness or impairment? No
0
If no, go to question 2. If yes, please list and give details: Yes 1
2. Over the last 12 months, how many days of school has your child missed through any 
illness?
Because of a chest problem Days
Fits or other neurological problem Days Office
Use
Other problem Days N
T
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3a. NoIn the last 12 months, has he/she been admitted to hospital for any 
other reasons? E.g. Fits, gastroenteritis
Yes
3b. If yes:
Age Condition Hospital
Approx stay 
(Days)
K44"(% >+%
N
T
4a. NoHas he/she ever been admitted to an intensive care unit?
Yes
4b. If yes:
Age Condition Hospital
Approx stay 
(Days)
N
T
C. Chest Problems
No0 Yes11a.
In the last 12 months, has your child had wheezing or whistling 
K44"(% >+%
G4 #)? ./%0+% 6) $) ;*%+$")# S _)# $5% #%J$ .06%b= 
G4 -%+? ./%0+% ()#$"#*% 3%/)8=
1b. In the last 12 months, how many attacks of wheezing has your child had?
None 0 1 to 3 1 4 to 12 2 More than 12 3
1c. In the last 12 months, how often has your child’s sleep been disturbed due to wheezing?
Never woken0 Less than one night per week1 One or more nights per week2
No0 Yes11d. In the last 12 months, has wheezing ever been severe enough 
to limit your child’s speech to only 1 or 2 words between 
breaths?
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2. Has any doctor ever said that your child has asthma? No0 Yes1
No0 Yes13. In the last 12 months, has your child’s chest sounded wheezy 
during or after exercise?
No0 Yes14. In the last 12 months, has your child had a dry cough at night, 
apart from a cough associated with a cold or a chest infection?
No0 Yes15. In the last 12 months, has your child seen a paediatrician or 
chest specialist about a chest or breathing problem?
No0 Yes16. In the last 12 months, has your child been treated for any 
respiratory or chest problems?
7. Please indicate which .%&)2 medications or inhalers your child is currently taking.
c% 8"// 0+< -)* 03)*$ )$5%& '%1"(0$")#+ /0$%& )#=
None
0
Prednisolone (oral) 1
Home Oxygen 2
Inhalers
!%/"%7%&+ Ventolin (blue) 3
Bricanyl (blue) 3
Atrovent (white) 4
Salmeterol (green) or other 
reliever  
5
2&%7%#$%&+ Any steroid inhaler 6
8.
If your child is taking a steroid inhaler, please state which one:
%=6= H%()$"1% _3&)8#b? 2*/'"()&$ _3&)8#b? W/"J)$"1% _)&0#6%b
Office Use
9. Please state any medicines or inhalers taken today.
None 0
Short 1
Long 2
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D. Neurological Problems
1. In the last 2 years, has your child had a fit or seizure? No
0
Yes
If no, please go to question 3. 
If yes, when was the last fit/seizure?
Last 1 month3 Last 6 months2 Over 6 months ago1
2. Have you been given regular medicine to control your child’s fits? No0
If yes, please give details: Yes1
Medication
Treatment 
continuing
Treatment
stopped
3a. Has your child ever had hydrocephalus? Yes
No0
3b. If yes, has your child ever had a shunt to treat this? Yes2
No1
E. Medications
10. Is your child .4''&*251 on any medicines not already mentioned? No
0
Yes
1
If no, go to section D (overleaf). 
If yes, please specify:
%=6= !"$0/"# _'%$5-/.5%#"10$%b
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F. Your Home 
I5% 4)//)8"#6 ;*%+$")#+ 0../- $) -)*& 5)'% 0#1 -)*& 40'"/-? 3- $5"+ 8% '%0# '*' _)& .0&$#%&b? 
101 _)& .0&$#%&b 0#1 3&)$5%&+ 0#1 +"+$%&+=
0 1 K44"(%
1a. Do you have any long-haired or feathered pets at home? No Yes E
1b. If the answer to 18 is B&), please specify: cats/dogs/birds etc.
2. Does your house have problems with damp? No Yes E
3. Does your house have problems with mould on the walls? No Yes E
4. Have any members of your family had any attacks of 
wheezing or whistling in the chest?
No Yes I
5. Has a doctor ever said that any member of your family has 
asthma?
No Yes I
6. Has any member of your family ever had hay fever? No Yes I
7.
Apart from asthma have you or any of the household had 
any long-term chest problems since your child was born?
No Yes I
K44"(%^ FM _O^ab GM_O^Pb
G. Smoking
1. Does anyone in the household smoke? No0 Yes1
If yes, please state who: Parent(s)
1 Sibling1 Study child2 Other1
No0 Yes12. Does your child have contact (more than 15 
hrs a week) with friends, family or childminders 
who smoke?
L*%+$")# a 0../"%+ $) $5% (5"/1A+ ')$5%&M
3. Did you smoke whilst you were pregnant with this child?
 
Not applicable9 No0 Yes1
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Name of person giving history 
Relationship to child
Interviewer
Interviewer’s Signature
Date
If you completed this form without an 
interviewer present, please sign here:
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9.6 Appendix F: Parental questionnaire
The B-CNEP Study
Parental questionnaire about your home and 
family, and your child.
Office Use Only:
Name
Study Number
Date
Entry 1
Entry 2
In this questionnaire we ask you for some important details about your home and family and 
about your child. Ideally, we would like one of the child's main carers to fill this in.Please complete the questions in this booklet as accurately as possible. If you have any 
questions, or need any help, please telephone us on:
(0115) 924 9924 extension 43358
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A. Your Home and Your Family
I5%+% ;*%+$")#+ 0../- $) -)*& 5)*+% 0#1 $5% 40'"/- 0$ 5)'%? 3- $5"+ 8% '%0# '*' _)& 
.0&$#%&b? 101 _)& .0&$#%&b 0#1 3&)$5%&+ 0#1 +"+$%&+ )4 $5% (5"/1 "# $5% +$*1-= 2/%0+% 
0#+8%& 0// ;*%+$")#+ $50$ 0../- $) -)* 0#1 -)*& .0&$#%&= 
1. How many children (age up to 18 years) are there in the household 
((*.54,(*> the child taking part in the study)?  
Children
2/%0+% /"+$ $5% #0'%+ 0#1 10$%+ )4 3"&$5 )4 $5% (5"/1&%#=
_h)* 1) #)$ #%%1 $) "#(/*1% 1%$0"/+ 4)& $5% (5"/1 8% 0&% 0++%++"#6 $)10-b=
NAME DATE OF BIRTH e.g. 24/06/1994
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Home Environment
2/%0+% $"(< $5% &%/%70#$ 3)J=
2. Do you rent or own your accommodation?
Owner (mortgage)
Council rented
Private rented (furnished)
Private rented (unfurnished)
Housing society or co-operative
Tied to occupation
K44"(% >+%
Other (please describe below)
3. How many rooms are there in your home?
_D) #)$ ()*#$ 30$5&))'+= D) #)$ ()*#$ $5% <"$(5%# *#/%++ *+%1 4)& 40'"/- '%0/+b=
&))'+
No4. Do you have the use of a car (including minibus, van etc.)?
Yes
No5. Does your partner have the use of a separate car/van etc?
Yes       
Yes
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About You
6. Please tell us your relationship to the child in the study:
;"*+(1 <*(0=;.7
>/*+(1 <*(0=?/'
@*+(1
A8 B"*+(1CD 0$(/)( )0(,-86D (9&9 &1/%'7"*+(1
7. Please tell us who your child lives with:
;"*+(1 /%' >/*+(1 ;"*+(1 /%' )*(0=?/'
;"*+(1 >/*+(1 /%' )*(0=;.7
>/*+(1 E(&/$ &./1'-/%
@*+(1 F0$(/)( )0(,-86G
8. Do any other adults live with you? Yes No
_2/%0+% )#/- +$0$% 01*/$+ #)$ '%#$")#%1 03)7%b 
If yes, please state how many. K44"(% >+%M :`
9a. Are you currently
<-%&$(4 9b. If you are single, have you previously been
;/11-('4 H-'"#('4
E-2-%& *"&(*+(14 <(0/1/*(' "1 '-2"1,('4
I"* /00$-,/J$( FA /7 %"* / I"%( "8 *+( /J"2(
0/1(%* "8 *+( )*.'6 ,+-$'G  
KL9 H+/* -) 6".1 ,.11(%* /&(4 M(/1) I"* /00$-,/J$(
KK9 H+/* -) 6".1 0/1*%(1C) ,.11(%* /&(4 M(/1) I"* /00$-,/J$(
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Education
!"#$ A&-$%#*+ /))=#-$ %* %"- 2*%"-, :*, $%-) 2*%"-,> *1 %"- $%&'( 8"#='?
12. Please state your highest qualification from school or college.
I"* /00$-,/J$(
No qualification
Vocational qualification or CSE
O-level or GCSE or Scottish Standards
A-levels or Highers
Nursing Qualification
Teacher Training Qualification
University Degree
Other qualification after A-level
If ‘other’ please describe:
!"#$ A&-$%#*+ /))=#-$ %* %"- 1/%"-, :*, $%-) 1/%"-,> *1 %"- $%&'( 8"#='?
13. Please state your highest qualification from school or college.
Not applicable
No qualification
Vocational qualification or CSE
O-level or GCSE or Scottish Standards
A-levels or Highers
Nursing Qualification
Teacher Training Qualification
University Degree
Other qualification after A-level
If ‘other’ please describe:
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Employment
B&-$%#*+$ CDE CF /))=( %* %"- 2*%"-, :*, $%-) 2*%"-,> *1 %"- $%&'( 8"#='?
G11#8- H$-
14. Are you in paid employment? No Yes
I"* /00$-,/J$(
15. Current/last occupation:
16. Industry:
17. How many hours do you work per week? Hours
18. Are you a: Manager?
Supervisor?
Trainee/Student?
None of the above?
Please describe:
19. Are you self-employed? No Yes
N+()( O.()*-"%) /00$6 *" *+( 8/*+(1 F"1 )*(0 8/*+(1G "8 *+( )*.'6 ,+-$'9
PL9 Q1( 6". -% 0/-' (70$"67(%*4 I" M()
PK9 R.11(%*S$/)* ",,.0/*-"%:
PP9 A%'.)*16:
PT9 !"# 7/%6 +".1) '" 6". #"13 0(1 #((34 !".1)
PU9 Q1( 6". /: ;/%/&(144
<.0(12-)"14
N1/-%((S<*.'(%*4
I"%( "8 *+( /J"2(4
V$(/)( '(),1-J(:
PW9 Q1( 6". )($8=(70$"6('4 I" M()
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Benefits
20. Please indicate which benefits you or your partner receive:
_I"(< 0// $50$ 0../-b
Child Benefit
Family Credit / Child Tax Credit / Working Family Tax 
Invalid Care Allowance / Carers Allowance
Income Support
Job Seekers Allowance
Disability Living Allowance
Incapacity Benefit
Housing Benefit
None of the above
Other
If ‘other’, please describe:
Office Use
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B. Your Child’s Health
c5%# 0#+8%&"#6 $5% 4)//)8"#6 ;*%+$")#+? ./%0+% $5"#< 03)*$ -)*& (5"/1A+ *+*0/ 5%0/$5 0#1 03"/"$- 
$) 1) $5"#6+ )# 0 10-^$)^10- 30+"+= 2/%0+% 1) #)$ &%.)&$ $5% %44%($ )4 +5)&$ "//#%++%+ +*(5 0+ 
()/1+= W)(*+ -)*& 0#+8%&+ )# -)*& (5"/1A+ 03"/"$"%+? 1"+03"/"$"%+ 0#1 5)8 5% )& +5% *+*0//- 4%%/+= 
h)* '0- $5"#< $50$ +)'% )4 $5%+% ;*%+$")#+ 1) #)$ 0../- $) -)*& (5"/1? 3*$ "$ "+ "'.)&$0#$ $50$ 
8% 0+< %7%&-)#% $5% +0'% ;*%+$")#+= :/+)? 0 4%8 ;*%+$")#+ 0&% 7%&- +"'"/0&M ./%0+% %J(*+% 
$5"+^ 8% 8)*/1 /"<% -)* $) 0#+8%& %0(5 ;*%+$")# "#1%.%#1%#$/-= 2/%0+% &%01 %0(5 ;*%+$")# 0#1 
()#+"1%& -)*& 0#+8%& (0&%4*//-= W)& %0(5 ;*%+$")#? +%/%($ )#% 0#+8%& $50$ 3%+$ 1%+(&"3%+ -)*& 
(5"/1A+ *+*0/ /%7%/ )4 03"/"$- )& 1"+03"/"$-= 2/%0+% "#1"(0$% $5% +%/%($%1 0#+8%& 3- $"(<"#6 $5% 3)J 
3%+"1% $5% 0#+8%&= I5%&% 0&% #) &"65$ )& 8&)#6 0#+8%&+= :// 8% 8)*/1 /"<% "+ -)*& )."#")# 03)*$ 
-)*& (5"/1A+ 5%0/$5=
1. Which one of the following best describes your child’s usual ability to see well enough to 
read ordinary newsprint?
Able to see well enough without glasses or contact lenses
Able to see well enough with glasses or contact lenses
Unable to see well enough even with glasses or contact 
Unable to see at all
2. Which one of the following best describes your child’s usual ability to see 
well enough to recognise a friend on the other side of the street?
Able to see well enough without glasses or contact lenses
Able to see well enough with glasses or contact lenses
Unable to see well enough even with glasses or contact lenses
Unable to see at all
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3. Which one of the following best describes your child’s usual ability to hear 
what is said in a group conversation with at least three other people?
Able to hear what is said without a hearing aid
Able to hear what is said with a hearing aid
Unable to hear what is said even with a hearing aid
Unable to hear what is said, but doesn’t wear a hearing aid
Unable to hear at all
4. Which one of the following best describes your child’s usual ability to hear 
what is said in a conversation with one other person in a quiet room?
Able to hear what is said without a hearing aid
Able to hear what is said with a hearing aid
Unable to hear what is said even with a hearing aid
Unable to hear what is said, but doesn’t wear a hearing aid
Unable to hear at all
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5. Which one of the following best describes your child’s usual ability to be understood when 
speaking his/her own language with people who do not know him/her?
Able to be understood completely
Able to be understood partially
Unable to be understood
Unable to speak at all
6. Which one of the following best describes your child’s usual ability to be understood when 
speaking with people who know him/her well?
Able to be understood completely
Able to be understood partially
Unable to be understood
Unable to speak at all
7. Which one of the following best describes how your child usually feels?
Happy and interested in life
Somewhat happy
Somewhat unhappy
Very unhappy
So unhappy that life is not worthwhile
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8. Which one of the following best describes your child’s usual level of pain 
and discomfort?
Free of pain and discomfort
Mild to moderate pain or discomfort that prevents no activities
Moderate pain or discomfort that prevents some activities
Moderate to severe pain or discomfort that prevents some activities
Severe pain or discomfort that prevents most 
activities  
9. Which one of the following best describes your child’s usual ability to walk? 
Note: walking equipment refers to mechanical supports such as braces, a cane, 
crutches or a walker.
Able to walk around the neighbourhood without difficulty, and without 
walking equipment
Able to walk around the neighbourhood with difficulty, but does not require
walking equipment or the help of another person
Able to walk around the neighbourhood with walking equipment, but 
without the help of another person
Able to walk only short distances with walking equipment, and requires
a wheelchair to get around the neighbourhood
Unable to walk alone, even with walking equipment. Able to walk short
distances with the help of another person, and requires a wheelchair to 
get around the neighbourhood
Unable to walk at all  
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10. Which one of the following best describes your child’s usual ability to use his/her 
hands and fingers?
Note: Special tools refers to hooks for buttoning clothes, gripping devices for opening 
jars or lifting small items, and other devices to compensate for limitations of hands or 
fingers.
Full use of two hands and ten fingers
Limitations in the use of hands or fingers, but does not require  
special tools or the help of another person
Limitations in the use of hands or fingers, independent with use of special
tools (does not require the help of another person)
Limitations in the use of hands or fingers, requires the help of 
another person for some tasks (not independent even with 
use of special tools)
Limitations in use of hands or fingers, requires the help of another  
person for most tasks (not independent even with the use of 
special tools)
Limitations in use of hands or fingers, requires the help of another person for all
tasks (not independent even with use of special tools)
11. Which one of the following best describes your child’s usual ability to remember things?
Able to remember most things
Somewhat forgetful
Very forgetful
Unable to remember anything at all
12. Which one of the following best describes your child’s usual ability to think and solve day 
to day problems?
Able to think clearly and solve day to day problems
Has a little difficulty when trying to think and solve day to day problems
Has some difficulty when trying to think and solve day to day problems
Has great difficulty when trying to think and solve day to day problems
Unable to think or solve day to day problems
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13. Which one of the following best describes your child’s usual ability to perform basic 
activities?
Eats, bathes, dresses and uses the toilet normally
Eats, bathes, dresses or uses the toilet independently with difficulty
Requires mechanical equipment to eat, bathe, dress or use the toilet 
independently
Requires the help of another person to eat, bathe, dress or use the 
toilet 
14. Which one of the following best describes how your child usually feels?
Generally happy and free from worry
Occasionally fretful, angry, irritable, anxious or depressed
Often fretful, angry, irritable, anxious or depressed
Almost always fretful, angry, irritable, anxious or depressed
Extremely fretful, angry, irritable or depressed, to the point of
needing professional help
15. Which one of the following best describes your child’s usual level of pain or discomfort?
Free of pain and discomfort
Occasional pain or discomfort.  Discomfort relieved by non-prescription 
drugs or self-control activity without disruption of normal activities.
Frequent pain or discomfort.  Discomfort relieved by oral medicines 
with occasional disruption of normal activities.
Frequent pain or discomfort. Frequent disruption of normal activities. 
Discomfort requires prescription narcotics (eg morphine) for relief.
Severe pain or discomfort. Pain not relieved by drugs and constantly
disrupts normal activities.
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C. Your Child’s Activities and School
2/%0+% 4"// )*$ $5"+ +%($")# $) &%4/%($ -)*& 7"%8 )4 -)*& (5"/1A+ 3%507")*&? %7%# "4 )$5%& 
.%)./% '"65$ #)$ 06&%%= W%%/ 4&%% $) .&"#$ 011"$")#0/ ()''%#$+ 3%+"1% %0(5 "$%' 0#1 "# 
$5% +.0(%+ .&)7"1%1=
1. Please list the sports your child most likes to take part in.
W)& %J0'./%M +8"''"#6? 
30+%30//? +<0$"#6? 
+<0$%3)0&1"#6? 3"<% 
&"1"#6? 4"+5"#6? %$(=
Compared to others of the same 
age, about how much time does 
he/she spend in each?
Compared to others of the same 
age, how well does he/she do each 
one?
Sport
Don’t 
Know
Less 
Than 
Average Average
More
Than 
Average
Don’t 
Know
Less 
Than 
Average Average
More
Than 
Average
a.
b.
c.
None
2. Please list your child’s favourite hobbies, activities and games other than sports.
W)& %J0'./%M +$0'.+? 
1)//+? 3))<+? ."0#)? 
(&04$+? (0&+? +"#6"#6 %$(= 
_D) #)$ "#(/*1% /"+$%#"#6 
$) $5% &01") )& Idb=
Compared to others of the same 
age, about how much time does 
he/she spend in each?
Compared to others of the same 
age, how well does he/she do each 
one?
Hobby
Don’t 
Know
Less 
Than 
Average Average
More
Than 
Average
Don’t 
Know
Less 
Than 
Average Average
More
Than 
Average
a.
b.
c.
None
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3. Please list any organisations, clubs, teams, or groups your child belongs to.
Compared to others of the same age, how active is he/she in each?
Group Don’t 
Know
Less Than 
Average Average
More Than 
Average
a.
b.
c.
None
4. Please list any jobs or chores your child has.
W)& %J0'./%M .0.%& &)*$%? 
303-+"$$"#6? '0<"#6 3%1? 8)&<"#6 "# 
+$)&%? %$(= _G#(/*1% 3)$5 .0"1 0#1 
*#.0"1 i)3+ 0#1 (5)&%+=b
Compared to others of the same 
age, how well does he/she carry 
them out?
Job Don’t 
Know
Less Than 
Average Average
More Than 
Average
a.
b.
c.
None
5. About how many friends does your child have?
(Do not include brothers and sisters.)
None 1 2 or 3 4 or more
6. About how many times a week does your child do things with friends outside of regular 
school hours?  (Do not include brothers and sisters.)
Less than 1 1 or 2 3 or more
7. Compared to others of his/her age, how well does your child:
Worse
About 
average Better
Has no brothers
or sisters
Get along with brothers and sisters?
Get along with other kids?
Behave with his/her parents?
Play and work alone?
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8. Performance in subjects
2/%0+% $"(< 0 3)J 4)& %0(5 +*3i%($ -)*& (5"/1 $0<%+
Failing
Below 
average Average
Above 
Average
Reading or English 
History or social studies
Arithmetic or maths
Science
Other school subjects, 
eg computer courses, Do not include PE
9.  Does your child attend a special needs school?  No Yes
10. Does your child receive additional support in class or attend a special class?
No Yes
If yes, please describe
11. Has your child repeated any grades?
No Yes
If yes, please state grades and reasons
12. Has your child had any learning problems in school?
No Yes
If Yes, please describe
When did these problems start?
Have these problems ended? No Yes
1 2 3 T
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D. Your Child’s Behaviour
I*, -/8" *1 %"- 1*==*J#+0 #%-2$K )=-/$- 2/,L %"- .*7 1*, 3*% !,&-K 5*2-J"/% !,&- *, M-,%/#+=( !,&-? N% J*&=' "-=) 
&$ #1 (*& /+$J-,-' /== %"- #%-2$ /$ .-$% (*& 8/+ -9-+ #1 (*& /,- +*% /.$*=&%-=( 8-,%/#+ *, %"- #%-2 $--2$ '/1%O  
P=-/$- 0#9- (*&, /+$J-,$ *+ %"- ./$#$ *1 (*&, 8"#='Q$ .-"/9#*&, *9-, %"- =/$% $#7 2*+%"$?
Not true
Somewhat 
true
Certainly 
true
Office 
Use
1. Considerate of other people’s feelings
2. Restless, overactive, cannot stay still for 
long
3. Often complains of headaches, stomach-
aches or sickness
4. Shares readily with other children (treats, 
toys, pencils etc.)
5. Often has temper tantrums or hot tempers
6. Rather solitary, tends to play alone
 7. Generally obedient, usually does what 
adults request
8. Many worries, often seems worried 
9. Helpful if someone is hurt, upset or feeling 
ill
10. Constantly fidgeting or squirming
11. Has at least one good friend
12. Often fights with other children or bullies 
them
13. Often unhappy, down-hearted or tearful
14. Generally liked by other children
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Not true Somewhat 
true
Certainly 
true
G11#8- 
H$-
15. Easily distracted, concentration wanders
16. Nervous or clingy in new situations, 
easily looses confidence
17. Kind to younger children
18. Often lies or cheats
19. Picked on or bullied by other children
20. Often volunteers to help others (parents, 
teacher, other children)
21. Thinks things out before acting
22. Steals from home, school or elsewhere
23. Gets on better with adults than with other
children
24. Many fears, easily scared
25. Sees tasks through to the end, good 
attention span
K44"(% >+%
P H
E
C
F
T 
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26. Overall, do you think that your child has difficulties in one or more of the following 
No   
Yes, minor difficulties
Yes, definite difficulties
Yes, severe difficulties
G4 @E)A? ./%0+% ()'./%$% $5% ;*%+$")#+ )# $5% #%J$ .06%=
G4 -)* 507% 0#+8%&%1 [h%+\? ./%0+% 0#+8%& $5% 4)//)8"#6 ;*%+$")#+ 03)*$ $5%+% 1"44"(*/$"%+M
27. How long have these difficulties been present?
Less than a month
1-5 months
6-12 months
Over a year
28. Do the difficulties upset or distress your child?
Not at all
Only a little 
Quite a lot
A great deal
29. Do the difficulties interfere with your child’s everyday life in the following areas?
Not at all Only a little Quite a lot A great deal
Home life
Friendships
Classroom/ Learning
Leisure activities
30. Do these difficulties put a burden on you or the family as a whole?
Not at all
Only a little 
Quite a lot
A great deal
31. Does your child need supervision more than half of the time?
Yes No
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E.   What is Your Child’s Ethnic Group
C5))+% KEF +%($")# 4&)' : $) F? $5%# $"(< $5% 0..&).&"0$% 3)J $) "#1"(0$% -)*& (5"/1A+ 
(*/$*&0/ 30(<6&)*#1= 
A.  White
British Irish 
Any other White background 
B. Mixed
White and Black Caribbean
White and Black African
White and Asian
Any other Mixed background:
C. Asian or Asian British
Indian 
Pakistani
Bangladeshi
Any other Asian background:
D. Black or Black British
Caribbean
African
Any other Black background:
E. Chinese or other ethnic group
Chinese
Any Other:
* census 2001
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If you have any other concerns about your child, please tell us about them here.
Please tell us the three best things about your child.
1
2
3
N+/%3 6". 8"1 6".1 *-7( /%' +($0 -% *+( 
,"70$(*-"% "8 *+-) O.()*-"%%/-1(
;5&/)& .+3=5&2& 2%& -+55+0(*>
N+-) 8"17 #/) ,"70$(*(' J6:
I/7(:
<-&%/*.1(: ?/*(
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9.7 Appendix G: Ethical approval
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